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Chapter 1
General introduction and 
outline of this thesis
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Breast cancer is the most prevalent cancer in Dutch women, with an incidence of 
over 14,000 cases in 2017 (1). Although the incidence is still on the rise, the survival 
percentages are also increasing. Between 2011 and 2015, the overall five-year 
survival rate of breast cancer in the Netherlands was 88 percent, compared to 78 
percent between 1991 and 1995 (1). This is on one hand due to an effective screening 
program, and on the other hand to the effective treatment of breast cancer by surgery, 
chemotherapy, radiotherapy, endocrine therapy, and targeted therapies. However, a 
substantial proportion of patients experience a relapse of the disease, often due to 
tumor cells that have become resistant to the applied treatment (2, 3). The prognosis 
of relapsed and metastasized breast cancer is considerably worse than that of the 
primary disease (4). 
This thesis focuses on resistance to endocrine therapy (tamoxifen) and radiotherapy. 
Mechanisms of resistance to either treatment modality have been described earlier (3, 
5-7). Remarkably, breast cancer cells that developed tamoxifen resistance were found 
to be cross-resistant to irradiation in vitro (8, 9). Therefore, common mechanisms may 
play a role in resistance to both tamoxifen treatment and irradiation. In this thesis, an 
untargeted approach is applied to find such mechanisms. Only when the biological 
basis of these types of resistance is well understood, new targets to treat resistant 
breast cancer can be proposed. 
Tamoxifen and radiotherapy in the treatment of breast cancer
Around 70% of all breast cancers is estrogen receptor (ER) positive (10). As proliferation 
of these cancer cells is estrogen-dependent, antiestrogen therapies have been 
developed as treatment strategy (11). The most commonly used endocrine agent is 
the ER-antagonist tamoxifen, which has been used since the 1970’s (12). It functions by 
physically interacting with the ER and thereby decreasing the proliferative response 
of estrogens (11, 13). Moreover, tamoxifen can have ER-independent effects, such as 
inhibition of metastasis and angiogenesis; activation of programmed cell death; and 
interaction with multidrug resistance proteins (14). 
Currently, tamoxifen is recommended as adjuvant therapy for women with a stage 
I-III ER-positive tumor in the Netherlands (15). Postmenopausal women, the largest 
group of breast cancer patients, receive endocrine therapy for five years. They are 
treated with tamoxifen for two to three years, and with aromatase inhibitors for the 
other two to three years. Premenopausal women receive tamoxifen up to ten years 
(15). Tamoxifen is also increasingly applied as neoadjuvant treatment, although in 
postmenopausal women aromatase inhibitors are preferred for this application (16, 
17). Finally, tamoxifen is used to treat metastasized breast cancer in premenopausal 
women with an ER-positive tumor (15). Moreover, locoregional recurrences that are 
ER-positive are primarily treated with surgery and additionally with a combination of 
radiotherapy and adjuvant systemic therapy, for example tamoxifen (15).
Radiotherapy is another treatment modality that is often used to treat breast cancer. 
The success of radiotherapy is based on the decreased DNA damage repair capacity 
that is inherent to cancer cells. Ionizing radiation causes the formation of free radicals, 
or reactive oxygen species (ROS), mostly due to the ionization of water. When ROS 
interact with DNA, they can cause double-strand breaks. In the presence of oxygen, 
this damage is fixed in the DNA, and due to the lack of functional DNA damage repair, 
tumor cells die when enough of these seriously damaging events have taken place 
(18-20).
In the Netherlands, adjuvant irradiation is applied to the whole or partial breast after 
lumpectomy in patients with ductal carcinoma in situ or invasive breast carcinoma, 
except in some very low-risk patients where omitting adjuvant radiotherapy can be 
considered (15). Postmastectomy  radiotherapy is applied in T3/4 and node-positive 
high-risk patients, or when the resection plane is positive for tumor cells. Adjuvant 
radiotherapy of the axillary lymph nodes (with or without the internal mammary 
lymph nodes) can be given in case of a positive sentinel node or an extensively 
involved lymph node dissection specimen (15).
Mechanisms of resistance to tamoxifen treatment
Within ten years after the introduction of tamoxifen in the clinic (12), the first cases of 
acquired and inherent resistance to this ER-antagonist were reported (2). Absence of 
the ER is one of the major causes for intrinsic tamoxifen resistance (21). In ER-positive 
breast cancer patients, it is mainly modulation of the ER that can lead to resistance 
to tamoxifen treatment. Firstly, mutations in the ER itself can cause constitutive 
activity, and thus confer tamoxifen resistance (22,23). Moreover, responses to 
tamoxifen treatment can be affected by coactivators of the ER (AIB1, RIP140, SRC-
1), ER corepressors (e.g. NCoR1) or ER phosphorylation by several kinases (e.g. ERK1, 
ERK3), that all modulate ER activity [reviewed in: (7)]. Downregulation of the PI3K/
AKT/mTOR pathway has been found to increase ER activity, facilitating resistance 
(24). Downstream transcription factors of the ER (GATA3, GREB1) can also play a role 
in tamoxifen resistance. Finally, epigenetic modification of the ER gene itself or its 
target genes modify responses to tamoxifen treatment [reviewed in: (7)].
Although the function of the ER is crucial in ER-positive breast cancer signaling, ER-
independent mechanisms can also cause tamoxifen resistance [reviewed in: (6)]. 
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One example is the unfolded protein response (UPR)/LAMP3/autophagy pathway, 
which was previously investigated in our group (25). The UPR stress response and 
autophagy, mediated by LAMP3, contribute to decreased sensitivity to tamoxifen. 
Another example is the DNA cytosine deaminase APOBEC3B. APOBEC3B was found 
to confer tamoxifen resistance in a mouse model, and was also associated with 
responses after tamoxifen treatment for advanced breast cancer patients (26).
Mechanisms of radioresistance
Three main mechanisms of radioresistance, that are present in many cancer types, 
are intrinsic radioresistance, accelerated proliferation and hypoxia (27). Intrinsic 
radioresistance in breast cancer is dependent on the patient’s genetic make-up (28) 
and the type of breast cancer (29). Accelerated proliferation is caused by the ability 
of proliferating cancer cells to repopulate the irradiated area (30). It is therefore that 
multiple fractions of irradiation are usually applied in a clinical setting (31), and the 
overall treatment time is limited (32, 33). Hypoxic tumor regions are characterized by 
increased radioresistance. As oxygen is needed to “fixate” the DNA damage caused 
by irradiation-induced ROS, hypoxic regions show less profound damage, and more 
repair by DNA damage repair proteins (18). 
Other mechanisms of radioresistance have also been identified [reviewed in: (3)]. 
The levels of tyrosine kinase IGF-IR are elevated in ER-positive breast cancer and 
this confers radioresistance. The PI3K pathway, which is implicated in tamoxifen 
resistance as well, also leads to radioresistance, although here the downregulation 
of this pathway sensitizes cells to treatment [reviewed in: (3)]. Like with tamoxifen 
resistance, growth factors and overexpression of growth factor receptors can cause 
resistance to irradiation. In particular Vascular Endothelial Growth Factor (VEGF) is 
involved in radioresistance, as it is a downstream factor of HIF-1α, the master hypoxia-
activated transcription factor [reviewed in: (3)]. Loss of the tumor suppressor p53, a 
central factor in cell cycle control and DNA damage repair, is associated with increased 
radioresistance. On the other hand, loss of function of DNA damage repair proteins 
BRCA1 and BRCA2 sensitizes cells to irradiation [reviewed in: (3)]. This highlights the 
importance of DNA damage repair in radiosensitivity. Previously, our group showed 
that the UPR/LAMP3/autophagy pathway contributes in radioresistance in breast 
cancer as well (34). All these mechanisms should be considered when investigating 
why tamoxifen-resistant breast cancer cells are also radioresistant.
Implications of cross-resistance
Paulsen et al. discovered in 1996 that ER-positive breast cancer cells that had been 
cultured resistant to tamoxifen had also developed resistance to irradiation (8). Further 
research on this phenomenon occurred only in 2015, when Luzhna et al. observed the 
same effect (9). This cross-resistance for irradiation in ER-positive tamoxifen-resistant 
breast cancer cells suggests that, to a certain extent, common mechanisms may play 
a role in both tamoxifen resistance and radioresistance. 
As both tamoxifen treatment and radiotherapy are sequentially administered in breast 
cancer patients, the identification of mechanisms that cause tamoxifen-resistant 
breast cancer cells to also develop radioresistance could be of paramount importance 
to patients. As mentioned, neoadjuvant endocrine therapy is on the rise (35). When 
these patients subsequently receive radiotherapy after surgery,  the development of 
tamoxifen resistance could also affect the outcome after radiotherapy. Moreover, in 
patients that are treated with adjuvant tamoxifen and later with irradiation for e.g. 
bone metastases, cross-resistance to irradiation in tamoxifen-resistant breast cancer 
cells could hamper the success of irradiation.
Therefore, we aimed to investigate this cross-resistance that was observed in vitro. An 
untargeted approach was used to identify new mechanisms that play a role in both 
tamoxifen resistance and radioresistance. Moreover, the expression of genes that 
could influence radiosensitivity was assessed in tamoxifen-resistant breast cancer 
cells. In this way, we wanted to identify common mechanisms in acquired tamoxifen 
resistance and radioresistance in breast cancer, as well as discover genes that cause 
the radioresistance in tamoxifen-resistant breast cancer cells.
Outline of this thesis
As tamoxifen-resistant ER-positive breast cancer cells are cross-resistant for irradiation 
in vitro, we aimed to identify mechanisms that play a role in both types of resistance. 
Chapter 2 reports on features that are activated in both tamoxifen-resistant and 
radioresistant ER-positive breast cancer cells. Genes that are upregulated in both 
types of resistance in vitro were identified by RNA sequencing and relevant genes 
were further characterized in vitro and associated with outcome in several breast 
cancer patient cohorts. In Chapter 3, the data from Chapter 2 are extended by 
assessing several signaling molecules that could be responsible for the activation 
of the pathway that was identified to be upregulated in tamoxifen-resistant and 
radioresistant breast cancer cells. Downregulated genes in tamoxifen-resistant and 
radioresistant breast cancer cells could also provide information about common 
mechanisms of resistance. Chapter 4 deals with the identification of these genes 
12
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and their relation with outcome in breast cancer patients. The cross-resistance for 
radiotherapy observed in tamoxifen-resistant breast cancer cells is further analyzed in 
Chapter 5. The expression of genes involved in DNA damage repair and cell cycle control 
in tamoxifen-resistant cells was investigated, in order to explain this cross-resistance. 
Finally, the role of APOBEC3B in radioresistance is assessed. Chapter 6 reports on the 
association of APOBEC3B with outcome in breast cancer patients after radiotherapy. 
Moreover, the role of APOBEC3B in radiosensitivity in vitro was investigated. Chapter 
7 places the findings of this thesis in a broader perspective. Future directions to better 
understand resistance to tamoxifen treatment and radiotherapy in breast cancer are 
addressed, in particular the role of immune cells in the tumor microenvironment that 
are likely to contribute significantly to treatment resistance. 
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Abstract
Purpose
Treatment resistance is the main cause of adverse disease outcome in breast cancer 
patients. Here, we aimed to investigate common features in tamoxifen-resistant and 
radioresistant breast cancer, as tamoxifen-resistant breast cancer cells are cross-
resistant to irradiation in vitro. 
Experimental Design
RNA sequencing of tamoxifen-resistant and radioresistant breast cancer cells was 
performed, and validated by quantitative PCR. Pathways were further investigated in vitro 
and in breast cancer patient cohorts to establish their relation with treatment resistance.
Results
Both tamoxifen-resistant and radioresistant breast cancer cells had increased expression 
levels of genes involved in type I IFN signaling compared with nonresistant cells. IFN-
stimulated genes (ISG) were induced in a dose-dependent and time-dependent manner 
after tamoxifen treatment and irradiation. Tamoxifen treatment also led to ssDNA 
presence in the cytoplasm, which is known to induce expression of ISGs, a phenomenon 
that has already been described for irradiation. Moreover, in a breast cancer patient 
cohort, high expression levels of ISGs were found in the primary tumor in around half of 
the patients. This was associated with a tumor-infiltrating lymphocyte (TIL) expression 
signature, although the ISGs were also expressed by the tumor cells themselves. 
Importantly, the expression of ISGs correlated with outcome in breast cancer patients 
treated with adjuvant tamoxifen or radiotherapy, but not in systemically untreated 
patients or chemotherapy-treated patients. 
Conclusions
Our data indicate that expression of ISGs by tumor cells is involved in acquired, treatment-
induced resistance to tamoxifen and radiotherapy, and might play a role in intrinsic 
resistance via interaction with TILs. 
Introduction
Endocrine treatment and radiotherapy are two mainstays in breast cancer treatment. 
Although breast cancer survival rates are generally high, in a substantial subset of 
patients, the development of therapy resistance results in adverse outcome (1,2). We 
have previously shown that the unfolded protein response/LAMP3/autophagy pathway 
is involved in resistance to both tamoxifen treatment and radiotherapy (3,4). Moreover, 
cross-resistance has been observed in tamoxifen-resistant breast cancer cells in vitro. 
These are less sensitive to irradiation (5,6), suggesting that common mechanisms underlie 
tamoxifen resistance and radioresistance. 
Endocrine therapy targets the estrogen signaling pathway, which is essential for 
tumor cell proliferation in a large percentage of breast cancers. Two major classes of 
endocrine therapy can be distinguished: aromatase inhibitors and estrogen receptor 
(ER) modulators, such as tamoxifen (7,8). Tamoxifen is an ER-antagonist, which has been 
used in breast cancer treatment for several decades (9). Although tamoxifen is effective 
in blocking proliferation of breast cancer cells, some tumors demonstrate intrinsic 
or acquired resistance to its action. Absence of the ER leads to intrinsic resistance to 
tamoxifen (10), whereas tamoxifen resistance in ER-positive breast cancer is caused by 
growth factor receptors stimulating estradiol-independent estrogen signaling (11). 
Acquired resistance to tamoxifen involves several different mechanisms, for example, 
pharmacological pathways and mutations in the ER (11,12). 
Radiotherapy aims to induce irreparable DNA damage in tumor cells, leading to tumor cell 
death. Different tumor types display varying degrees of radiosensitivity, and even within 
a single tumor radiosensitivity may vary. Three main mechanisms underlie resistance 
to radiotherapy: intrinsic resistance, tumor proliferation and hypoxia (13). The patient’s 
genetic makeup (14) and the type of breast cancer (15) are also known to influence 
radiosensitivity. Moreover, several pathways such as the DNA damage response, cell-
cycle regulation, and apoptosis are involved in radioresistance (2,16). 
Here, we describe the activation of the IFN signaling pathway in tamoxifen-resistant 
and radioresistant breast cancer. We performed RNA sequencing of tamoxifen-resistant 
and radioresistant breast cancer cells, followed by pathway analyses, in vitro studies, 
and clinical validation in three human breast cancer patient cohorts. Expression of IFN-
stimulated genes (ISG) by tumor cells is involved in treatment-induced acquired resistance 
and possibly in intrinsic resistance related to tumor-infiltrating lymphocytes (TIL).
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Material and methods
Cell culture
MCF-7 cells obtained in 2011 (LCG Standards) were cultured at 37°C with 
5% CO2 in DMEM (Lonza) supplemented with 10% (v/v) fetal bovine serum, 
20 mmol/L HEPES, 1x nonessential amino acids, 20 U/mL penicillin, 20 µg/mL 
streptomycin (all from Gibco), and 2 mmol/L L-glutamine (Lonza). T47D cells purchased 
in 2015 (LCG Standards) were cultured in RPMI (Lonza) containing identical supplements. 
All cells were cultured up to 40 passages after thawing. Wild-type cell lines and their 
resistant progeny were authenticated by short tandem repeat analysis. Mycoplasma 
tests were performed at regular intervals. 4-hydroxytamoxifen was purchased from 
Sigma Aldrich (#H7904). Cells were irradiated using an X-Rad 320ix Biological Irradiator 
(Precision X-Ray) at a dose rate of 3.1 Gy/minute. 
Creating resistant cell lines
MCF-7 or T47D cells were cultured with increasing doses of 4-hydroxytamoxifen 
up to a total dose of 10 μmol/L to acquire tamoxifen-resistant cells (4). To obtain 
radioresistant cells, wild-type cells were irradiated with 4 Gy every 2 weeks or 4 times 
1 Gy a week, in daily fractions, up to total doses of 64 Gy.
Colony forming assay
Clonogenic cell survival after treatment with 4-hydroxytamoxifen or irradiation was 
performed as described before (3,4).
Cell viability assay 
MCF-7 cells were seeded in a 96-well plate and allowed to adhere for 24 hours. Then, 
the cells were treated with different concentrations of doxorubicin (PharmaChemie 
BV) for 24 hours, after which the cells were allowed to grow for 5 days before analyzing 
cell viability using Cell Counting Kit 8 (Sigma Aldrich) according to the manufacturer’s 
instructions. Absorption values were measured using an iMark microplate absorbance 
reader (Bio-Rad Laboratories Inc.).
RNA isolation
RNA was isolated using the Total RNA Purification Kit (Norgen Biotek Corp.), with on 
column DNase treatment (RNase-Free DNase Set #79254 ; Qiagen), according to the 
manufacturer’s instructions. 
RNA sequencing
RNA from wild-type MCF-7, tamoxifen-resistant MCF-7, and radioresistant MCF-7 
cells was used as input for the Illumina TruSeq stranded RNA-seq protocol (Illumina). 
Subsequently, high-throughput sequencing was performed on an Illumina Next-seq, 
generating reads of 76 bases, using a paired end protocol. Quality control on the raw 
fastq files was performed using fastQC. Next, the fastq files were aligned to the human 
reference genome (GRCh37) using STAR_v2.4.1d (17), and raw readcounts per gene 
were estimated using HTseq (18). Raw readcounts were normalized using EdgeR (19). 
qRT-PCR
Reverse transcription of RNA and qRT-PCR were performed as described before (4). 
The following primers were used:  DDX60: FW, 5’-GTCCTTCAAGCAACCCAG-3’; and REV, 
5’-ATCTAAATAGCCCTCTTTCACC-3’; STAT1: FW, 5’-CCAAAGGAAGCACCAGAG-3’; and 
REV, 5’-TCAGACACAGAAATCAACTCAG-3’; OAS1: FW, 5’-ACTATCTCTTGCCAGACACG-3’; 
and REV, 5’-AGCCACCCTTTACCACCT-3’; IFI6: FW, 5’-CTTGTGCTACCTGCTGCT-3’; and 
REV, 5’-TTCTTACCTGCCTCCACC-3’; IFI27: FW, 5’-AGTCACTGGGAGCAACTG-3’; and REV, 
5’-CTGGCATGGTTCTCTTCTC-3’; HPRT: FW, 5’-TATTGTAATGACCAGTCAACAG-3’; and 
REV, 5’-GGTCCTTTTCACCAGCAAG-3’ (Biolegio). 
Fluorescence microscopy for BrdU staining
MCF-7 cells were seeded in glass chamberslides [Nunc™ Lab-Tek™ II (154526); 
ThermoFisher Scientific] and incubated with 10 µmol/L 5-Bromo-2’-deoxyuridine [BrdU 
(#B5002); Sigma Aldrich] for 38 hours (1.5 cell cycles). After washing, cells were treated 
with 1 µmol/L 4-hydroxytamoxifen. Cells were fixed 10 minutes in acetone at 4°C after 
0, 1, and 4 hours. Before staining, cells were rehydrated in PBS for at least 30 minutes, 
treated with 2 N HCl for 10 minutes, and neutralized with 0.1 mol/L Borax for 10 
minutes. Cells were stained with mouse anti-BrdU [B44 (#347580); BD Biosciences], 1:50 
in primary antibody diluent (PAD; Bio-Rad Laboratories Inc.). The secondary antibody 
used was CF-488-conjugated goat anti-mouse IgG [F(ab’)2 fragment (#20011); Biotium]. 
Nuclei were visualized using Hoechst 33342 (1 mg/mL) in a 1:2,000 dilution in PBS. 
Images were acquired using a Leica DM6000 microscope (Leica).
Patients: Rotterdam cohort
Expression levels of relevant genes were investigated in a cohort of 155 ER-positive 
breast cancer patients, all of whom were treated with first-line tamoxifen after 
disease recurrence. Additional details and clinical characteristics were described 
previously (20).  Microarray expression data of this cohort were used for a pathway 
analysis, using BioCarta as pathway database (https://cgap.nci.nih.gov/Pathways/
BioCarta_Pathways) and the R-package “globaltest”. Multiple testing correction was 
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performed using the Bonferroni-Holm method. Furthermore, a 1,000x resampling 
was performed to determine the number of times a randomly selected group of 
genes of equal size was at least as significant as the true set of genes assigned to a 
pathway. Pathways were considered significant when both the corrected P-value and 
the resampling probability were below 0.05.
Patients: Kaplan-Meier plotter
To assess the relation between expression of genes of interest and outcome in 
adjuvant tamoxifen-treated breast cancer patients, we used the Kaplan-Meier plotter 
at http://kmplot.com/analysis/. The characteristics of the included patients have been 
previously described (21). Analysis was restricted on the basis of received therapy 
and patients were assessed for relapse-free survival. We selected patients receiving 
endocrine treatment alone (n = 867, 85.6% ER+), (neo)adjuvant chemotherapy 
treatment alone (n = 602, 25.6% ER+) or no systemic treatment (n = 1010, 49.8% ER+). 
Patient samples were grouped on the basis of the expression of the desired gene of 
interest (Jetset best probeset) using the median cut-off value.
Patients: Radboudumc cohort 
In this cohort, the correlation between genes of interest and sensitivity to radiotherapy 
was assessed. Patients with resectable breast cancer that did not receive adjuvant 
systemic therapy and had a follow-up of at least 5 years or an event before that time, 
were selected from a previously described cohort (22,23). Comparison of the patients 
that were excluded from the original cohort by this latter criterion indicated no 
significant differences in stage, grade, or histology. Postoperative radiotherapy was 
given to the thoracic wall after an incomplete resection, infiltration of the chest or 
skin wall, or in case of nodal involvement. Parasternal irradiation was applied when 
the tumor was medially localized. Finally, whole breast irradiation was performed as 
part of breast-conserving treatment. Patients who received radiotherapy as part of 
their primary treatment (n = 243) were compared with patients who did not (n = 123). 
Statistical analysis
Statistical analysis of clonogenic survival assays, cell survival assays, and qRT-PCR 
experiments were performed using GraphPad Prism software with two-sided Student 
t test or ANOVA where appropriate. In particular, to analyze colony-forming assays for 
radiotherapy response, a linear-quadratic model for curve fitting [S = exp(αD-βD2)] 
was used and compared between the curves. 
Enriched pathways in the gene sets found after RNA sequencing were analyzed using 
the PANTHER overrepresentation test (24,25), including a Bonferroni correction for 
multiple testing. Pathways with a corrected P < 0.05 were considered significant. SPSS 
software was used to carry out all further statistical tests (SPSS Inc.). Mann-Whitney U 
and χ2 tests were used to analyze correlations between genes of interest and patient 
characteristics in the Rotterdam cohort. Relations between genes of interest and 
outcome in this cohort were assessed by Cox regression analysis, using the Breslow 
method for ties. In the Radboudumc cohort, survival curves were generated using 
the Kaplan-Meier method and differences in survival were tested with a Breslow test. 
Results
Tamoxifen-resistant breast cancer cells are cross-resistant to 
irradiation
ER-positive MCF-7 breast cancer cells that were cultured to resistance to 10 μmol/L 
4-hydroxytamoxifen [MCF-7TAM, (4)] did not show any decrease in survival when treated 
with up to 10 μmol/L of 4-hydroxytamoxifen (Fig. 1A). Wild-type MCF-7 cells (MCF-
7WT) showed a significant decrease in survival, with a surviving fraction of 0.21 after 
treatment with 1 μmol/L of 4-hydroxytamoxifen (P = 0.02 compared with MCF-7TAM), 
and surviving fractions of 0.26 and 0.15 after 5 and 10 μmol/L of 4-hydroxytamoxifen, 
respectively (P = 0.006 and P = 0.002).
Next, the radiosensitivity of MCF-7TAM was examined. In a clonogenic survival assay, 
MCF-7TAM displayed increased survival after irradiation compared with MCF-7WT (Fig. 
1B). The surviving fraction after 6 Gy was 0.01 for MCF-7WT compared with 0.09 for 
MCF-7TAM, and the surviving fraction after 8 Gy was 0.001 for MCF-7WT compared 
with 0.02 for MCF-7TAM. There was a significant difference between the curves fitted 
according to the linear-quadratic model (P < 0.0001). The β-component significantly 
differed: for the curve fitted for MCF-7WT, it was 0.08 [95% confidence interval (CI), 
0.06 - 0.09], whereas for the curve fitted for MCF-7TAM, the β-component was 0.02 
(95% CI: 0.003 - 0.04). 
MCF-7 cells that were independently cultured to tamoxifen resistance also survived 
doses up to 10 μmol/L 4-hydroxytamoxifen in a clonogenic survival assay 
(Supplementary Fig. S1A). These tamoxifen-resistant cells similarly exhibited increased 
survival after irradiation compared with wild-type MCF-7 cells (Supplementary 
Fig. S1B).
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Figure 1. Cross-resistance for radiotherapy in tamoxifen-resistant MCF-7 cells, but not for 
doxorubicin in tamoxifen-resistant and radioresistant MCF-7 cells. A and B, Clonogenic survival 
of MCF-7WT and MCF-7TAM after 24-hour treatment with 4-hydroxytamoxifen (A) or after treatment with 
irradiation (B). C, Clonogenic survival of MCF-7WT and MCF-7RT after treatment with irradiation. Curves 
in B and C were plotted using a linear-quadratic model for survival after irradiation. D, Cell viability of 
MCF-7WT, MCF-7TAM, and MCF-7RT after treatment with doxorubicin for 24 hours. Curve was plotted 
using a sigmoidal dose-response model. Data are represented as mean + SD (technical replicates, 
n = 3), and statistical significance was determined by Student t tests (A), comparison of fitted curves 
(B and C), or one-way ANOVA (D). *, P < 0.05; **, P < 0.01.
Tamoxifen-resistant and radioresistant breast cancer cells are 
not resistant to doxorubicin chemotherapy 
In a clonogenic survival assay, MCF-7 cells that were cultured to radioresistance using 
13 fractions of 4 Gy (MCF-7RT) showed an increased survival after treatment with 
increasing radiation doses compared with MCF-7WT (Fig. 1C). The surviving fraction 
after 4 Gy was 0.04 for MCF-7WT compared with 0.10 for MCF-7RT, and the surviving 
fraction after 6 Gy was 0.003 for MCF-7WT compared with 0.02 for MCF-7RT. Curves 
fitted according to the linear-quadratic model differed significantly (P < 0.0001), 
though this could not be attributed to either the α- or β-component. This phenotype 
was replicated in MCF-7 cells that were independently cultured to radioresistance 
(Supplementary Fig. S1C).
A B
C D
Both MCF-7TAM and MCF-7RT did not show an altered response to doxorubicin 
treatment compared with MCF-7WT (Fig. 1D). Because MCF-7TAM and MCF-7RT were 
not broadly resistant, it is more likely that a specific mechanism causes tamoxifen 
resistance and radioresistance, which is not involved in resistance to chemotherapy. 
This observation was repeated with MCF-7 cells independently cultured with up to 5 
μmol/L 4-hydroxytamoxifen and MCF-7 cells that had been irradiated 16 times with 
4 Gy. Again, no altered responses were observed in the resistant cell lines compared 
with wild-type MCF-7 cells  (Supplementary Fig. S1D).
Tamoxifen-resistant and radioresistant breast cancer cells show 
increased expression of ISGs
To evaluate common features of resistance in tamoxifen resistance and radioresistance, 
gene expression analysis of MCF-7WT, MCF-7TAM, and MCF-7RT was performed using 
RNA sequencing. We focused on genes that had at least 2-fold increased expression 
levels in either of the resistant cells compared with MCF-7WT. To avoid false positive 
hits due to low read coverage, genes that had less than 10 normalized read counts in 
all three samples (MCF-7WT, MCF-7TAM, and MCF-7RT) were excluded. Following these 
guidelines, expression levels of 584 genes were increased in MCF-7TAM compared with 
MCF-7WT, whereas in MCF-7RT, expression levels of 302 genes were increased (Fig. 2A). 
An overrepresentation test was performed using the PANTHER Classification system 
(24,25) to elucidate biological processes (Gene Ontology, GO) that were enriched 
within the gene set with increased expression levels in MCF-7TAM or MCF-7RT. In both 
types of resistant cells, the significantly enriched pathways (corrected P < 0.05) were 
related to the GO terms “response to IFN-α/β”, “type I IFN signaling pathway”, “IFNγ-
mediated signaling pathway”, “negative regulation of viral genome replication”, 
and “defense response to virus” (Fig. 2A).  Furthermore, 94 genes were increased in 
both MCF-7TAM and MCF-7RT (Supplementary Table S1). The only pathways that were 
significantly enriched in these 94 genes (corrected P < 0.05) were related to the GO 
terms “response to IFN-α/β/γ”, “type I IFN signaling pathway”, “negative regulation 
of viral genome replication”, “defense response to virus”, and “negative regulation of 
cellular process” (Fig. 2A). 
To further investigate the role of IFN-related signaling in tamoxifen resistance and 
radioresistance, we chose five ISGs, based on literature (26,27), to assess in in vitro 
experiments: nucleic acid recognition protein DDX60, signal transducer STAT1, and 
downstream effectors OAS1, IFI6 and IFI27. These five genes had increased mRNA 
expression levels in both types of resistant cells (Supplementary Table S1) and 
represent various steps of the IFN signaling pathway. 
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Figure 2. Higher expression of genes involved in IFN signaling in tamoxifen-resistant and 
radioresistant MCF-7 cells. A, The Venn diagram shows the number of genes with at least 2-fold increased 
expression levels in MCF-7TAM and/or MCF-7RT compared with MCF-7WT, determined by RNA sequencing. 
Significantly increased pathways (corrected P < 0.05, GO biological process) in the tamoxifen-resistant and/
or radioresistant MCF-7 cells are depicted as fold enrichment compared with the occurrence in the human 
genome, as determined by PANTHER overrepresentation test. B and C, mRNA expression of DDX60, STAT1, 
OAS1, IFI6, and IFI27 in MCF-7TAM and MCF-7RT, compared with MCF-7WT (B), and in T47D cells that have been 
cultured with up to 5 µmol/L 4-hydroxytamoxifen or have been irradiated 38 times with 1 Gy (C). qRT-PCR 
data are represented as mean + SD (technical replicates, n = 2) normalized to expression in wild-type cells, 
and statistical significance was determined by one-way ANOVA and post hoc Tukey test. *, P < 0.05; **, 
P < 0.01; ***, P < 0.001 (compared with expression levels in wild-type cells).
A
B
C
First, the increased expression levels of DDX60, STAT1, OAS1, IFI6, and IFI27 in 
MCF-7TAM and MCF-7RT were validated by qRT-PCR (Fig. 2B). In independent wild-type 
MCF-7 cells treated with increasing doses of 4-hydroxytamoxifen up to 5 µmol/L 
or weekly irradiated with 4 Gy to a total of 20 Gy, the phenotype was reproduced 
(Supplementary Fig. S1E). The different dosing regimens used here might explain 
the quantitative differences with Figure 2B. Similarly, another ER-positive breast 
cancer cell line, T47D, was cultured with increasing doses of 4-hydroxytamoxifen up 
to 5 μmol/L, or daily irradiated with 1 Gy to a total of 38 Gy. These cells also showed 
increased expression levels of DDX60, STAT1, OAS1, IFI6, and IFI27 compared with 
wild-type T47D cells (Fig. 2C). 
Tamoxifen treatment and irradiation induce ISG expression  
in vitro
The increased expression levels of DDX60, STAT1, OAS1, IFI6, and IFI27 in MCF-7TAM and 
MCF-7RT suggest that ISGs could be part of a survival mechanism induced after treatment, 
ultimately leading to a resistant phenotype. To investigate this, expression levels of 
DDX60, STAT1, OAS1, IFI6, and IFI27 were measured after a single dose of tamoxifen or 
irradiation. 
MCF-7WT was treated with 1 or 10 μmol/L 4-hydroxytamoxifen, and gene expression levels 
were measured after 24 hours. Expression levels of all five genes were increased 24 hours 
after tamoxifen treatment in a dose-dependent manner (Fig. 3A). Expression levels of 
DDX60, STAT1, OAS1, IFI6, and IFI27 were also measured 24 and 48 hours after irradiating 
MCF-7WT with 4 Gy. DDX60, OAS1, IFI6, and IFI27 showed a time-dependent increase after 
irradiation, whereas STAT1 was only slightly increased 48 hours after irradiation (Fig. 3B). 
Tamoxifen treatment induces cytoplasmic ssDNA
An earlier study showed that increased ISG expression levels after irradiation were 
caused by ssDNA in the cytoplasm (28). We hypothesized that the increased expression 
levels of ISGs after tamoxifen treatment might also be caused by cytoplasmic ssDNA. 
MCF-7WT was labelled with BrdU for 38 hours (1.5 cell cycle), and then treated with 
1 µmol/L 4-hydroxytamoxifen. After 0, 1, and 4 hours of tamoxifen treatment, BrdU 
was visualized. One hour after 4-hydroxytamoxifen treatment, we observed BrdU foci 
in the cytoplasm, which were more profound 4 hours after treatment (Fig. 3C). We 
semiquantitatively scored the cells as containing “low”, “medium”, or “high” levels of 
cytoplasmic ssDNA (Supplementary Fig. S2). The majority of cells in the untreated 
sample contain hardly any foci, whereas after 1 or 4 hours of tamoxifen treatment, 
more foci are observed in the cytoplasm of the cells (Fig. 3D). Because this particular 
BrdU antibody only recognizes BrdU incorporated in ssDNA (29), and the signal of the 
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Figure 3. ISG expression levels are increased after tamoxifen treatment or irradiation, possibly 
induced by cytoplasmic ssDNA. A and B, Gene expression of DDX60, STAT1, OAS1, IFI6, and IFI27 after 
24-hour treatment with 4-hydroxytamoxifen (A) or a single dose of 4 Gy irradiation (B). qRT-PCR data are 
represented as mean + SEM [biological replicates, n = 4 (tamoxifen) or n = 3 (irradiation)], and statistical 
significance was determined by Student t tests. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (compared with 
expression in nontreated MCF-7 cells). C, Representative images of wild-type MCF-7 cells that were 
labelled with BrdU for 38 hours and then treated with 1 µmol/L tamoxifen. Cells were fixed 0 (left), 1 
(middle), or 4 (right) hours after tamoxifen treatment and stained with Hoechst (blue) and BrdU (green). 
The experiment was performed 3 times, with all experiments showing comparable results. Scale bar, 
50 µm. D, At least 100 cells per condition were scored as having “low,” “medium,” or “high” levels of 
cytoplasmic ssDNA. Representative images of cells having “low,” “medium,” and “high” numbers of ssDNA 
foci can be found in Supplementary Fig. S2. Data, mean + SEM (biological replicates, n = 2).
dsDNA intercalator Hoechst was absent in the cytoplasm, the foci represent ssDNA. 
This indicates that tamoxifen treatment, like irradiation (28), can induce cytoplasmic 
ssDNA, which in turn is known to induce ISG expression.
Expression levels of ISGs are correlated in patients with breast 
cancer and are associated with a TIL signature
Several cohorts and specific subgroups of patients were analyzed to investigate 
the relation of ISG expression with treatment sensitivity. In the Rotterdam cohort, 
consisting of ER-positive breast cancer patients (n = 155) who were treated with first-
line tamoxifen for advanced breast cancer [Supplementary Table S2, (20)], we analyzed 
the relation of ISG expression with tamoxifen sensitivity. 
First, the 25 genes that showed the highest increase in expression levels in both MCF-7TAM 
and MCF-7RT, according to RNA sequencing (Supplementary Table S1), were analyzed in 
primary tumors of these patients. A correlation analysis revealed that expression levels 
of specifically those 18 genes that play a role in antiviral type I IFN signaling were highly 
correlated in the primary tumors from these patients (Fig. 4A; Supplementary Table S1). 
On the basis of the relative expression of those 18 ISGs, the patients could be clustered in a 
group with high expression of ISGs (ISGHIGH) and a group with low expression of ISGs (ISGLOW, 
Fig. 4B). To investigate mechanisms responsible for this a priori increase in expression of 
ISGs, we performed a Biocarta pathway analysis. Fourteen pathways were differentially 
expressed in the ISGHIGH patients compared with the ISGLOW patients (Supplementary Fig. 
S3). In 5 of these 14 pathways, there is a remarkably large contribution of STAT1 alone. 
Because STAT1 is a major regulator in the IFN signaling pathway, we investigated the 
expression of STAT1 in this cohort. The ISGHIGH patients displayed a higher expression of 
STAT1, compared with ISGLOW patients (P < 0.0001, Fig. 4C). 
There was no difference in clinical parameters (age, T/N/M staging, grade, histology, 
and subtype), or in response to tamoxifen treatment for advanced breast cancer 
(Supplementary Table S2) between the ISGHIGH and ISGLOW patients, and only in the case 
of P2RY6 was there a correlation between gene expression and treatment response in 
this cohort (P = 0.03; Supplementary Fig. S4). 
Because several of these patients showed high ISG expression levels in their primary 
tumor prior to any treatment, the increased expression of ISGs could not be caused by 
the treatment itself, as we showed in vitro. We hypothesized that the high expression 
of ISGs might be related to immune infiltration of the tumor. A previously identified TIL 
expression signature (30) was investigated in the ISGHIGH and ISGLOW patients. Indeed, 
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Figure 4. ISGs are coexpressed in breast tumors, and correlate with a TIL expression signature. 
A, Pearson correlation coefficients between the top 25 of the 94 common genes in MCF-7TAM and MCF-
7RT were clustered and visualized (red shows positive correlation, green negative) for a cohort of breast 
cancer patients. The rectangle indicates genes involved in IFN signaling. B, Heatmap showing relative 
gene expression of the 18 correlated ISGs (individual probes for each gene on vertical axis; green, 
levels below median; red, above median) in 155 primary breast cancer patients (on horizontal axis). 
C and D, Boxplot of STAT1 expression (C) and boxplot of a TIL signature expression (D) in ISGHIGH and 
ISGLOW patients, showing the median, 25th and 75th percentile. The whiskers extend to the minimum and 
maximum values. Statistical significance was determined by Mann-Whitney U testing. ***, P < 0.0001.
A
B
C D an association was found, showing an increased TIL level in the ISGHIGH patients (P < 
0.0001, Fig. 4D).
Increased ISG expression in the bulk tumor tissues of ISGHIGH patients could be due 
to expression of these genes in TILs, instead of in tumor cells as we showed in vitro. 
Therefore, IHC expression patterns of DDX60, STAT1, OAS1, IFI6, and IFI27 were 
investigated in breast cancer tissue via the publicly available database Protein 
Atlas (31). Besides expression in the TILs, identified based on their morphological 
characteristics, these five ISGs were found to be highly expressed by the tumor cells 
themselves (Supplementary Fig. S5), which is in line with our in vitro data.
High ISG expression levels are correlated with worse outcome in 
breast cancer patients treated with adjuvant tamoxifen
The online available database Kaplan-Meier plotter (21) was used to identify the 
relation between ISG expression and relapse-free survival in patients treated with 
adjuvant tamoxifen. The correlation between the five ISGs that were investigated 
in vitro and outcome was first assessed. High expression levels of DDX60 and STAT1 
were significantly associated with a shorter relapse-free survival in tamoxifen-treated 
patients only (P = 0.03 and P = 0.002), but not in patients who did not receive adjuvant 
systemic treatment or who received chemotherapy (Fig. 5A). In addition, the effects 
of the 14 other ISGs that showed correlation in patients with advanced breast cancer 
(Supplementary Table S1) were investigated. Seven of these (IFI44L, IFI44, P2RY6, 
MX1, IFIT1, OAS3, and LGASLS3BP) were also significantly correlated with relapse-free 
survival in breast cancer patients treated with adjuvant tamoxifen (P = 0.03, P = 0.03, 
P = 0.02, P = 0.001, P = 0.008, and P = 0.04), but not in patients who did not receive any 
adjuvant systemic treatment or who received chemotherapy (Fig. 5A). 
High expression levels of ISGs are correlated with worse 
outcome in breast cancer patients treated with radiotherapy
Finally, we investigated the association of DDX60, STAT1, OAS1, IFI6, and IFI27 
expression with outcome in a cohort of breast cancer patients (n = 366) who had 
not received systemic therapy and had at least 5-year follow-up or an event before 
that. To assess the association of ISGs with radiosensitivity, the cohort was analyzed 
separately for those who did or did not receive radiotherapy, as reported earlier in 
a smaller cohort (22). In patients who did not receive radiotherapy as part of their 
primary treatment (n = 123), none of the five tested ISGs exhibited any relation 
with disease-free survival (Fig. 5B). However, patients treated with radiotherapy 
(n = 243) and with upper tertile expression levels of DDX60, STAT1, OAS1, IFI6, and IFI27 
had worse disease-free survival, which reached significance in three of five genes 
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(P = 0.08, P = 0.04, P = 0.05, P = 0.06, and P = 0.01, respectively). 
Discussion
Here, we show that the IFN signaling pathway is activated in tamoxifen-resistant 
and radioresistant breast cancer. After validating the cross-resistance for irradiation 
in tamoxifen-resistant breast cancer cells in vitro, we observed increased expression 
levels of genes related to IFN signaling in both tamoxifen-resistant and radioresistant 
breast cancer cells. Expression of ISGs was induced by tamoxifen treatment or 
irradiation in vitro, potentially triggered by the presence of cytoplasmic ssDNA, which 
was observed after tamoxifen treatment and in an earlier study shown after irradiation 
Figure 5. High expression levels of ISGs are associated with worse outcome after tamoxifen 
treatment or irradiation. A, Forest plot showing the association (HRs and 95% CIs) between ISG 
expression and relapse-free survival after no systemic treatment [n = 1,010, # n = 61 (# = OAS2, IFIT3, 
APOL6, and DDX58)], or after chemotherapy (n = 421, # n = 104), or tamoxifen treatment (n = 867, # 
n = 181). B, A cohort of 366 breast cancer patients was divided into patients treated with (n = 123) or 
without radiotherapy (n = 243). For each group, disease-free survival was assessed for patients with 
high (upper tertile, black) levels of DDX60, STAT1, OAS1, IFI6, or IFI27, or those with low levels of these 
genes (grey). Statistical significance was determined with the Breslow method.
A
B
(28). We hypothesize that prolonged treatment with tamoxifen or repeated fractions 
of irradiation leads to the increased ISG expression found in tamoxifen-resistant and 
radioresistant breast cancer cells. In a breast cancer patient cohort, we investigated 
the 25 genes whose expression levels were most increased in both tamoxifen-resistant 
and radioresistant breast cancer cells. Specifically, the expression of genes related to 
IFN signaling was highly correlated in breast cancer patients. On the basis of this set 
of correlated genes, the patients could be clustered in groups with high and low ISG 
expression levels, which in turn significantly correlated with STAT1 expression and a 
TIL expression signature in these patients. 
Of note, in tumor samples ISGs were expressed by tumor cells, instead of being solely 
expressed by TILs. This suggests that increased ISG expression levels by the tumor 
itself could influence the antitumor immune response. Finally, high ISG expression 
in breast cancer patients was correlated to worse outcome in patients treated with 
adjuvant tamoxifen or radiotherapy. Although our in vitro data point to a role of IFN 
signaling in acquired treatment resistance, our patient data indicate that the same 
pathway may also be involved in intrinsic resistance. 
Although the decreased radiosensitivity of tamoxifen-resistant breast cancer cells 
has been observed before (5,6), and we have previously identified mechanisms that 
play a role in both tamoxifen resistance and radioresistance (3,4), this is the first 
nontargeted approach to find common features of resistance in these two types 
of treatment resistance in breast cancer. The only pathways that were significantly 
increased in both tamoxifen-resistant and radioresistant breast cancer cells were 
related to IFN signaling. Similarly, an immune-associated gene signature is increased 
in tamoxifen-resistant mice bearing a targeted overexpression of the ER (32), and a 
comparable signature is a predictive marker for radiation in breast cancer (33). Our 
data confirm and extend the data on IFN signaling as an important pathway that 
tamoxifen-resistant and radioresistant breast cancer cells share. 
However, we have not assessed the direct cause of the cross-resistance for radiation 
in tamoxifen-resistant breast cancer cells. Previous research (34) showed that there is 
differential expression of DNA damage (repair) genes in tamoxifen-resistant breast cancer 
cells after irradiation, which may explain the cross-resistance we and others observe. 
In this study, we chose five genes to represent the IFN signaling pathway, spanning 
the entire IFN response. DDX60 is involved in recognition of viral RNA/DNA (35), STAT1 
is an important mediator directly downstream of the IFN receptor (36), and OAS1, IFI6, 
and IFI27 are all IFN-induced effectors that perform different functions in mediating 
34
2 
In
te
rfe
ro
n-
sti
m
ul
at
ed
 g
en
es
35
the IFN response. OAS1 is involved in inhibiting viral replication (37), whereas IFI6 
and IFI27 play a role in apoptosis (38). All five were increased after a single dose of 
tamoxifen treatment or irradiation. It had already been established that tamoxifen 
induces mRNA expression of ISGs (39), and that DNA damage caused by radiation 
can induce an IFN response (33, 40). However, this had not yet been investigated in 
the context of treatment resistance. Earlier studies showed that ISG expression after 
irradiation is induced by cytoplasmic DNA, mediated by DNA sensors (28, 41). We 
show here that tamoxifen treatment also induced cytoplasmic ssDNA, which is likely 
to cause the increased mRNA expression of ISGs after tamoxifen treatment. Although 
the exact mechanism mediating this is currently unknown, tamoxifen is known to 
have genotoxic effects (42), which might lead to cytoplasmic DNA. DNA sensors such 
as STING and DDX60 could subsequently mediate an IFN response. 
Our data suggest that treatment induction of ISG expression leads to the increased 
ISG expression levels found in tamoxifen-resistant and radioresistant cells. This 
is illustrated by the fact that both MCF-7 cells cultured for longer periods of time 
with 10 µmol/L tamoxifen, as well as those that were cultured with only 5 µmol/L 
tamoxifen, showed increased mRNA levels of ISGs. Similarly, different irradiation 
schedules increase ISG expression levels in MCF-7 and T47D cells. Prolonged exposure 
to tamoxifen or repeated fractions of irradiation, as are applied clinically, could 
provide a survival advantage for a subset of cells and contribute to the development 
of therapy resistance. 
Cross-resistance for radiotherapy induced by tamoxifen treatment could pose a 
problem for breast cancer patients, as neoadjuvant endocrine treatment before 
surgery is now considered a viable treatment option. In several ongoing clinical 
trials, patients with ER-positive breast cancer are given three or four months of 
endocrine treatment before surgical removal of the tumor (43). When radiotherapy 
is subsequently applied after surgery, these patients could face an increased risk of 
radioresistance induced by endocrine treatment. In addition, patients that have been 
treated with adjuvant endocrine treatment might respond poorly to radiotherapy 
when applied after recurrence to, for instance, painful bone metastases. Our results 
suggest that these patients might benefit from additional treatment specifically 
targeting the IFN signaling pathway. This approach has been tested in vitro in the 
case of aromatase inhibitor resistance. Aromatase inhibitor-resistant breast cancer 
cells show increased expression levels of ISGs in vitro, and targeting these genes 
resulted in a sensitization of the resistant cells (27). A similar approach should be 
further investigated for tamoxifen resistance.
The interaction between IFN signaling and breast cancer treatment is not 
unambiguous. The ISG signature published by Weichselbaum et al. (33) is not only 
predictive for poor outcome after radiotherapy, but also after chemotherapy. 
However, we show here that the cross-resistance for irradiation in tamoxifen-
resistant breast cancer cells did not extend to doxorubicin in vitro and that ISGs 
were not linked to outcome after chemotherapy in a breast cancer patient cohort. 
Moreover, in another study chemo-responsive, patient-derived, ER-negative breast 
cancer xenografts show activation of the IFN signaling pathway (44). These opposite 
results found in different studies highlight the diverse effects that IFN signaling can 
have on treatment outcome. IFN signaling can both stimulate and suppress immune 
functions, and also has immune-independent effects (45). This is illustrated by the 
fact that in earlier studies IFN was administered to breast cancer patients treated 
with tamoxifen to prevent resistance (46-48). However, as IFN induces expression of 
ISGs (36), our data suggest that administration of IFN could promote resistance. This 
complex interplay between ISG expression and breast cancer treatment, its effects 
on tumor cells and immune cells in the tumor microenvironment, and the relation 
with patient outcome need to be further investigated before translating these data 
to the clinic. 
Patient and tumor characteristics are likely to impact the relation between ISG 
expression, treatment, and outcome. We have investigated the association between 
ISG expression and outcome in a set of cohorts, in which patient characteristics differ 
greatly. The Rotterdam cohort consists of all ER-positive breast cancer patients, who 
have not been systemically treated for their primary disease (20). They have all had a 
recurrence of the disease, for which they have been treated with first-line tamoxifen. 
In another patient set, using an online available database (21), we compared 
systemically untreated patients with patients receiving adjuvant tamoxifen or (neo)
adjuvant chemotherapy. Although the group that received endocrine treatment was 
almost completely ER-positive, only 25.6% of the patients receiving chemotherapy 
and 49.8% of the systemically untreated patients were ER-positive. 
Moreover, immune infiltration in the tumor microenvironment differs between 
breast cancer subtypes, and this influences disease outcome (49). The presence of 
TILs in the tumor microenvironment is generally associated with a better outcome 
in breast cancer (50), although this is highly dependent on breast cancer subtype. 
TILs inducing a suppressive immune phenotype may result in worse disease outcome 
(49). We show that ISG expression levels in primary breast tumors correlated with 
a TIL expression signature. An earlier study already found that STAT1 expression is 
correlated to macrophage infiltration in breast cancers and a worse outcome (51). This 
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also raises the question whether ISG expression by tumor cells increases the presence 
of TILs in the tumor microenvironment, or whether TILs induce ISG expression in the 
tumor cells. An interesting approach to investigate this further would be to directly 
compare TIL percentages in breast tumors to ISG expression of the bulk tumor. The 
effect that IFN-related signaling by tumor cells has on immune cells in the tumor 
microenvironment could then be further investigated. 
In conclusion, we show here that resistance to tamoxifen treatment and irradiation 
share a common feature: activation of the IFN signaling pathway. We show that this 
pathway plays a role in acquired therapy resistance, as it is induced by treatment in 
vitro. It might also be involved in intrinsic therapy resistance, based on the increased 
expression of ISGs in a substantial amount of breast cancer patients in their primary 
tumor before treatment and an association with a TIL expression signature. The 
interaction between IFN signaling by tumor cells and immune cell infiltration in 
the tumor microenvironment should be studied in detail before potential targeted 
therapies toward this pathway can be considered.
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Supplementary data
Supplementary Figure 1. Resistant phenotypes and increased expression levels of ISGs in MCF-7 
cells that were independently cultured to tamoxifen resistance and radioresistance. A, Clonogenic 
survival after 24-hour treatment with 4-hydroxytamoxifen of wild-type MCF-7 cells and MCF-7 cells 
cultured with up to 9 μmol/L 4-hydroxytamoxifen. There is a significant difference between the wild-
type and tamoxifen-resistant cells at each dose. B, Clonogenic survival of cells in A after treatment 
with irradiation. There was a significant difference between the curves fitted according to the linear-
quadratic model (P < 0.0001). C, Clonogenic survival  after treatment with irradiation of wild-type MCF-
7 cells and MCF-7 cells that had been irradiated 13 times with 4 Gy. There was a significant difference 
between the curves fitted according to the linear-quadratic model (P < 0.0001). This was due to a 
significant difference in the β-component. Curves in B and C were plotted using a linear-quadratic 
model for survival after irradiation. D, Cell viability after treatment with doxorubicin for 24 hours of 
wild-type MCF-7 cells, MCF-7 cells cultured with up to 5 μmol/L 4-hydroxytamoxifen, and MCF-7 cells 
that were irradiated 16 times with 4 Gy. Curve was plotted using a sigmoidal dose-response model. E, 
mRNA expression levels of DDX60, STAT1, OAS1, IFI6, and IFI27 after MCF-7 cells have been cultured with 
up to 5 µmol/L 4-hydroxytamoxifen or have been irradiated 5 times with 4 Gy. Data are represented 
as mean + SD (technical replicates, n = 3 or n = 2 for qRT-PCR data) and statistical significance was 
determined by Student t tests (A), comparison of fitted curves (B and C) or one-way ANOVA (D and E). 
qRT-PCR data are normalized to mRNA expression levels in wild-type MCF-7 cells, and one-way ANOVA 
was followed by post hoc Tukey tests. * P < 0.05, ** P < 0.01, *** P < 0.001.
Supplementary Figure 2. Representative images showing MCF-7 cells with “low”, “medium” and 
“high” amounts of BrdU foci. Wild type MCF-7 cells were labelled with BrdU for 38 hours, and then 
treated with 1 µmol/L tamoxifen. Cells were fixed 0, 1, or 4 hours after tamoxifen treatment and stained 
with anti-ssDNA BrdU. These three figures were randomly chosen from among those time points to 
show representative images that were scored as having A, “low”; B, “medium”;  and C, “high” amounts of 
BrdU foci. Scale bars equal 50 µm.
A
C
B
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Supplementary Figure 3. Pathways associated with high or low ISG expression levels in breast cancer 
patients. Significantly associated pathways identified by Biocarta pathway analysis, based on microarray 
expression data of the Rotterdam cohort. The length of the bar indicates the statistical contribution of a single 
gene to the P-value of the pathway. Green bars indicate genes with higher expression levels in the ISGHIGH patients, 
red bars are genes with higher expression levels in ISGLOW patients. The horizontal black lines in a bar indicate the 
mean (thick line) and SD (thin line) of a gene. 
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Supplementary Figure 4. Correlation of ISG expression levels to outcome in patients with 
advanced breast cancer. Forest plot showing the association (Cox regression and Breslow; hazard 
ratios and 95% confidence intervals) between ISG expression levels and time to progression after 
first-line tamoxifen treatment in the Rotterdam cohort (n = 155).
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Supplementary Figure 5. Protein expression of ISGs in human breast tumors.
Staining patterns of A, DDX60 (patients 1874 & 1775); B, STAT1 (patient 2174, ab HPA000982 & patient 
1953, ab HPA000931); C, OAS1 (patient 1977, ab HPA003657 & patient 1953, ab CAB021104); D, IFI6 
(patients 1977 & 2898); and E, IFI27 (patients 1916 & 2428). Bars equal 100 µm.
Links to the Human Protein Atlas:
DDX60: http://www.proteinatlas.org/ENSG00000137628-DDX60/cancer
STAT1: http://www.proteinatlas.org/ENSG00000115415-STAT1/cancer
OAS1: http://www.proteinatlas.org/ENSG00000089127-OAS1/cancer
IFI6: http://www.proteinatlas.org/ENSG00000126709-IFI6/cancer
IFI27: http://www.proteinatlas.org/ENSG00000165949-IFI27/cancer
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Gene name Fold increase Fold increase Correlated in IFN-
MCF-7TAM MCF-7RT patients related
IFI44L 274.3 25.4 Yes Yes
IFI27 155.3 45.5 Yes Yes
DDX60 96.3 78.5 Yes Yes
IFI44 120.3 16.0 Yes Yes
P2RY6 73.0 16.9 Yes Yes
XAF1 85.3 3.8 Yes Yes
OAS2 77.8 4.3 Yes Yes
IFI6 41.7 20.9 Yes Yes
ATP8A2 37.1 25.0 No No
MMP16 29.2 32.4 No No
LGI1 4.1 48.6 No No
LRFN5 37.1 4.3 No No
CEMIP 24.5 5.0 No No
MX1 18.5 7.6 Yes Yes
ABCA4 22.9 2.5 No No
IFIT1 15.0 8.0 Yes Yes
OAS3 13.0 8.4 Yes Yes
IFIT3 11.0 9.4 Yes Yes
BST2 13.7 6.4 Yes Yes
APOL6 14.4 4.8 Yes Yes
APOD 7.3 9.4 No No
OAS1 12.4 4.3 Yes Yes
PSMB8 11.8 3.1 Yes Yes
LGALS3BP 10.4 4.2 Yes Yes
DDX58 6.6 7.8 Yes Yes
LIMCH1 11.6 2.3 NA NA
PARP10 9.3 4.1 NA NA
RP11-6N13.1 9.3 3.3 NA NA
CRYBG3 10.5 2.1 NA NA
HERC6 4.3 7.5 NA NA
VTCN1 3.2 8.4 NA NA
UBE2L6 7.6 3.7 NA NA
NAV3 7.8 3.2 NA NA
Supplementary Table 1
List of the 94 genes with increased expression levels in both MCF-7TAM and MCF-7RT
For each gene, the fold increase in expression levels in MCF-7TAM and MCF-7RT compared to MCF-7WT is 
shown (based on normalized read counts). Moreover, the genes that are correlated in breast cancer 
patients and the relation of these genes to IFN signaling are indicated. The genes used for in vitro 
experiments are represented in bold. NA = not assessed.
Gene name Fold increase Fold increase Correlated in IFN-
MCF-7TAM MCF-7RT patients related
ST8SIA4 4.6 6.4 NA NA
IFITM1 6.1 4.8 NA NA
LINC00052 3.9 6.5 NA NA
IRF9 7.2 2.6 NA NA
ANXA9 7.5 2.1 NA NA
SHISA2 3.0 6.2 NA NA
REC8 6.8 2.3 NA NA
SGCG 5.7 3.1 NA NA
PRKAR2B 3.1 5.7 NA NA
AMOT 6.0 2.7 NA NA
ISYNA1 6.2 2.4 NA NA
MALRD1 5.5 3.1 NA NA
AR 3.3 5.1 NA NA
INPP5J 5.1 3.2 NA NA
DOCK10 3.2 5.1 NA NA
CPAMD8 4.6 3.5 NA NA
PARP9 5.2 2.8 NA NA
GBP3 4.3 3.7 NA NA
C15orf59 2.2 5.7 NA NA
HNRNPU-AS1 5.7 2.2 NA NA
SFMBT2 5.8 2.0 NA NA
TMOD2 4.3 3.4 NA NA
IL1R1 2.8 4.8 NA NA
SERPINA1 5.0 2.6 NA NA
IGFBP3 5.1 2.4 NA NA
DMRTA1 4.0 3.4 NA NA
IFIH1 4.7 2.3 NA NA
DHRS2 3.8 3.1 NA NA
SERPINA5 3.6 3.0 NA NA
FSTL4 3.9 2.5 NA NA
SFXN5 2.4 3.9 NA NA
TSPAN12 2.4 3.9 NA NA
PARP14 3.8 2.4 NA NA
ALDH3B2 3.7 2.4 NA NA
RNF43 3.3 2.6 NA NA
CYP4F11 3.5 2.4 NA NA
RP5-1024G6.8 3.4 2.5 NA NA
VDR 3.1 2.7 NA NA
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Gene name Fold increase Fold increase Correlated in IFN-
MCF-7TAM MCF-7RT patients related
LRP1B 3.4 2.3 NA NA
CLU 2.3 3.4 NA NA
IFIT2 2.2 3.3 NA NA
CHST11 3.2 2.3 NA NA
ISG15 3.2 2.2 NA NA
MDK 2.5 2.9 NA NA
IL6ST 2.8 2.5 NA NA
STAT1 3.2 2.1 NA NA
DOC2A 2.9 2.3 NA NA
SHROOM3 2.4 2.8 NA NA
CCDC159 3.0 2.2 NA NA
IFITM3 2.7 2.3 NA NA
CAMK1D 2.1 2.7 NA NA
REEP6 2.6 2.2 NA NA
STC1 2.7 2.0 NA NA
SNED1 2.4 2.3 NA NA
BAMBI 2.6 2.0 NA NA
GCAT 2.5 2.1 NA NA
SP110 2.1 2.4 NA NA
EIF2AK2 2.4 2.1 NA NA
TFAP2A 2.4 2.0 NA NA
PLCXD1 2.1 2.2 NA NA
SAMHD1 2.1 2.0 NA NA
Used in in vitro studies 
NA: not assessed
Average Total ISGLOW ISGHIGH P
Age 55.7 57.3 53.9 0.11 a
n Total ISGLOW ISGHIGH P
155 82 73
Histological grade 0.66 b
I/II 23 13 10
III 85 45 40
Histology 0.18 b
Ductal 99 52 47
Lobular 19 10 9
Subtype 0.38 b
Basal 3 2 1
Her2 17 8 9
LumA 33 21 12
LumB 97 47 50
Tumor size 0.87 b
pT1 44 23 21
pT2 85 46 39
pT3/4 19 9 10
Nodal status 0.44 b
Negative 82 41 41
Positive 73 41 32
Metastasis 0.78 b
Negative 135 72 63
Positive 20 10 10
n Total ISGLOW ISGHIGH P
Tamoxifen response
Good 102 55 47 0.73 b
Poor 53 27 26
a Mann-Whitney U
b χ2
Supplementary Table 2
Clinicopathological characteristics of all patients in the Rotterdam cohort and comparison 
between ISGHIGH and ISGlow subgroups
Age, tumor characteristics, and response to first line tamoxifen are shown for the Rotterdam cohort, 
separated in ISGHIGH and ISGLOW patients. The statistical test used to analyze differences between the 
subgroups is indicated for each variable.
52
2 
In
te
rfe
ro
n-
sti
m
ul
at
ed
 g
en
es
53
Average Total No RT RT P
Age 60 61.4 59.2 0.09 a
n Total No RT RT P
366 123 243
Histological grade 0.69 b
I/II 132 35 97
III 118 34 84
Histology 0.07 b
Ductal 247 67 180
Lobular 59 23 36
Tumor size <0.01 b
pT1 191 46 145
pT2 148 68 80
pT3/4 27 9 18
Nodal status 0.005 b
Negative 290 101 189
Positive 65 11 54
Metastasis 0.78 b
Negative 366 123 243
Positive 0 0 0
a Mann-Whitney U
b χ2
Supplementary Table 3
Clinicopathological characteristics of all patients in the Radboudumc cohort and comparison 
between groups that did or did not receive radiotherapy
Age and tumor characteristics are shown for the Radboudumc cohort, separated in patients that did 
receive radiotherapy and those that did not receive radiotherapy. The statistical test used to analyze 
differences between the subgroups is indicated for each variable.
Chapter 3
The role of DNA sensing pathways 
in response to tamoxifen treatment 
or irradiation in breast cancer
In progress
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Abstract
Purpose
The success of radiotherapy and tamoxifen in the treatment of breast cancer is 
hampered by the occurrence of treatment resistance. We previously showed with 
an untargeted approach that IFN-stimulated genes (ISGs) were increased in both 
radioresistant and tamoxifen-resistant breast cancer cells in vitro. Together with 
the induction of ISGs, irradiation and tamoxifen treatment caused the presence of 
ssDNA in the cytoplasm. Here, we aimed to find the DNA sensors and subsequent 
signaling pathways involved in recognizing ssDNA in the cytoplasm and inducing an 
IFN response in breast cancer cells after irradiation or tamoxifen treatment. 
Experimental Design
Estrogen receptor-positive breast cancer cells (MCF-7) were treated with a single dose 
of irradiation or tamoxifen. First, the location of several DNA sensors after irradiation 
was visualized using fluorescence microscopy. Second, the expression of ISGs after 
treatment was measured, and compared to cells in which DNA sensors or signaling 
proteins were inhibited.
Results
The location of two DNA sensors, DNA-PKcs and DDX60, was visualized after 
irradiation. DNA-PKcs was localized in the nucleus, while DDX60 was present in the 
cytoplasm. For both DNA-PKcs and DDX60, knock-down or inhibition – in combination 
with irradiation or tamoxifen treatment – caused an increase of ISGs or did not affect 
expression of ISGs compared to control-treated cells that were irradiated or treated 
with tamoxifen. On the other hand, treatment with an aspecific inhibitor of STING, a 
downstream effector of several DNA sensors, seemed to decrease the expression of 
ISGs after irradiation or tamoxifen treatment, compared to control-treated cells that 
were irradiated or treated with tamoxifen.
Conclusions
The two investigated DNA sensors are not involved in the activation of an IFN response 
after irradiation or tamoxifen treatment. The STING pathway is likely to play a role in 
this process. The DNA sensor recognizing the cytoplasmic ssDNA and subsequently 
activating STING has yet to be identified.
Introduction
Radiotherapy and endocrine treatment (e.g. tamoxifen) are important components in 
the treatment of breast cancer. The mechanism by which these treatment modalities 
target tumor cells is different. While radiotherapy induces DNA double-strand breaks 
to induce cell death, tamoxifen’s mode of action is to block estradiol binding to the 
estrogen receptor (ER). In this way, tamoxifen inhibits a vital signaling pathway that 
regulates survival in a large percentage of breast cancers (1). Both radiotherapy and 
tamoxifen treatment contribute to the relatively high survival rates in patients with 
breast cancer (2). However, resistance to treatment leads to recurrences and adverse 
outcome in breast cancer patients (3,4). 
Strikingly, ER-positive MCF-7 breast cancer cells that acquired tamoxifen resistance 
are cross-resistant to irradiation in vitro (5-7). This has led us to investigate common 
mechanisms in both types of resistance. We previously investigated the IFN signaling 
pathway, which was found to be activated in radioresistant and tamoxifen-resistant 
breast cancer cells (7). IFN-stimulated genes (ISGs) were upregulated after a single 
dose of irradiation or tamoxifen treatment in vitro. Moreover, tamoxifen treatment 
induced the presence of ssDNA in the cytoplasm of breast cancer cells (7). Others 
already showed that cytoplasmic ssDNA occurs after irradiation (8).
Cytoplasmic DNA is usually encountered by cells as a result of viral infections. 
Dedicated DNA sensors recognize single-stranded or double-stranded DNA in the 
cytoplasm, and trigger an immune response via IFN signaling (9). After irradiation, 
the DNA sensor cGAS responds to cytoplasmic DNA and cooperates with signal 
transducer STING (TMEM173) to induce an IFN response (8, 10, 11). 
Other DNA sensors that could be involved in recognizing cytoplasmic ssDNA are DNA-
PKcs (PRKDC) and DDX60. Together with Ku70 and Ku80, DNA-PKcs forms the DNA-PK 
complex, which is well known for its role in non-homologous end joining to repair 
DNA damage (12). Its DNA sensing role is not well characterized (13,14). As a DNA 
damage repair protein, DNA-PKcs could play a role in the increased radioresistance 
observed in tamoxifen-resistant breast cancer cells (5-7). DDX60 is part of a protein 
complex required for the recognition of RNA or DNA in the cytoplasm after viral 
infection, and the subsequent initiation of a type I IFN response (15). We have 
previously investigated DDX60 as one of the reporter genes to measure the induction 
of an IFN response after irradiation or tamoxifen treatment (7). Therefore, it would 
be interesting to investigate further if DNA-PK or DDX60 could be a possible link in 
sensing ssDNA and inducing an IFN response. 
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Here, we investigated the role of DNA sensors DNA-PKcs and DDX60, and signal 
transducer STING in inducing an IFN response after irradiation or tamoxifen treatment. 
The role of DNA-PKcs and DDX60 in sensing cytoplasmic ssDNA was investigated 
by visualization of these proteins by fluorescent microscopy to identify possible 
colocalization with ssDNA. The role of DNA-PKcs, DDX60, and STING in inducing an 
IFN response was evaluated by measuring the expression of ISGs after irradiation or 
tamoxifen treatment while inhibiting expression of these three proteins. Identifying 
the pathway that links ssDNA presence in the cytoplasm and the induction of an IFN 
response after irradiation and tamoxifen treatment will add to the characterization of 
the activation of an IFN response in radioresistance and tamoxifen resistance.
Materials and methods
Cell culture
ER-positive MCF-7 breast cancer cells (LCG Standards) were cultured as described 
before (7). Creating radioresistant and tamoxifen-resistant cells was performed as 
reported earlier (7, 16). 
Chemicals
4-hydroxytamoxifen was purchased from Sigma Aldrich (H7904). The DNA-PKcs 
inhibitor NU7441 was purchased from Selleckchem (S2638) and the STING inhibitor 
CCCP was from MedChemExpress (HY-100941).
RNA isolation
RNA to be used for RNA sequencing was isolated using the Total RNA purification 
Kit (Norgen Biotek Corp.), with on column DNase treatment (RNase-Free DNase Set 
#79254; Qiagen), according to the manufacturer’s instructions. RNA for qRT-PCR 
analysis was isolated using the Quick-RNA™ Miniprep kit (Zymo Research), with on 
column DNase treatment, according to the manufacturer’s instructions.
RNA sequencing
RNA sequencing of wild-type MCF-7 cells, radioresistant MCF-7 cells, and tamoxifen-
resistant MCF-7 cells was described previously (7).
Fluorescence microscopy 
MCF-7 cells were seeded in glass chamberslides [Nunc™ Lab-Tek™ II (154526); 
ThermoFisher Scientific]. After being allowed to attach, cells were irradiated with 2 Gy 
(for DNA-PKcs imaging) or 4 Gy (for DDX60 imaging), using an X-Rad 320ix Biological 
Irradiator (Precision X-Ray) at a dose rate of 3.1 Gy/minute. Slides were fixed in acetone 
at 4°C for 10 minutes: 0, 1, 4, and 24 hours after irradiation for DNA-PKcs imaging; or 
24 and 48 hours after irradiation for DDX60 imaging. Chamberslides were rehydrated 
in PBS and stained overnight at 4 °C with rabbit anti-DNA-PKcs (ab230; Abcam) 
diluted 1:200, or rabbit anti-DDX60 (#HPA046952; Sigma-Aldrich) diluted 1:50. Both 
antibodies were diluted in primary antibody diluent (PAD; Bio-Rad Laboratories Inc.). 
The secondary antibody used was Alexa Fluor 488-conjugated donkey anti-rabbit IgG 
(#A21206; Invitrogen) diluted 1:400 in PAD, and stained for 1h at room temperature. 
Nuclei were visualized using Hoechst 33342 (1mg/ml) in a 1:3000 dilution in PBS. 
Images were acquired using a Leica DM6000 microscope (Leica). 
Transfection
MCF-7 cells were seeded in 6-well plates 24 hours before transfection. Cells were 
transfected with siRNA against DDX60 (sc-89167), DNA-PKcs (sc-35200) or a control 
siRNA (sc-37007; all from Santa Cruz Biotechnology). Lipofectamine RNAiMAX reagent 
(#13778075; Invitrogen) was diluted in Opti-MEM Medium (Gibco). The siRNAs were 
diluted in Opti-MEM Medium separately with a final concentration of 25 pmol/well. 
The siRNA dilution was added to the Lipofectamine dilution (ratio 1:1) and incubated 
at room temperature for 5 minutes. The siRNA-lipid complex was then added to the 
cells. 
cDNA synthesis
500 ng of isolated RNA was reverse transcribed to cDNA. First, RNA was incubated 
with random hexamer primers (#11034731001; Roche Diagnostics) and dNTPs (#NU-
0020-50; Kaneka Eurogentec) at 65°C for 5 min. Next, first strand buffer (#1843648; 
Invitrogen), DTT (M-MLV Reverse Transcriptase Buffer #18057-018; Invitrogen), 
RNAsin (#N2515; Promega), and reverse transcriptase (#28025-021; Invitrogen) were 
added. The following program was run on a thermocycler: 10 min at 25°C, 50 min at 
37°C and 15 min at 70°C. The newly acquired cDNA was diluted 6.5 times and used for 
quantitative real time pcr (qRT-PCR).
qRT-PCR
Gene expression was analyzed using a CFX96 real-time PCR detection system 
(Bio-Rad Laboratories Inc.) with SYBR Green (#18168621, Roche) and primers as 
described before (7). Primers for DNA-PKcs and STING were as follows: DNA-PKcs: FW, 
5’-GCTATATTGGATGGAATTGTGGAC-3’; and REV, 5’-GCGATTTGGTGTTTACTGGA-3’; 
STING: FW, 5’-GCACTGAACATCCTCCTG-3’; and REV, 5’-GTAATATGACCATGCCAGCC-3’ 
(Biolegio). 
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and MCF-7TAM, respectively. STING expression was 4.1 times increased in MCF-7RT and 
4.8 times increased in MCF-7TAM. As these genes were upregulated in radioresistant 
and tamoxifen-resistant cells, they could indeed play a role in recognizing cytoplasmic 
ssDNA or inducing an IFN response after irradiation or tamoxifen treatment in MCF-7 
breast cancer cells.
Visualization of DNA-PKcs after irradiation and measuring ISG 
expression after irradiation or tamoxifen treatment combined 
with DNA-PKcs knock-down or inhibition
To investigate whether DNA-PKcs can bind cytoplasmic ssDNA after irradiation, DNA-
PKcs localization was visualized in MCF-7WT after irradiation (Fig. 2). MCF-7 cells were 
irradiated with 2 Gy and fixed after 0, 1, 4, and 24 hours. DNA-PKcs was located inside 
the nucleus at all timepoints after irradiation and only a weak signal was observed in 
the cytoplasm. Based on localization, DNA-PKcs is not likely to recognize cytoplasmic 
ssDNA after irradiation. 
Next, we investigated the role of DNA-PKcs in inducing an IFN response after irradiation. 
MCF-7 cells were transfected with a siRNA for DNA-PKcs and subsequently irradiated 
with 4 Gy. Expression levels of IFI6, IFI27, OAS1, DDX60 and STAT1 were measured 24 
and 48 hours after irradiation. These five ISGs were previously chosen to represent the 
activation of the IFN signaling pathway (7). The expression of all five ISGs was increased 
in cells with a knock-down of DNA-PKcs compared to the cells where a control siRNA 
was transfected (Fig. 3A-E). This was the case both for unirradiated and irradiated cells. 
The knock-down was successfully performed (Fig. 3F). 
Protein isolation
Cells were harvested in RIPA buffer (#9806; Cell Signaling Technology) to which 
phosphatase and protease inhibitors (Roche Diagnostics) were added. Protein 
concentrations were measured using the Pierce BCA Assay (ThermoFisher Scientific).
Western blot
Equal amounts of protein (20 µg) were loaded on 4-12% Criterion XT Bis-Tris gels 
(Bio-Rad Laboratories Inc.). After electrophoresis, samples were transferred to PVDF 
membranes (Millipore Immobilon) for 30 minutes at 4°C. After blocking with 5% (w/v) 
bovine serum albumin (BSA; Sigma Aldrich) in Tris-buffered saline with 0.1% Tween-20 
(TBS-T; SRE0031; Sigma Aldrich), membranes were incubated overnight at 4°C with 
rabbit anti-TMEM173/STING (#19851-1-AP; Proteintech Group Inc.) or rabbit anti-
phospho-STING (Ser366; #19781S; Cell Signaling Technology Inc.) diluted 1:1000 in 5% 
BSA. Next, membranes were incubated with horseradish peroxidase (HRP)-labeled goat 
anti-rabbit IgG (#7074S; Cell Signaling Technology), 1:5000 in 5% BSA for 1 hour at room 
temperature. As loading control, mouse anti-α-tubulin IgG (#2144S; Cell Signaling 
Technology) was used in a dilution of 1:1000 in 5% BSA followed by HRP-labeled anti-
mouse IgG (#7076S, Cell Signaling Technology Inc.) 1:5000 in 5% BSA. Proteins were 
visualized using chemiluminescent peroxidase substrate (Sigma Aldrich) and imaged 
on a ChemiDoc XRS+ imaging system (Bio-Rad Laboratories Inc.). 
Statistics
Statistical analyses of qRT-PCR experiments were performed using GraphPad Prism 
software with two-sided Student t test. Two-sided P-values of less than 0.05 were 
considered statistically significant.
Results
Expression of DNA-PKcs, DDX60, and STING in radioresistant and 
tamoxifen-resistant breast cancer cells
Here, we aimed to investigate the role of DNA-PKcs, DDX60, and STING in recognizing 
cytoplasmic ssDNA and activating an IFN response after irradiation or tamoxifen 
treatment in breast cancer cells. First, the expression of DNA-PKcs, DDX60, and STING 
was assessed in RNA sequencing data from MCF-7 breast cancer cells that were cultured 
to radioresistance (MCF-7RT) or tamoxifen resistance [MCF-7TAM, (7)]. All three genes had 
an increased expression in both MCF-7RT and MCF-7TAM compared to wild-type MCF-7 
cells (MCF-7WT, Fig. 1). DNA-PKcs expression was 1.6 times increased in MCF-7RT and 1.4 
times increased in MCF-7TAM. DDX60 was 79 and 96 times higher expressed in MCF-7RT 
Figure 1. Expression of DNA-PKcs, DDX60 and STING in radioresistant and tamoxifen-resistant 
MCF-7 cells. RNA sequencing of resistant cell lines was performed, and relative expression compared 
to wild-type MCF-7 cells calculated.
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The experiment was repeated using a DNA-PKcs inhibitor instead of performing a 
knock-down. The DNA-PKcs inhibitor NU7441 (1 µmol/L) was added to the cells for 1 
hour. ISGs were again measured 24 and 48 hours after irradiation. In most conditions, 
there was no significant change in expression of ISGs when NU7441 had been added 
to the cells, compared to those treated with DMSO (Fig. 4A-C) In the few cases where 
a significant change was observed, there was an increased gene expression (Fig. 4D-
E).
Next, the role of DNA-PKcs in mediating an IFN response after tamoxifen treatment 
was investigated. MCF-7 cells were transfected with a siRNA for DNA-PKcs and 
subsequently treated with 4-hydroxytamoxifen (0, 1 or 10 µmol/L) for 24 hours. 
Expression levels of IFI6, IFI27, OAS1, DDX60 and STAT1 were measured. IFI6 expression 
was increased in cells treated with a siRNA for DNA-PKcs compared to the cells 
transfected with a control siRNA (Fig. 5A). The expression of the other four ISGs was 
not significantly altered (Fig. 5B-E). The knock-down was performed successfully, with 
less than 25 percent of DNA-PKcs expression remaining (Fig. 5F). 
Figure 2. DNA-PKcs in wild-type MCF-7 cells irradiated with 2 Gy. Cells were fixed 0, 1, 4, or 24 hours 
after irradiation and stained with Hoechst (blue; nuclei) or anti-DNA-PKcs (green). Representative 
images of 2 independent experiments.
Figure 3. The effect of DNA-PKcs knock-down on ISG expression after irradiation. MCF-7 cells 
were transfected with siRNA for DNA-PKcs for 24 hours, irradiated with 4 Gy and harvested after 24 
and 48 hours. RNA expression of A, IFI6; B, IFI27; C, OAS1; D, DDX60; E, STAT1; and F, DNA-PKcs was 
measured. Gene expression was calculated relative to HPRT (housekeeper gene) and subsequently 
relative to the unirradiated, control-treated samples at 24 or 48 hours. Data are represented as mean 
+ SD (technical replicates, n = 2), and statistical significance was determined by Student t tests. * P < 
0.05, ** P < 0.01, *** P <0.001  (DNA-PKcs siRNA-treated samples were compared to similarly treated 
sample with control siRNA).
Figure 4. The effect of DNA-PKcs inhibition on ISG expression after irradiation. MCF-7 cells 
were treated with NU7441 for 1 hour, subsequently irradiated with 4 Gy and harvested after 24 and 
48 hours. RNA expression of A, IFI6; B, IFI27; C, OAS1; D, DDX60; and E, STAT1 was measured. Gene 
expression was calculated relative to HPRT and subsequently relative to the unirradiated, control-
treated samples at 24 or 48 hours. Data are represented as mean + SEM (biological replicates, n = 
2), and statistical significance was determined by Student t tests. * P < 0.05, ** P < 0.01, *** P < 0.001 
(NU7441-treated samples were compared to similarly treated sample with DMSO).
64
3 
DN
A 
se
ns
or
s
65
When the experiment was repeated using 1 µmol/L of the DNA-PKcs inhibitor 
NU7441 and subsequent treatment with 4-hydroxytamoxifen, the expression of most 
ISGs was not significantly altered in NU7441-treated cells after tamoxifen treatment, 
compared to DMSO-treated cells (Fig. 6A-C, E). DDX60 expression was increased in 
NU7441-treated cells (Fig. 6D).
In conclusion, we show here that DNA-PKcs is not present in the cytoplasm after 
irradiation. Moreover, DNA-PKcs is not responsible for the induction of an IFN 
response after irradiation or tamoxifen treatment. Knock-down and pharmacological 
inhibition of DNA-PKcs increase ISG expression instead of decreasing it, as was to be 
expected for the DNA sensor involved in the induction of ISGs after treatment. 
Visualization of DDX60 after irradiation and measuring ISG 
expression after irradiation or tamoxifen treatment combined 
with DDX60 knock-down
To investigate whether DDX60 recognizes cytoplasmic ssDNA after irradiation, DDX60 
was visualized in MCF-7WT after irradiation. Cells were fixed 24 or 48 hours after 4 Gy 
irradiation. DDX60 was primarily observed in the cytoplasm, both in the unirradiated 
control and after irradiation (Fig. 7). Although no distinct translocation or increased 
Figure 5. The effect of DNA-PKcs knock-down on ISG expression after tamoxifen treatment. 
MCF-7 cells were transfected with siRNA for DNA-PKcs for 24 hours, treated with 1 or 10 µmol/L 
4-hydroxytamoxifen (Tam) and harvested after 24 hours. RNA expression of A, IFI6; B, IFI27; C, OAS1; 
D, DDX60; E, STAT1; and F, DNA-PKcs was measured. Gene expression was calculated relative to 
HPRT and subsequently relative to the control-treated sample. Data are represented as mean + SEM 
(biological replicates, n = 2), and statistical significance was determined by Student t tests. * P < 0.05, 
** P < 0.01, *** P < 0.001  (DNA-PKcs siRNA-treated samples were compared to similarly treated sample 
with control siRNA).
Figure 6. The effect of DNA-PKcs inhibition on ISG expression after tamoxifen treatment. MCF-
7 cells were treated with NU7441 for 1 hour, subsequently treated with 4-hydroxytamoxifen (Tam) 
and harvested after 24 hours. RNA expression of A, IFI6; B, IFI27; C, OAS1; D, DDX60; and E, STAT1 
was measured. Gene expression was calculated relative to HPRT and subsequently relative to the 
control-treated sample. Data are represented as mean + SD (technical replicates, n = 2), and statistical 
significance was determined by Student t tests. * P < 0.05, ** P < 0.01, *** P <0.001  (NU7441-treated 
samples were compared to similarly treated sample with DMSO).
Figure 7. DDX60 in wild-type MCF-7 cells irradiated with 4 Gy. Cells were fixed 24 or 48 hours after 
irradiation and stained with Hoechst (blue) or anti-DDX60 (green). Control cells were not irradiated 
and fixed after 24 hours. Representative images of two independent experiments.
66
3 
DN
A 
se
ns
or
s
67
ISG expression after irradiation or tamoxifen treatment in 
combination with STING inhibition 
Finally, the role of STING in inducing an IFN response after irradiation was investigated. 
STING activation was inhibited by 50 µmol/L CCCP [(17), 2-hour pre-incubation 
before irradiation). Expression of IFI6, IFI27, OAS1, DDX60 and STAT1 was measured 
24 and 48 hours after irradiation with 4 Gy (Fig. 10A-E). The expression of all five 
ISGs was not significantly altered by CCCP treatment, although in some conditions 
a downward trend was observed for the ISG expression after CCCP treatment. STING 
mRNA expression was increased by the inhibitor (Fig. 10F), while protein expression 
levels of STING and phospho-STING (data not shown) were inconclusive. 
Next, we investigated whether STING induces an IFN response after tamoxifen 
treatment. ISG expression was measured after STING inhibition for 2 hours and 
subsequent 4-hydroxytamoxifen treatment (0, 1 or 10 µmol/L) for 24 hours.  No 
significant change in the expression of IFI6 or STAT1 was observed after treatment 
with CCCP (Fig. 11A, E). The expression of IFI27, OAS1, and DDX60 was decreased 
after inhibition with STING in all CCCP-treated samples compared to control-treated 
samples (Fig. 11B-D). STING mRNA expression were unchanged when pre-treated with 
CCCP treatment, compared to control-treated cells (Fig. 11F). However, differences in 
protein expression levels could not be distinguished (data not shown).
focal expression was seen after irradiation, DDX60s localization roughly colocalizes 
with the ssDNA observed after irradiation, namely in the cytoplasm.
Next, the role of DDX60 in the induction of an IFN response after irradiation was 
investigated. A knock-down of DDX60 was performed in MCF-7WT and the expression of 
IFI6, IFI27, OAS1, DDX60 and STAT1 was measured 24 and 48 hours after irradiation with 4 
Gy. In most conditions, the expression of ISGs was increased after knock-down of DDX60 
compared to the control-transfected cells. (Fig. 8A-C, E). The knock-down was performed 
successfully (Fig. 8D).
The effect of DDX60 knock-down was also investigated in combination with 
4-hydroxytamoxifen treatment. MCF-7 cells were transfected with a siRNA for DDX60 
for 24 hours. Subsequently, IFI6, IFI27, OAS1, DDX60 and STAT1 expression was measured 
after 24 hours of 4-hydroxytamoxifen treatment (0, 1 or 10 µmol/L). No differences were 
observed in ISG expression after knock-down of DDX60 compared to control siRNA-
treated cells. (Fig. 9A-C, E). The knock-down was performed successfully (Fig. 9D). 
In conclusion, although DDX60 is present in the cytoplasm and could therefore colocalize 
with ssDNA, DDX60 is not responsible for inducing an IFN response after irradiation or 
tamoxifen treatment. Its knock-down increases ISG expression after treatment, instead of 
decreasing it as expected for the DNA sensor involved in the induction of IFN signaling.
Figure 8. The effect of DDX60 knock-down on ISG expression after irradiation. MCF-7 cells 
were transfected with siRNA for DDX60 for 24 hours, irradiated with 4 Gy and harvested after 24 and 
48 hours. RNA expression of A, IFI6; B, IFI27; C, OAS1; D, DDX60; and E, STAT1 was measured. Gene 
expression was calculated relative to HPRT and subsequently relative to the unirradiated, control-
treated samples at 24 and 48 hours. Data are represented as mean + SD (technical replicates, n = 2), 
and statistical significance was determined by Student t tests. * P < 0.05, ** P < 0.01, *** P < 0.001 
(DDX60 siRNA-treated samples were compared to similarly treated sample with control siRNA).
Figure 9. The effect of DDX60 knock-down on ISG expression after tamoxifen treatment. MCF-7 
cells were transfected with siRNA for DDX60 for 24 hours, treated with 1 or 10 µmol/L 4-hydroxytamoxifen 
(Tam) and harvested after 24 hours. RNA expression of A, IFI6; B, IFI27; C, OAS1; D, DDX60; and E, STAT1 
was measured. Gene expression was calculated relative to HPRT and subsequently relative to the 
control-treated sample. Data are represented as mean + SEM (biological replicates, n = 2), and statistical 
significance was determined by Student t tests. * P < 0.05, ** P < 0.01, *** P < 0.001  (DDX60 siRNA-
treated samples were compared to similarly treated sample with control siRNA).
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In conclusion, STING inhibition using CCCP seems to decrease the induction of an IFN 
response after irradiation or tamoxifen treatment.
Discussion 
Here, we investigated the role of DNA sensors DNA-PKcs and DDX60, and signaling 
molecule STING in inducing an IFN response after irradiation or tamoxifen treatment. 
These three genes involved in DNA sensor signaling were all higher expressed 
in radioresistant MCF-7 breast cancer cells and tamoxifen-resistant MCF-7 cells 
compared to wild-type MCF-7 cells. The localization of DNA-PKcs and DDX60 was 
visualized after irradiation using fluorescent microscopy, to investigate possible 
colocalization with cytoplasmic ssDNA. DNA-PKcs was present in the nucleus, while 
DDX60 was located in the cytoplasm. To investigate the role of these two sensors 
and the signaling molecule STING in inducing an IFN response after irradiation or 
tamoxifen treatment; inhibition or knock-down of DNA-PKcs, DDX60, and STING 
was performed. Inhibition or knock-down of the sensor that is responsible for the 
induction of an IFN response, was expected to negate the induction of ISGs after 
irradiation or tamoxifen treatment. In order to investigate the IFN response, five 
ISGs were chosen to represent the IFN signaling pathway, based on previous studies 
(18,19). Inhibition or knock-down of DNA-PKcs or DDX60 did not negate the induction 
of an IFN response after irradiation or tamoxifen treatment. However, STING inhibition 
seemed to decrease the expression of ISGs after irradiation or tamoxifen treatment. 
Therefore, we pose that a DNA sensor upstream of STING may recognize cytoplasmic 
ssDNA after irradiation or tamoxifen treatment, and subsequently induces an IFN 
response.
STING had previously been shown to induce an IFN response after irradiation, both 
in immune cells and tumor cells (8, 11, 20). As a key regulator in DNA-mediated 
immune signaling pathways (21), STING can be activated by various DNA sensors, 
of which cGAS is the best known and most essential cytoplasmic sensor (22). Other 
sensors that activate STING include DDX41 and IFI16 (23, 24). It is likely that multiple 
factors in this pathway cooperate to induce an IFN response. IFI16, cGAS and STING 
– amongst others – are all required for stimulation of the IFN response after infection 
with bacterial exogenous DNA in human macrophages (25).
In this study, the STING pathway was inhibited by CCCP, an aspecific inhibitor for STING. 
Its function is to disrupt the mitochondrial membrane potential, but how this leads to 
STING inhibition is unknown (17). To be able to discern the effect of STING inhibition 
Figure 10. The effect of STING inhibition on ISG expression after irradiation. MCF-7 cells were 
treated with STING inhibitor CCCP (50 µmol/L) for 2 hours, irradiated with 4 Gy and harvested 
after 24 and 48 hours. RNA expression of A, IFI6; B, IFI27; C, OAS1l D, DDX60l E, STAT1; and F, STING 
was measured. Gene expression was calculated relative to HPRT and subsequently relative to the 
unirradiated, control-treated samples at 24 or 48 hours. Data are represented as mean + SEM 
(biological replicates, n = 2), except for F, which is represented as mean + SD (technical replicates, 
n = 2). Statistical significance was determined by Student t tests. * P < 0.05, ** P < 0.01, *** P < 0.001 
(CCCP-treated samples were compared to similarly treated sample with DMSO).
Figure 11.The effect of STING inhibition on ISG expression after tamoxifen treatment. MCF-
7 cells were treated with STING inhibitor CCCP (50 µmol/L) for 2 hours, subsequently treated with 
4-hydroxytamoxifen (0, 1, and 10 µmol/L)  and harvested after 24 hours. RNA expression of A, IFI6; 
B, IFI27; C, OAS1; D, DDX60; E, STAT1; and F, STING was measured. Gene expression was calculated 
relative to HPRT and subsequently relative to the control-treated sample. Data are represented as 
mean + SEM (biological replicates, n = 2), except for F, which is represented as mean + SD (technical 
replicates, n = 2). Statistical significance was determined by Student t tests. * P < 0.05, ** P < 0.01, *** 
P < 0.001  (CCCP-treated samples were compared to similarly treated sample with DMSO).
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In conclusion, we show the possible involvement of STING in the induction of an IFN 
response in breast cancer cells after irradiation and tamoxifen treatment. We showed 
that two DNA sensors, DNA-PKcs and DDX60, are not involved in this process. The 
role of cGAS and other STING activators in the recognition of cytoplasmic ssDNA 
after tamoxifen treatment or irradiation should be further studied, as well as more 
specific inhibition of STING itself, to further characterize this pathway that has major 
implications for treatment-resistant breast cancer and the addition of immune 
therapy to treatment schedules in breast cancer. 
more precisely, future experiments should include controls to check for side effects 
of CCCP, or a knock-down of STING should be performed using siRNA. Moreover, the 
increase in ISG expression that was previously observed after irradiation or tamoxifen 
treatment (7), was not observed here in all experiments. To correctly identify the role 
of the signaling pathway between cytoplasmic ssDNA and the activation of the IFN 
response after irradiation or tamoxifen treatment, clear increases of ISGs should be 
observed in control conditions. Additionally, the effect of irradiation or tamoxifen 
treatment on expression of STING itself has not been extensively investigated here, 
while this could influence the way results are interpreted.
Here we identified a possible role for STING in inducing an IFN response after 
irradiation and tamoxifen treatment, but the DNA sensor responsible for recognizing 
cytoplasmic ssDNA in this situation has not yet been identified. Sensors activating 
STING should be investigated for colocalization with cytoplasmic ssDNA after 
irradiation and tamoxifen treatment, and their role in the subsequent activation of 
STING and an IFN response elucidated. cGAS remains the most promising candidate, 
as others already found it to play a role in the induction of an IFN response after 
irradiation (8, 11). However, most research so far has focused on the recognition of 
dsDNA after irradiation, while we and others have previously shown that specifically 
ssDNA is observed after irradiation or tamoxifen treatment (7, 8). 
The identification of a DNA sensor that induces an IFN response after irradiation and 
tamoxifen treatment is relevant for several reasons. First, IFN signaling was found 
to be activated in radioresistant and tamoxifen-resistant breast cancer cells in vitro 
and high expression of genes involved in this pathway was associated with worse 
outcome after radiotherapy or tamoxifen treatment in patients (7). The thorough 
characterization of this response in the development of treatment resistance could 
lead to new treatment targets for radioresistant or tamoxifen-resistant breast cancer. 
Second, the induction of an IFN response in tumor cells has major implications for 
the antitumor immune response by cells in the tumor microenvironment. We showed 
earlier that ISG expression in tumor cells is associated with the presence of tumor-
infiltrating lymphocytes in the tumor (7). However, as IFN signaling can have both 
immune stimulatory and repressing effects (26), the role of IFN signaling by tumor 
cells on the activity of immune cells in the tumor microenvironment should be 
further investigated.
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Chapter 4
Downregulation of matrix 
Gla protein is a biomarker for 
tamoxifen-resistant and 
radioresistant breast cancer
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Abstract
Purpose 
To establish downregulated biomarkers for cross-resistance to radiotherapy in 
tamoxifen-resistant breast cancer cells. 
Experimental Design
RNA sequencing was performed on tamoxifen-resistant and radioresistant breast 
cancer cells. Breast cancer patient cohorts were queried in silico for associations 
between genes of interest and outcome after tamoxifen treatment or irradiation.
Results
Twenty genes showed decreased expression in both tamoxifen-resistant and 
radioresistant breast cancer cells. Only the expression of matrix Gla protein in 
the primary tumor was associated with outcome after tamoxifen treatment or 
radiotherapy in breast cancer patients. 
Conclusions
Matrix Gla protein is a biomarker for therapy sensitivity in breast cancer. 
Introduction
Over fifty percent of breast cancer patients are treated with radiotherapy as part of 
their primary treatment. Additionally, patients with estrogen receptor (ER) positive 
tumors are frequently treated with adjuvant systemic endocrine therapy, such as the 
antiestrogen tamoxifen. Resistance to these types of treatment, either intrinsic or 
acquired, is the main cause of disease progression in a substantial number of breast 
cancer patients (1,2). 
Characteristics of resistance to tamoxifen treatment and radiotherapy have been 
investigated extensively (2-5). Strikingly, tamoxifen-resistant breast cancer cells were 
shown to be resistant to radiation as well (6-8). Therefore our goal is to find common 
pathways that are involved in both types of treatment resistance. We have previously 
investigated several mechanisms that play a role in both tamoxifen resistance and 
radioresistance. First, we identified a role for the unfolded protein response/LAMP3/
autophagy pathway in tamoxifen resistance and radioresistance (9,10). Recently, we 
analyzed common features of tamoxifen-resistant and radioresistant breast cancer 
cells using a nontargeted approach, by assessing genes that were overexpressed in 
both types of resistant cell lines (8). We found that IFN signaling is activated in both 
tamoxifen-resistant and radioresistant breast cancer cells, and that this pathway 
is associated with poor outcome in breast cancer patients treated with adjuvant 
tamoxifen or radiotherapy (8). As the RNA sequencing data from this study yielded 
much more information, we here investigated genes with decreased expression in 
both tamoxifen-resistant and radioresistant cell lines to identify additional common 
features of these types of treatment resistance. We identified matrix Gla protein 
as a downregulated gene in tamoxifen-resistant and radioresistant breast cancer 
cells, and show its association with outcome in breast cancer patients treated with 
tamoxifen or radiotherapy.
Methods
Cell culture
MCF-7 cells from LCG Standards  were cultured as described earlier (8). Cells were 
kept alive for a maximum of 40 passages. Short tandem repeat analysis was used to 
authenticate all cell lines and cells were tested negative for mycoplasma. 
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Creating resistant cell lines
MCF-7 cells were cultured to tamoxifen resistance by increasing doses of 
4-hydroxytamoxifen in the culture medium weekly up to a total dose of 10 μmol/L 
(10). 4-hydroxytamoxifen was purchased from Sigma Aldrich (#H7904). Wild-type 
cells were irradiated with 4 Gy every two weeks to obtain radioresistant cells, up to a 
total dose of 52 Gy (8). Cells were irradiated using an X-Rad 320ix Biological Irradiator 
(Precision X-Ray) at a dose rate of 3.1 Gy/min. The fractionation was chosen for 
practical reasons, in order to create resistant cells that remain alive. A more clinically 
relevant fractionation schedule of 2 Gy daily (as is applied in breast cancer treatment) 
would kill all cells within a week. We observed previously that various irradiation 
schedules have similar results (8).
RNA isolation and RNA sequencing
RNA isolation and RNA sequencing of wild-type MCF-7 cells, tamoxifen-resistant 
MCF-7 cells and radioresistant MCF-7 cells was performed as described previously (8). 
Patients: Kaplan-Meier plotter
The Kaplan-Meier plotter (11) was used to evaluate the association between 
expression of genes of interest and relapse-free survival in adjuvantly tamoxifen-
treated breast cancer patients. Characteristics of the included patients have been 
previously described (12). Patients receiving endocrine treatment alone (n = 867, 
85.6% ER-positive) were selected and patient samples were grouped based on the 
expression of the desired gene of interest (Jetset best probe set) at the median cut-
off value.
Patients: TCGA database 
The breast cancer cohort of the cancer genome atlas data (TCGA) project (13)  was 
used to assess the relation of expression of genes of interest with patient outcome 
after radiotherapy using the University of California at Santa Cruz Xena Browser (14). 
Patients with node-negative and metastasis-free breast cancer were divided into 
groups that were treated with radiotherapy (n = 194) or without radiotherapy (n = 
209), and assessed for relapse-free survival.
Statistics
Enriched pathways in the 20-gene set were identified using the PANTHER 
overrepresentation test [Release date 12 May 2017; (15,16)], and the GO Ontology 
database “biological process complete” (Release date 4 April 2018). Pathways were 
considered significant when the Fisher’s Exact test with FDR multiple test correction 
yielded a corrected P-value < 0.05. The Kaplan-Meier plotter provided Kaplan-Meier 
survival plots, a hazard ratio with 95% confidence intervals and Log Rank P-values. 
Xena Browser TCGA data were imported into SPSS (SPSS Inc., Chicago, IL, USA) and 
Breslow P-values at median cut-off were calculated for all genes of interest. 
Results
Genes with decreased expression in both tamoxifen-resistant 
and radioresistant breast cancer cells
ER-positive MCF-7 breast cancer cells were cultured to tolerate up to 10 μmol/L 
4-hydroxytamoxifen [MCF-7TAM, (8,10)], and separately to become less sensitive to 
irradiation using 13 fractions of 4 Gy, which amounts to a total dose of 52 Gy [MCF-7RT, 
(8)]. Strikingly, MCF-7TAM cells were also resistant to irradiation (8). RNA sequencing 
was performed on both resistant cell lines and the parental cell line (MCF-7WT), after 
which gene expression was analyzed for all three cell lines. Protein coding genes with 
sufficient read coverage, i.e. more than 10 read counts in at least one of the three 
samples (MCF-7WT, MCF-7TAM, or MCF-7RT), were included in the analysis. In total 20,459 
protein coding genes were measured, of which 9,764 passed the read coverage 
threshold. Many genes were similarly expressed in MCF-7TAM and MCF-7RT, compared 
to MCF-7WT (Fig. 1A). However, several genes were differentially expressed in either 
MCFTAM, MCF-7RT, or both of the resistant cell lines compared to MCF-7WT (Fig. 1A). In a 
previous publication, we analyzed the genes with increased expression in MCF-7TAM 
and MCF-7RT (8), and here we aimed to evaluate the genes with decreased expression 
in MCF-7TAM and MCF-7RT.
We focused on genes whose expression was more than 4 times decreased in the 
resistant cells, in order to find the most relevant functions that were downregulated 
in both tamoxifen-resistant and radioresistant breast cancer cells. In MCF-7TAM 
and MCF-7RT, 156 and 119 genes had at least 4 times decreased expression levels, 
respectively, compared to MCF-7WT (Fig. 1B). Twenty genes had more than 4 times 
decreased expression levels in both types of resistant cells (Table 1). We performed 
a pathway analysis using the PANTHER overrepresentation test (15,16) to elucidate 
biological processes (Gene Ontology, GO) that were enriched in this set of 20 genes. 
The significantly overrepresented functions in these 20 genes (corrected P < 0.05) 
were related to the GO terms “vitamin D receptor signaling pathway”, “collagen fibril 
organization”, and “ossification” (Fig. 1C).
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Expression of matrix Gla protein in the primary tumor is 
associated with outcome in breast cancer patients treated with 
tamoxifen or radiotherapy
To assess the relevance of the genes that were downregulated in both MCF-7TAM  and 
MCF-7RT, the association of these 20 genes with outcome in breast cancer patients 
treated with tamoxifen or radiotherapy was investigated. Using the online available 
database Kaplan-Meier plotter (11,12), we found that 4 out of the 20 genes, when 
used to dichotomize patients at the median value, were significantly associated with 
relapse-free survival in breast cancer patients treated with adjuvant tamoxifen (Fig. 
2A, Table 1). One of these genes, SERPINE1, was associated with a worse outcome after 
tamoxifen treatment when highly expressed (Fig. 2A; P = 0.002). In the case of MGP, 
GABRP, and MATN3, a higher gene expression was associated with better outcome in 
breast cancer patients (Fig. 2A; P = 0.0002, P = 0.007, P = 0.004, respectively). 
Next, we analyzed the association of the 20 downregulated genes with relapse-free 
survival in breast cancer patients treated with radiotherapy, using data generated by 
the TCGA Research Network (13). Patients with T1-4,N0,M0 tumors were selected, and 
the cohort was divided in patients that did or did not receive radiotherapy as part of 
their primary treatment (systemic treatment status was unknown for this patient cohort). 
Patients were dichotomized by the median value of each of the 20 genes downregulated 
in MCF-7TAM and MCF-7RT. Out of these 20 genes, only MGP expression was associated with 
Table 1. Downregulated genes in MCF-7TAM and MCF-7RT
The 20 genes that were commonly downregulated in MCF-7TAM and MCF-7RT. Depicted are the relative 
expression levels of these genes in the resistant cell lines compared to MCF-7WT, the gene function, 
and the P-values of the association with relapse-free survival in patients treated with adjuvant 
tamoxifen (Kaplan-Meier plotter), or in patients treated with or without radiotherapy (RT; TCGA).
Gene 
name
Gene function Fold change P-valuea P-valueb
MCF-7RT MCF-7TAM KM-plotter TCGA: RT- TCGA: RT+
CYP24A1 Cytochrome P450 protein, vitamin D regulation 0.01 0.03 0.76 0.62 0.25
LOXL4 Lysyl oxidase gene family member, biogenesis  
connective tissue
0.05 0.02 0.39 0.49 0.31
MGP Inhibition of tissue calcification 0.07 0.01 0.0002 0.23 0.049
COL5A2 Alpha chain of fibrillar collagen 0.04 0.06 0.85 0.30 0.96
AREG Epidermal growth factor family member 0.04 0.07 0.40 0.79 0.52
ARHGAP36 Rho GTPase activator 0.13 0.003 0.97 0.71 0.49
CCDC85A Coiled coil domain containing protein 0.009 0.16 0.59 0.051 0.71
SHH Sonic hedgehog 0.08 0.13 0.45 0.25 0.86
SERPINE1 Serine proteinase inhibitor family member 0.10 0.12 0.002 0.26 0.069
RBM24 RNA binding motif 0.19 0.05 0.65 0.995 0.31
SNAI2 Zinc finger transcription factor, epithelial-mesenchymal 
transition
0.15 0.09 0.44 0.92 0.53
TMEM40 Transmembrane protein 0.09 0.16 0.19 0.22 0.80
RBP7 Retinol-binding protein family member, vitamin A 
metabolism
0.16 0.10 0.05 0.42 0.91
COL12A1 Alpha chain of type XII collagen 0.09 0.17 0.56 0.02 0.98
SPOCK1 Protein core of proteoglycan 0.08 0.19 0.17 0.39 0.33
PIM1 Ser/Thr protein kinase 0.20 0.20 0.09 0.90 0.052
GABRP GABA receptor, chloride channel 0.16 0.24 0.007 0.86 0.72
MATN3 Von Willebrand factor A domain containing protein 
family member
0.18 0.22 0.004 0.84 0.71
FBLN2 Extracellular matrix protein, fibulin family member 0.24 0.19 0.88 0.41 0.84
LOXL1 Lysyl oxidase gene family member, biogenesis connective 
tissue
0.21 0.24 0.40 0.89 0.78
Figure 1. Gene expression analysis of MCF-7TAM and MCF-7RT A, Fold change of protein coding 
genes crossing the read count threshold in MCF-7TAM (y-axis) and MCF-7RT (x-axis) compared to MCF-
7WT. Red: genes with more than 4 times decreased expression in MCF-7TAM and MCF-7RT. B, Number 
of genes that have 4-fold decreased expression in MCF-7TAM, MCF-7RT, or in both resistant cell types 
compared to MCF-7WT. C, Functions significantly overrepresented (corrected P < 0.05, GO biological 
process) in the 20 genes that are commonly downregulated in MCF-7TAM and MCF-7RT.
a Log Rank test, b Breslow test
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outcome after radiotherapy (Table 1, Fig. 2B; P = 0.049). In the patient group that did not 
receive radiotherapy, MGP expression was not associated with outcome (Fig. 2B, P = 0.23), 
suggesting that MGP is indeed associated with response to radiotherapy specifically.
Figure 2. Association between genes of interest and relapse-free survival in breast cancer 
patients A, Forest plot showing the association (hazard ratio’s and 95% confidence intervals) between 
the expression of the 20 downregulated genes and relapse-free survival after tamoxifen treatment (n 
= 867, # n = 181). B, Relapse-free survival was assessed in the TCGA breast cancer cohort, divided into 
patients treated without (left, n = 209) or with radiotherapy (right, n = 194). Patients with high levels 
of MGP (dotted) were compared to those with low levels of MGP (bold).
Matrix Gla protein expression is variable in breast cancer 
patients
To further characterize matrix Gla protein (MGP) in breast cancer, we consulted the 
online tool Protein Atlas (17). MGP is expressed in a wide range of cancers, but only 
in breast cancer is its expression highly variable (Fig. 3A), as shown in data generated 
by the TCGA Research Network (13). The variability of MGP expression in breast cancer 
patients is illustrated by the heterogeneity in protein expression in tumors, as shown 
Figure 3. MGP expression in breast cancer A, RNA expression of MGP in several cancer types 
(https://www.proteinatlas.org/ENSG00000111341-MGP/pathology). RNA sequencing data are 
represented as median number of fragments per kilobase of exon per million reads (FPKM). Data 
generated by the TCGA Research Network (https://cancergenome.nih.gov/). B, Staining patterns of 
MGP (patient 4850, patient 2392 & patient 1910) in breast tumors in the Human Protein Atlas. Bars 
equal 50 µm.
(https://www.proteinatlas.org/ENSG00000111341-MGP/pathology/tissue/breast+cancer#img) 
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by various examples of tumor tissue stained for MGP (Protein Atlas, Fig. 3B). While 
some tumors have high expression of MGP in the majority of cells (right), other tumors 
contain a minority of cells that have low intensity expression of MGP (left and middle).
Discussion
After previously identifying IFN signalling as an important pathway that is 
overexpressed in both tamoxifen-resistant and radioresistant breast cancer cells (8), we 
here turn our attention to downregulated genes. Although IFN signalling is apparently 
an important signalling pathway in tamoxifen resistance and radioresistance in 
breast cancer, many more mechanisms are likely to play a role. Here we report on 
genes with decreased expression in tamoxifen-resistant and radioresistant breast 
cancer cells and investigated the possibility of using these as biomarkers for therapy 
sensitivity. We identified 20 genes that were downregulated at least 4 times in both 
types of resistant cells compared to wild-type MCF-7 cells, and might therefore be 
involved in the cross-resistance that tamoxifen-resistant cells exhibit for radiotherapy 
(6-8). Of these genes, MGP was the only gene whose expression was associated with 
relapse-free survival in patients treated with tamoxifen or radiotherapy. MGP might 
be a biomarker related to cross-resistance for radiotherapy in tamoxifen-treated 
breast cancer patients.
In this paper we used both in vitro studies and data from breast cancer patient cohorts 
to find potential biomarkers for resistance to tamoxifen and radiotherapy in breast 
cancer. Our in vitro methods to create breast cancer cells resistant to either treatment 
modality were chosen for practical reasons, not to reflect treatment schedules in 
breast cancer patients. Our intention was to create resistant cells; the schedule used 
to achieve this is not essential to the outcome. In order to assess clinical relevance, 
we analyzed the role of the genes that were identified in vitro in breast cancer patient 
cohorts. 
MGP was first isolated from the matrix of bovine bone (18). It is an inhibitor of 
calcification (19), and besides in bone also present in cartilage, lung, kidney and 
heart (20,21). In several types of cancer, MGP was found to be differentially expressed 
compared to normal tissue, e.g. in breast cancer, colon cancer, and glioblastoma (22-
24). Chen et al. reported that MGP expression was increased in breast cancer cells, but 
could not confirm this on protein level (22). The TCGA data we present here show that 
MGP expression in breast cancer patients is highly variable, although these data were 
not compared to MGP expression in normal breast tissue. The high variability in MGP 
expression in breast cancer patients makes it an interesting candidate for prognostic and 
predictive studies. Indeed, MGP is one of the genes represented in the multi-gene test 
EndoPredict (25). This test for ER-positive, HER2-negative breast cancer patients treated 
with endocrine therapy alone predicts the risk of recurrences in this patient group (26). 
High MGP expression levels add to a good prognosis in this test (25), consistent with the 
strong induction of MGP by estradiol (27). To the best of our knowledge, no studies have 
so far reported on an association between MGP expression and radiosensitivity.
Though its exact role in tumorigenesis has not been elucidated, MGP has been shown 
to play a role in angiogenesis by stimulating VEGF expression (28,29). While Boström 
et al. identified this process in endothelial cells, Kuzontkoski et al. demonstrated that 
glioblastoma tumor cells express MGP and that MGP mediates tumor angiogenesis 
in glioblastoma xenografts. In the present study we present Protein Atlas stainings 
exemplifying that tumor cells, and not merely endothelial cells, express MGP (Fig. 3B). 
Interestingly, in earlier studies we found that tumor VEGF expression levels are involved 
in tamoxifen resistance (30) and radioresistance in breast cancer patients (31). However, 
in these studies we found high VEGF expression levels to denote a poor prognosis. 
Here, we found that high MGP expression levels were associated with better outcome in 
breast cancer patients treated with tamoxifen or radiotherapy, and as MGP induces VEGF 
expression (28,29), these data are not consistent with a role for MGP via VEGF-induced 
angiogenesis as a cause for treatment resistance.
High expression levels of MGP have earlier been described as an indicator of poor outcome 
in breast cancer patients, though the study had a very small sample size [n = 9; (32)]. In 
contrast, a later study showed that MGP expression levels were low in chemoresistant 
breast cancer cells, and this finding was validated by analyzing patients treated with 
adjuvant chemotherapy in the Kaplan-Meier plotter (33). Tuo and Ye found that high 
MGP expression is associated with better relapse-free survival in ER-positive patients 
treated with systemic therapy (33). We show in the current study that high expression 
levels of MGP are associated with better outcome in breast cancer patients treated with 
tamoxifen or radiotherapy. However, in patients that did not receive radiotherapy as 
part of their treatment, MGP expression was not associated with outcome. Our in vitro 
data and the observation by Tuo and Ye suggest that treatment resistance, whether 
it be to chemotherapy, tamoxifen treatment or radiotherapy, is associated with 
downregulation of MGP expression in breast cancer. Additionally, when MGP expression 
is low in the primary tumor, it is associated with worse outcome in patients treated with 
chemotherapy (33), tamoxifen treatment or radiotherapy (the present study). 
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The expression of MGP is regulated by vitamin D and vitamin K, amongst others (34). 
Strikingly, we identified vitamin D receptor signaling as a pathway that is significantly 
overrepresented in the 20 genes with decreased expression in tamoxifen-resistant 
and radioresistant breast cancer cells. Both vitamin K and vitamin D have tumor-
suppressing functions and are related to cancer metastasis (35-37). Moreover, 
microRNA miR-155 was shown to repress MGP expression in MCF-7 cells (38). MiR-
155 is upregulated in breast cancer (39), and is associated with poor prognosis and 
metastasis (40).
Which pathways are responsible for the downregulation of MGP in treatment 
resistance remains to be identified. Moreover, additional studies concerning the 
role of MGP in other model systems may aid in understanding its role in tamoxifen 
resistance and radioresistance in breast cancer. Although the diversity of patients 
in the in silico analyses makes for a very robust assessment of the role of MGP in 
outcome after tamoxifen treatment or radiotherapy in breast cancer, the biological 
background ought to be further investigated.
In conclusion, matrix Gla protein was the only gene that has decreased expression levels 
in both tamoxifen-resistant and radioresistant breast cancer cells of which a relevant 
relation to outcome could be identified in patient cohorts either treated with tamoxifen 
or radiotherapy. Whether MGP is a biomarker or actually mechanistically involved in 
radiotherapy cross-resistance after tamoxifen treatment remains to be established. 
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Abstract
Purpose
Tamoxifen-induced radioresistance, reported in vitro, might pose a problem for 
patients who receive neoadjuvant tamoxifen treatment and subsequently receive 
radiotherapy after surgery. Previous studies suggested that DNA damage repair 
genes or cell cycle genes are involved, and these could therefore be targeted to 
preclude the occurrence of cross-resistance.
Experimental Design
We aimed to characterize the observed cross-resistance by investigating gene 
expression of DNA damage repair genes and cell cycle genes in estrogen receptor-
positive MCF-7 breast cancer cells that were cultured to tamoxifen resistance. RNA 
sequencing was performed and expression of genes characteristic for several DNA 
damage repair pathways was investigated; as well as expression of genes involved 
in different phases of the cell cycle. The association of differentially expressed genes 
with outcome after radiotherapy was assessed in silico in a large breast cancer cohort.
Results
None of the DNA damage repair pathways showed differential gene expression in 
tamoxifen-resistant cells compared to wild-type cells. Two DNA damage repair genes 
were more than 2 times upregulated: NEIL1 and EME2; and three DNA damage repair 
genes were more than 2 times downregulated: PCNA, BRIP1, and BARD1. However, 
these were not associated with outcome after radiotherapy in the TCGA breast 
cancer cohort. Genes involved in G1, G1/S, G2, and G2/M phase were lower expressed 
in tamoxifen-resistant cells compared to wild-type cells. Individual genes that were 
more than 2 times upregulated (MAPK13) or downregulated (E2F2, CKS2, GINS2, PCNA, 
MCM5, and EIF5A2) were not associated with response to radiotherapy in the patient 
cohort investigated.
Conclusions
We assessed the expression of DNA damage repair genes and cell cycle genes in 
tamoxifen-resistant breast cancer cells. Though several genes in both pathways were 
differentially expressed, these could not explain the cross-resistance for irradiation in 
these cells, as no association to response to radiotherapy in the TCGA breast cancer 
cohort was found.
Introduction
Radiotherapy and hormonal treatment (tamoxifen) are both corner stones of breast 
cancer treatment, and are successful in a large number of patients. However, when 
resistance to these treatment modalities occurs, adverse outcomes are likely for 
the patient. Previously, we, and others, showed that breast cancer cells cultured to 
tamoxifen resistance also acquire radioresistance in vitro (1-3). In the classical breast 
cancer treatment regimen, where tamoxifen is given after radiotherapy following 
surgery, this poses no problem for patients. However, neoadjuvant endocrine 
therapy, such as tamoxifen, is increasingly given to breast cancer patients. Endocrine 
treatment-induced radioresistance could pose a problem for these patients when 
they receive radiotherapy later in the treatment schedule (4). Moreover, patients that 
receive radiotherapy as treatment for metastasized disease could suffer from reduced 
efficiency due to earlier adjuvant tamoxifen treatment.
In order to prevent cross-resistance for irradiation in tamoxifen-treated tumors, it 
is imperative to identify the genes and/or pathways that cause radioresistance in 
tamoxifen-resistant breast cancer. Several studies have addressed the expression of 
DNA damage repair genes in tamoxifen-resistant cells. Luzhna et al. described that 
while after irradiation wild-type MCF-7 cells had decreased levels of genes making 
up the base excision repair (BER), homologous recombination (HR), and mismatch 
repair (MMR) pathways, these genes were not differentially expressed in tamoxifen-
resistant MCF-7 cells after irradiation.  Moreover, the tamoxifen-resistant cells 
displayed more efficient repair of double-strand breaks and were less susceptible to 
apoptosis (2). Others found that tamoxifen-resistant MCF-7 cells exhibited increased 
levels of PARP1 and LIG3, both part of the alternative non-homologous end joining 
(NHEJ) pathway, and that these cells are dependent on this pathway for repair of 
double-strand breaks. Significantly more yH2AX foci and a large number of genomic 
aberrations were present in those resistant cells (5). Another study showed that 
BRCA1 and its associated protein BARD1 are upregulated in tamoxifen-resistant 
breast cancer cells, which render the cells resistant to DNA-damaging chemotherapy 
(6). Thus, DNA damage repair is reportedly altered in tamoxifen-resistant breast 
cancer cells, possibly explaining their cross-resistance to radiotherapy. 
Next to DNA damage repair genes, differential expression of cell cycle genes might 
also contribute to the altered radiosensitivity observed in tamoxifen-resistant cells. 
Tamoxifen treatment decreases the percentage of cells in S phase, while inducing a 
G1 block (7-10). The efficiency of radiotherapy depends on the cell cycle phase cells 
are in, a phenomenon that has been studied for a long time (11). The most sensitive 
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phases of the cell cycle are the G2 and M phases, while cells in the G1 phase are more 
resistant to irradiation and cells in S phase are the most resistant [reviewed in (12)]. A 
previous study showed that tamoxifen-resistant cells have increased levels of genes 
regulating the G1/S transition (CCNE1, CDK2, and E2F1), and higher percentages of 
tamoxifen-resistant cells were present in S phase compared to parental cells (13). Also, 
CCND1 and MYC are reportedly upregulated in tamoxifen resistance, which could lead 
to G1/S phase blockade (14). Higher expression of these genes in tamoxifen-resistant 
cells could also explain the cross-resistance to irradiation. 
Here we aim to assess differentially regulated genes in estrogen receptor (ER) positive 
breast cancer cells cultured to tamoxifen resistance, in order to explain the increased 
radioresistance observed in these cells. To this end, we analyzed the expression of 
DNA damage repair genes and cell cycle genes in tamoxifen-resistant breast cancer 
cells compared to wild-type cells, and validated their predictive power in a large 
breast cancer cohort in silico. 
Materials and methods
Cell culture
The culturing of ER-positive MCF-7 cells (LCG Standards) was described previously, 
including the number of passages and authentication of the cell lines (3). Tamoxifen-
resistant cells were acquired by culturing MCF-7 cells with 4-hydroxytamoxifen 
(#H7904; Sigma Aldrich), increasing the dose weekly up to 10 μmol/L (15). 
RNA isolation
The Total RNA Purification Kit (Norgen Biotek Corp.) was used to isolate RNA. On 
column DNase treatment (RNase-Free DNase Set #79254; Qiagen) was performed, all 
according to the manufacturer’s instructions. 
RNA sequencing
RNA sequencing was performed on wild-type MCF-7 and tamoxifen-resistant MCF-7 
cells as described earlier (3).
Patients: TCGA database 
Data from the cancer genome atlas data (TCGA) project’s breast cancer cohort 
(https://portal.gdc.cancer.gov/projects/TCGA-BRCA) were analyzed for expression of 
genes of interest and associated to patient outcome after radiotherapy. Data were 
accessed and processed with the University of California at Santa Cruz Xena Browser 
at http://xena.ucsc.edu/. Node-negative and metastasis-free patients were selected 
and grouped into radiotherapy-treated (n = 209) and nonradiotherapy-treated (n = 
194) patients. Relapse-free survival was assessed.
Statistics
Mean deviation from 1 was calculated for the genes in different DNA damage repair 
pathways or cell cycle phase with a Student t test. Xena Browser TCGA data were 
imported into SPSS (SPSS Inc.) and Breslow P-values at median cut-off were calculated 
for all genes of interest. 
Results
RNA sequencing of tamoxifen-resistant cells (MCF-7TAM) and MCF-7 wild-type cells 
(MCF-7WT) was performed. For further analyses, only protein coding genes were 
included that had more than 10 reads in either MCF-7WT or MCF-7TAM. The relative 
expression of these genes in MCF-7TAM compared to MCF-7WT was assessed (Fig. 1A). 
Many genes were not differentially expressed in MCF-7TAM compared to MCF-7WT. 
However, 487 genes were more than two times increased, and 493 genes were more 
than two times decreased. The genes with the highest change in expression were 500 
times increased, or over 6,000 times decreased in MCF-7TAM compared to MCF-7WT. 
Expression of DNA damage repair genes in tamoxifen-resistant 
breast cancer cells
We assessed the expression of genes that are known to be involved in various types 
of DNA damage repair [https://www.mdanderson.org/documents/Labs/Wood-
Laboratory/human-dna-repair-genes.html; (16,17)]. 148 of these genes, that were 
protein coding and passed our read count threshold were further analyzed (Fig. 1B). 
The genes of interest were subdivided in the following groups: BER, MMR, nucleotide 
excision repair (NER), HR and NEHJ (Fig. 1B). None of the groups were differentially 
expressed in MCF-7TAM compared to MCF-7WT (two-sided t test compared to mean = 1; 
BER: P = 0.5483, MMR: P = 0.2744, NER: P = 0.4092, HR: P = 0.7267, NHEJ: P = 0.5107). 
Out of these 148 genes, we identified individual genes with a minimum 2-fold change 
in expression (Table 1). Only two DNA damage repair genes, NEIL1 and EME2, were 
upregulated in MCF-7TAM, while two other DNA damage repair genes, BRIP1 and PCNA, 
were downregulated. 
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We further included genes that were shown to be differentially expressed in tamoxifen-
resistant MCF-7 cells according to literature: LIG3, PARP1, BRCA1, and BARD1 [Table 1; 
(5,6)]. Of these, only BARD1 had a more than twofold decreased expression in MCF-
7TAM compared to MCF-7WT. In contrast, BARD1 has previously been found to exhibit 
increased expression in tamoxifen-resistant MCF-7 cells (6).
Figure 1. Expression of DNA damage repair genes and cell cycle genes in tamoxifen-resistant 
breast cancer cells. The expression of A, all genes; B, DNA damage repair genes; and C, cell cycle 
genes in MCF-7TAM compared to MCF-7WT. For each gene, the fold change in expression levels 
in MCF-7TAM compared to MCF-7WT is shown (based on normalized read counts), as measured by 
RNA sequencing.
Expression of cell cycle genes in tamoxifen-resistant breast 
cancer cells
Besides DNA damage repair genes, differential expression of cell cycle genes in 
tamoxifen-resistant breast cancer cells might also contribute to radioresistance (12). 
One hundred and twenty genes characteristic of six different phases in the cell cycle 
[twenty each for G1, G1/S, S, G2, G2/M, and M; (18)] were analyzed for their expression 
in MCF-7TAM. After selecting for genes that were protein coding and that had more 
than ten reads in either MCF-7WT or MCF-7TAM, one hundred genes were left (G1: 
18, G1/S: 18, S: 13, G2: 14, G2/M: 18, M: 19; Fig. 1C). Gene expression was plotted as fold 
increase in MCF-7TAM compared to MCF-7WT. Four of the groups showed differential 
expression in MCF-7TAM compared to MCF-7WT (two-sided t test compared to mean = 1; G1: 
P = 0.0072, G1/S: P < 0.0001, S: P = 0.0907, G2: P < 0.0001, G2/M: P = 0.0017, M: P = 0.2806). 
We also analyzed the individual genes for those that had at least 2 times increased 
expression or decreased expression in MCF-7TAM compared to MCF-7WT (Table 2). Only one 
gene was more than 2 times upregulated: MAPK13. Six genes were downregulated in 
MCF-7TAM: E2F2, CKS2, GINS2, PCNA, MCM5, and EIF5A2. 
Cell cycle genes upregulated in tamoxifen-resistant cells, according to literature 
(13,14), were also investigated here. CCNE1, CDK2, and E2F1 were marginally (13-41%) 
downregulated in MCF-7TAM, but less than our threshold of 2-fold change. MYC and CCND1 
had a decreased expression more than 2-fold, contrary to the increase that was reported 
Table 1. Differential expression of DNA damage repair genes in tamoxifen-resistant breast 
cancer cells. 
List of the differentially expressed DNA damage repair genes in MCF-7TAM, and genes that had 
previously been found to be differentially expressed in tamoxifen-resistant breast cancer cells (5,6). 
For each gene, the fold change in expression levels in MCF-7TAM compared to MCF-7WT is shown (based 
on normalized read counts), as measured by RNA sequencing.
Gene name Gene function Fold change MCF-7TAM
NEIL1 DNA glycoslase, initiation of base excision repair 3.24
EME2 Endonuclease, homologous recombination 2.19
BRIP1 Helicase, BRCA1-interacting 0.42
PCNA DNA polymerase cofactor, non-homologous end joining 0.41
LIG3 DNA ligase, base excision repair 1.25
PARP1 Base excision repair 1.18
BRCA1 Homologous recombination 0.63
BARD1 BRCA1-interacting 0.42
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before (14).
Association of in vitro differentially expressed genes to 
outcome in a breast cancer patient cohort
Thus, only a limited number of DNA damage repair genes and cell cycle genes exhibit 
differential expression in tamoxifen-resistant breast cancer cells. To assess the clinical 
association of these DNA damage repair genes and cell cycle genes with radioresistance, we 
analyzed data generated by the TCGA Research Network (https://cancergenome.nih.gov/) 
for relations between the expression of genes of interest and outcome after radiotherapy. 
Patients with T1-4,N0,M0 tumors were selected, and the cohort was divided in patients 
that did or did not receive radiotherapy as part of their primary treatment. Patients 
were dichotomized by the median value of each of the investigated genes. Of the five 
differentially expressed DNA damage repair genes, none was significantly associated with 
outcome in patients who received radiotherapy as part of their primary treatment (Table 
3). Only expression of EME2 was specifically associated with poor outcome in patients who 
did not receive radiotherapy, but not in patients that had received radiotherapy. 
The cell cycle genes that were differentially expressed in MCF-7TAM were also examined 
for an association between their expression and outcome after radiotherapy in the 
TCGA cohort. None of the more than 2 times upregulated or downregulated genes 
were associated with outcome in patients either treated with or without 
Table 2. Differential expression of cell cycle genes in tamoxifen-resistant breast cancer cells.
List of the differentially expressed cell cycle genes in MCF-7TAM. For each gene, the fold change in 
expression levels in MCF-7TAM compared to MCF-7WT is shown (based on normalized read counts), as 
measured by RNA sequencing.
radiotherapy (Table 3). 
Therefore, we conclude that none of the differentially expressed genes (DNA damage 
repair or cell cycle-related) are associated with radioresistance in the breast cancer 
patient cohort investigated.
Discussion
Here we aimed to identify possible mechanisms of radioresistance in acquired 
tamoxifen-resistant breast cancer cells by investigating the expression of DNA 
damage repair genes and cell cycle genes in breast cancer cells cultured to tamoxifen 
resistance. Increased expression of genes that stimulate DNA damage repair 
could mean that these are responsible for radioresistance observed in these cells. 
Conversely, decreased expression of genes that inhibit DNA damage repair could 
Table 3. Association of differentially expressed DNA damage genes and cell cycle genes with 
outcome after radiotherapy. 
For each of the DNA damage genes and cell cycle genes that were differentially expressed in MCF-
7TAM, the P-values of the association with relapse-free survival in patients treated with or without 
radiotherapy in the TCGA breast cancer cohort are depicted, based on the Breslow test.
Gene name Gene function Cell cycle phase Fold change MCF-7TAM
MAPK13 Cellular stress induced signaling protein M 2.95
E2F2 Cell cycle control G1/S 0.48
CKS2 Maintenance of cell wall integrity M 0.47
GINS2 Initiation of DNA replication G1/S 0.45
PCNA DNA polymerase cofactor G1/S 0.41
MCM5 Initiation of DNA replication G1/S 0.41
EIF5A2 Cell cycle control G2/M 0.34
CCNE1 CDK2 regulator G1 0.87
CDK2 Initiation of DNA synthesis G1/S 0.71
E2F1 Cell cycle control G1/S 0.59
MYC Cell cycle progression 0.33
CCND1 CDK4/6 regulator G1/S 0.31
DNA damage repair P-value TCGA: RT- P-value TCGA: RT+
Increased EME2 0.03 0.37
NEIL1 0.44 0.10
Decreased PCNA* 0.56 0.38
BRIP1 0.19 0.30
BARD1 0.78 0.32
Cell cycle P-value TCGA: RT- P-value TCGA: RT+
Increased MAPK13 0.31 0.16
Decreased E2F2 0.74 0.47
CKS2 0.62 0.77
GINS2 0.40 0.26
PCNA* 0.56 0.38
MCM5 0.67 0.33
EIF5A2 0.37 0.89
CCND1 0.28 0.68
MYC 0.15 0.08
* PCNA is both a DNA damage repair gene and a cell cycle gene   
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also lead to radioresistance. Moreover, increased expression of cell cycle genes that 
correspond to radioresistant parts of the cell cycle could explain radioresistance 
observed in tamoxifen-resistant cells. Interestingly, cross-resistance for irradiation 
was previously observed in hormone treatment-insensitive prostate cancer cells. 
These show increased radioresistance and upregulated genes involved in cell cycle 
arrest and DNA damage repair, suggesting common mechanisms might be involved 
in various hormone-sensitive cancers (19).
None of the known pathways involved in DNA damage repair (BER, MMR, NER, HR, 
or NEHJ) were as a whole differentially expressed in the tamoxifen-resistant cells. 
Luzhna et al. also investigated the expression of genes in DNA repair pathways in 
tamoxifen resistance, albeit after irradiation, and found that genes in these pathways 
are not upregulated or downregulated as well (2). Interestingly, proteins involved in 
DNA damage repair are poor prognostic factors in ER-positive breast cancer patients 
treated with endocrine therapy (17). Therefore, differential expression of DNA damage 
repair genes could merely be associated with the occurrence of tamoxifen resistance, 
and not specifically with the radioresistant phenotype. Moreover, ER-positive breast 
cancer patients have increased levels of damaging mutations in NER, BER, and NHEJ 
genes (17).
The specific DNA damage repair genes that were upregulated or downregulated in 
tamoxifen-resistant cells in our current study cannot explain radioresistance observed 
in those cells. Although NEIL1 and EME2 (both > 2-fold increased RNA expression in 
tamoxifen resistance) are both stimulators of DNA damage repair (20,21), we did not 
find an association of their gene expression with outcome after radiotherapy in the 
TCGA patient cohort, meaning that the genes are not likely to induce radioresistance 
in patients. BRIP1 and PCNA were downregulated in tamoxifen-resistant breast 
cancer cells. As these are both stimulators of DNA damage repair as well (22,23), 
their decreased expression does not explain radioresistance observed in these 
cells. BRIP1 is associated with the repair of DNA double-strand breaks, as evidenced 
by assessment of γH2AX foci, after chemotherapy (24). Its lower expression in the 
tamoxifen-resistant cells in this study is therefore unclear. 
Interestingly, PCNA is involved both in DNA damage repair as well as in cell cycle 
regulation. In a study with radiotherapy-treated oral cancer patients, low expression of 
PCNA was associated with a better patient survival (25), which indeed points towards 
an opposite role for PCNA in radioresistance than its expression in tamoxifen-resistant 
cells in this study suggests. However, in pancreatic tumor cells, PCNA was increased 
in cells treated with rapamycin, which was associated with decreased radioresistance 
(26). In another study PCNA inhibition increased the number of double-strand breaks 
after treatment with DNA-damaging chemo agent cisplatin and therefore sensitized 
cells to this treatment (27). PCNA may therefore have a dual role, either promoting or 
inhibiting DNA damage repair, and this may differ in different cancer models. 
A BRCA1-interacting protein, BARD1, also showed decreased gene expression in 
tamoxifen-resistant cells, as well as BRCA1 itself, which had a slightly decreased 
expression, contrary to earlier reports (6). We did not observe an increased expression 
of LIG3 or PARP1, as Tobin et al. did (5). This shows that even though some aspects 
of tamoxifen resistance are consistent when creating tamoxifen-resistant cells from 
wild-type MCF-7 cells, heterogeneity remains an important issue.
Cells are relatively resistant to irradiation in G1 and S phases, as DNA damage repair 
genes are highly expressed in those phases to guarantee correct DNA replication. 
We found a decrease in genes related to G1 and G1/S phases, which is not in line with 
the radioresistant phenotype of these cells. The only cell cycle gene with increased 
expression was MAPK13. Although it is present in the M phase, a relative radiosensitive 
phase, it has previously been associated with paclitaxel resistance in breast cancer (28), 
and it is expressed in radioresistant gynecological cancer stem cells (29). One of the 
genes with decreased expression, E2F2, is a mediator of apoptosis that is induced after 
DNA damage (30,31). Its decreased expression could lead to a decrease in radiation-
induced apoptosis, and therefore contribute to radioresistance in tamoxifen-resistant 
cells. CKS2, which slows down the cell cycle in order to allow repair of DNA damage 
(32), is associated with enhanced sensitivity to different chemotherapeutic agents 
when overexpressed (33), which could correspond to enhanced radioresistance 
in tamoxifen-resistant breast cancer cells where it is downregulated. However, 
in another study high expression levels of CKS2 were associated with decreased 
overall survival in breast cancer patients, which is contrary to these data (34). 
MCM5 and GINS2 showed decreased expression in the tamoxifen-resistant cells. 
These genes are essential for DNA replication (35). MCM5 is associated with worse 
outcome in patients when highly present in breast cancer patients (36). GINS2 was 
previously associated with tamoxifen resistance when higher expressed in breast 
cancer patients, in contrast to what we found (37). In another study, GINS2 knock-
down was found to induce apoptosis (38). These observations are contrary to the 
implications that our findings here have. EIF5A2 was earlier found to be upregulated 
in radioresistant colorectal cancer cell lines (39), contrary to our findings, and high 
levels of EIF5A2 were associated with poor outcome after chemoradiotherapy in 
nasopharyngeal carcinoma patients (40). In breast cancer high expression levels of 
EIF5A2 were associated with chemoresistance as well (41). Finally, CCND1, a regulator 
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of G1/S transition (42), and MYC were also downregulated in tamoxifen-resistant 
breast cancer cells. CCND1 overexpression was previously associated with tamoxifen 
resistance (43,44), while it was also associated with increased radiosensitivity in 
MCF-7 cells (45). The latter is in line with our data. However, CCND1 knock-down in 
prostate cancer cells sensitized them to irradiation (46). Downregulation of MYC has 
previously been shown to impair cell cycle progression (47). High expression levels of 
MYC were present in radioresistant breast cancer cells (48), and similarly in docetaxel-
resistant lung cancer cells that were cross-resistant to irradiation (49). 
Many of the genes that were differentially expressed in tamoxifen-resistant breast 
cancer cells are associated with radiosensitivity. However, we did not find an 
association between the expression of these genes and outcome after radiotherapy 
in a breast cancer patient cohort. In some cases, our findings were contradictory to 
what others found in terms of association with radiosensitivity. This can partly be 
explained by the fact that we found these genes to be differentially expressed after 
chronic tamoxifen treatment. This change in expression could be an effect of this 
treatment alone and not involved in the cross-resistance for radiotherapy that we 
observed. Therefore, the effect of these genes on radiosensitivity should indeed be 
further investigated in tamoxifen-resistant cells. 
Other pathways involved in radioresistance ought to be investigated for their role 
in the cross-resistance observed in tamoxifen-resistant cells, such as hypoxia, one 
of the three crucial factors in radioresistance, next to proliferation and DNA damage 
repair (50). Tamoxifen has been shown to induce hypoxia in MCF-7 xenografts (51). 
Therefore, the role hypoxia-induced genes play in radioresistance in tamoxifen-
resistant breast cancer should be further investigated. Moreover, in vitro studies may 
lack information that is crucial for therapy outcome in patients. Other cells in the 
tumor microenvironment can also contribute to responses to treatment. Another 
related factor is neovascularization, which is known to codetermine the response to 
cancer treatment (52). Therefore we wanted to confirm the results in clinical data-sets 
to establish correlations of DNA damage repair genes and cell cycle genes on patient 
outcome. Finally, the results obtained from retrospective clinical studies may be 
biased by the fact that patients who have been treated with radiotherapy differ from 
patients who have not been thus treated. Therefore, more clinical data is necessary 
before final conclusions about the role of these DNA damage repair genes and cell 
cycle genes can be drawn. 
In conclusion, we identified differentially expressed DNA damage repair genes and 
cell cycle genes in tamoxifen-resistant breast cancer cells. Many of these are related 
to radiosensitivity according to literature. However, a direct relation between these 
genes and radioresistance could not be identified, as none of them was associated 
with outcome after radiotherapy in a breast cancer patient cohort. Thus, changes in 
DNA damage repair or cell cycle genes do not explain cross-resistance of tamoxifen-
resistant breast cancer cells for radiotherapy and are not likely targets to preclude the 
occurrence of this cross-resistance.
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Chapter 6
APOBEC3B expression is associated 
with radioresistance and RAD51 
expression in breast cancer patients 
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Abstract
Purpose
APOBEC3B, a DNA cytosine deaminase, is highly expressed in breast cancers and 
induces signature mutations in these tumors. APOBEC3B promotes genetic instability 
and thereby facilitates clonal selection and subsequent therapy resistance. Here, we 
aimed to investigate the role of APOBEC3B in radioresistance, both in a breast cancer 
patient cohort and in an in vitro model system. 
Results
In breast cancer patients, high levels of APOBEC3B were associated with worse disease-
free survival only when patients received radiotherapy. In MCF-7 breast cancer cells 
carrying an APOBEC3B knock-down in vitro, increased 53BP1 foci were observed 
directly after irradiation. Moreover, MCF-7 breast cancer cells containing either a 
stable APOBEC3B knock-down or a vector overexpressing APOBEC3B could not be 
cultured to radioresistance. In the TCGA breast cancer patient cohort, expression 
of genes involved in homologous recombination, in particular RAD51, was highly 
correlated with APOBEC3B expression. MCF-7 cells with stable APOBEC3B knock-
down or overexpressed APOBEC3B were not differentially sensitive to the RAD51 
inhibitor B02. However, APOBEC3B knock-down prevented B02-induced sensitization 
to irradiation.
Conclusions
APOBEC3B is involved in radioresistance in breast cancer patients, possibly via RAD51. 
Further research investigating the interaction between these two genes is necessary, 
to unravel the precise mechanism by which they mediate radioresistance.
Introduction
Radiotherapy is an essential cornerstone of breast cancer treatment, especially after 
breast-conserving surgery (1). Although radiotherapy decreases the local recurrence 
rate and improves survival, intrinsic or acquired treatment resistance leads to adverse 
outcome in a substantial group of patients. Radioresistance in breast cancer has been 
extensively investigated in vitro (2,3), and gene signatures have been identified that 
predict responses to radiotherapy (4,5). These gene signatures were investigated in 
clinical practice and were found to be prognostic for recurrences. Thus, they were 
able to stratify patients for adjuvant radiotherapy (6).
Here, we investigate the role of APOBEC3B (apolipoprotein B mRNA-editing enzyme, 
catalytic polypeptide-like 3B) in acquired radioresistance in breast cancer. APOBEC3B 
is a DNA cytosine deaminase that is part of the APOBEC family (7). Initially, a role in 
innate immune defense was described for this protein family, but APOBEC mutation 
signatures have since also been found in various types of cancer (8). In breast cancer, 
APOBEC3B was the only upregulated APOBEC family member in various breast cancer 
cell lines compared to breast epithelial cells (9). Moreover, APOBEC3B was shown to 
have DNA editing capacity in this context. The upregulation of APOBEC3B was also 
observed in human breast cancer tissue compared to normal tissue (9). 
DNA editing by APOBEC3B in breast cancer leads to APOBEC signature mutations 
(8), and promotes heterogeneity of the tumor. Selection pressure on the tumor, 
for example resulting from therapy, promotes clonal selection and the survival of 
resistant clones (10). Indeed, increased APOBEC gene expression, as well as APOBEC 
mutation signatures were detected in therapy-resistant breast cancer subclones 
(11,12). In a mouse model, APOBEC3B conferred tamoxifen resistance, and APOBEC3B 
was also associated with responses after tamoxifen treatment for advanced breast 
cancer patients (13).
As we and others have shown that estrogen receptor-positive MCF-7 breast 
cancer cells that obtained tamoxifen resistance are also radioresistant (14-16), we 
investigated the role of APOBEC3B in radioresistance in breast cancer. We assessed 
the association between APOBEC3B expression and outcome after radiotherapy in a 
breast cancer patient cohort, and aimed to further explore its role in radioresistance 
with radiosensitivity assays in vitro. 
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Materials and methods
Patients: Radboudumc cohort 
In this cohort, the association between tumor APOBEC3B expression and sensitivity 
to radiotherapy was assessed retrospectively. Patients with resectable breast cancer 
that did not receive adjuvant systemic therapy were selected from a previously 
described cohort (17,18). Postoperative radiotherapy was given to the thoracic 
wall after an incomplete resection, infiltration of the chest wall or skin, or in case of 
nodal involvement. Periclavicular and axillar irradiation was applied based on axillar 
node involvement. Parasternal irradiation was applied when the tumor was medially 
localized. Finally, whole breast irradiation was performed as part of breast-conserving 
treatment. Patients who received radiotherapy as part of their primary treatment (n = 
392) were compared with patients who did not receive radiotherapy (n = 240). 
Cell culture
MCF-7 cells from LCG Standards were cultured as described earlier (16). Radioresistant 
cells for RNA sequencing were obtained by irradiating MCF-7 cells weekly with 4 
Gy, until they had received 13 fractions (16). Irradiation was performed using an 
X-Rad 320ix Biological Irradiator (Precision X-Ray) at a dose rate of 3.1 Gy/minute. 
MCF-7 cells transduced with short-hairpin RNA against APOBEC3B (shA3B) or control 
[shCTRL, both described in (9)], or carrying a vector expressing functional APOBEC3B 
(OE-A3B) or catalytically inactive APOBEC3B [OE-DCM, both described in (13)] were 
obtained from Reuben Harris (Minneapolis, USA). These cells were cultured to 
radioresistance by irradiating them daily with 1 Gy, 4 times a week, until they had 
received 40 fractions. Cell lines were authenticated by short tandem repeat analysis. 
Cells tested negative in regularly performed mycoplasma tests.
RNA isolation
RNA to be used for RNA sequencing was isolated using the Total RNA purification 
Kit (Norgen Biotek Corp.), with on column DNase treatment (RNase-Free DNase Set 
#79254; Qiagen), according to the manufacturer’s instructions. RNA for qRT-PCR 
analysis was isolated using the Quick-RNA™ Miniprep kit (Zymo Research), with on 
column DNase treatment, according to the manufacturer’s instructions.
RNA sequencing
RNA sequencing of wild-type MCF-7 and radioresistant MCF-7 cells was performed as 
described previously (16).
cDNA synthesis
500 ng of isolated RNA was reverse transcribed to cDNA. First, RNA was incubated 
with random hexamer primers (#11034731001; Roche Diagnostics) and dNTPs (#NU-
0020-50; Kaneka Eurogentec) at 65°C for 5 min. Next, first strand buffer (#1843648; 
Invitrogen), DTT (M-MLV Reverse Transcriptase Buffer #18057-018; Invitrogen), 
RNAsin (#N2515; Promega), and reverse transcriptase (#28025-021; Invitrogen) were 
added. The following program was run on a thermocycler: 10 min at 25°C, 50 min at 
37°C and 15 min at 70°C. The newly acquired cDNA was diluted 6.5 times and used for 
quantitative real time pcr (qRT-PCR).
qRT-PCR
Gene expression was analyzed using a CFX96 real-time PCR detection system 
(Bio-Rad Laboratories Inc.) with SYBR Green (#18168621, Roche). The following 
primers were used: APOBEC3B: FW, 5’- CGCCAGACCTACTTGTGCTA-3’; and REV, 5’- 
GCCACAGAGAAGATTCTTAGCC -3’; RAD51: FW, 5’-TCTCTGGCAGTGATGTCCTGGA-3’; and 
REV, 5’-TAAAGGGCGGTGGCACTGTCTA-3’; HPRT: FW, 5’-TGACACTGGCAAAACAATGCA-3’; 
and REV, 5’-GGTCCTTTTCACCAGCAAG-3’. APOBEC3B expression analysis was 
performed using the following thermocycler program: 10 min at 95°C, followed by 35 
cycli of 30 sec at 95°C, 30 sec at 62°C and 30 sec at 72°C. RAD51 and HPRT expression 
analysis was performed using the following thermocycler program: 10 min at 95°C, 
followed by 35 cycli of 15 sec at 95°C and 1 min at 60°C. 
Colony forming assay
To assess clonogenic cell survival after irradiation, MCF-7 cells were seeded in 6-well 
plates and allowed to adhere overnight, before the cells received a single dose of 4 
or 6 Gy. Rad51 inhibitor B02 (10 μmol/L; #553525, Merck) was added 2 hours before 
irradiation, and medium was changed 24 hours after irradiation. Once colonies in the 
control conditions consisted of at least 50 cells, fixation and staining was performed 
with 0.5% (w/v) crystal-violet (Sigma-Aldrich) in a solution of 50% methanol and 30% 
ethanol. Colonies of at least 50 cells were counted manually.
Cell viability assay 
Two thousand MCF-7 cells were seeded per well of a 96-well plate and allowed to 
adhere for 24 hours. Then, cells were treated with different concentrations of B02 
(ranging from 1 to 100 μmol/L; Merck) for 24 hours, after which the cells were 
allowed to grow for 4 days before analyzing cell viability using Cell Counting Kit 8 
(Sigma Aldrich) according to the manufacturer’s instructions. Absorption values were 
measured using an iMark™ microplate absorbance reader (Bio-Rad Laboratories Inc.).
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Fluorescence microscopy for 53BP1 and Rad51 staining
For 53BP1 foci analysis, MCF-7 cells were seeded in glass chamberslides (Nunc™ Lab-
Tek™ II #154526; ThermoFisher Scientific) and allowed to attach for 24 hours. The 
slides were irradiated with 2 Gy, and fixed 10 minutes in 10% formalin after 0, 1, 6, 
and 24 hours. Slides were incubated for 30 minutes with 0.1% Triton-X in PBS. Cells 
were stained with rabbit anti-53BP1 (PA1-16565, ThermoFisher Scientific), at a 1:1000 
dilution in primary antibody diluent (PAD; Bio-Rad Laboratories Inc.). For baseline 
RAD51 staining, MCF-7 cells seeded in glass chamberslides were fixed in 10% formalin 
when confluence was around 70%. Slides were incubated for 30 minutes with 0.1% 
Triton-X in PBS. Cells were stained with rabbit anti-RAD51 (ab133534, Abcam), at a 
1:1000 dilution in primary antibody diluent (PAD; Bio-Rad Laboratories Inc.). In both 
cases, the secondary antibody used was donkey anti-rabbit Alexa Fluor-488 (A21206, 
ThermoFisher Scientific). Nuclei were visualized using Hoechst 33342 (1 mg/ml) in 
a 1:3000 dilution in PBS. Images were acquired using a Leica DM6000 microscope 
(Leica).
Patients: TCGA database 
The breast cancer cohort of the cancer genome atlas data (TCGA) project 
(https://portal.gdc.cancer.gov/projects/TCGA-BRCA) was used to assess the association 
of APOBEC3B expression with the expression of genes of interest using the University 
of California at Santa Cruz Xena Browser at http://xena.ucsc.edu/. Individual sets of 
genes involved in different DNA damage repair pathways [https://www.mdanderson.
org/documents/Labs/Wood-Laboratory/human-dna-repair-genes.html; (19,20)] were 
uploaded to Xena Browser, and correlated with APOBEC3B expression in all 1218 tumor 
samples of the TCGA breast cancer cohort.
Statistics
Statistical analysis of the Radboudumc patient cohort was performed using SPSS 
(SPSS Inc.). For comparison of categorical variables, Pearson χ2 tests were applied. 
Survival curves were generated using the Kaplan-Meier method, and differences in 
survival were tested with a Breslow test. Statistical analysis of colony forming assays, 
and qRT-PCR experiments were performed using GraphPad Prism software with 
two-sided Student t tests. For correlation analysis of the TCGA data, nonparametric 
Spearman’s Rank-Order correlation tests were used and Spearman’s rank ρ values 
were plotted. Genes with a correlation coefficient of ρ ≥ 0.5 were considered to 
correlate strongly with APOBEC3B expression.
Results
High APOBEC3B expression is associated with higher grade 
breast cancers and a worse relapse-free survival after 
radiotherapy
MCF-7 breast cancer cells were cultured to radioresistance, and RNA sequencing was 
performed on these cells (16). Of the ten APOBEC family members, only APOBEC3B 
was expressed above threshold levels (>10 read counts) in wild-type MCF-7 cells and 
radioresistant MCF-7 cells (Fig. 1A). APOBEC3B expression was 1.9 times higher in 
radioresistant MCF-7 cells compared to wild-type cells.
To assess whether APOBEC3B plays a role in radioresistance, APOBEC3B expression was 
quantified by qRT-PCR in tumors of 632 breast cancer patients from the Radboudumc 
(Fig. 1B). First, patient characteristics were compared between patients who had 
expression levels of APOBEC3B above the median with those who had APOBEC3B 
expression levels below the median (Table 1). Patients with high APOBEC3B levels 
had significantly larger tumors (P = 0.016), with more nodal involvement (P = 0.001) 
and a higher grade (P = 0.001). Moreover, although hormone receptor status was only 
known for a small percentage of patients, patients with high APOBEC3B levels had 
more hormone receptor-negative tumors (ER: P = 0.001; PgR: P = 0.005), compared 
to patients with APOBEC3B levels that were below the median. HER2 status was not 
different for patients with high or low APOBEC3B levels (P = 0.096), nor were there 
differences in the type of treatment (surgery: P = 0.501, adjuvant systemic therapy: P = 
0.456, or radiotherapy: P = 0.427). In general, patients with high APOBEC3B expression 
levels had more aggressive tumors.
Next, the relation between APOBEC3B expression and disease-free survival was 
assessed in these patients. The cohort was divided in patients who were treated with 
radiotherapy (n = 392), and those who were not (n = 240). In patients who were not 
treated with radiotherapy, there was no difference in disease-free survival between 
patients with high expression levels of APOBEC3B and those with low gene expression 
when dichotomized at the median value of APOBEC3B expression (Fig. 1C, P = 0.297). 
However, when patients received radiotherapy as part of their primary treatment, 
patients with high levels of APOBEC3B had a worse outcome compared to those with 
low expression levels (P < 0.001). As patients who receive radiotherapy differ from 
those who do not receive radiotherapy, especially with respect to the type of surgery 
that is performed, the analysis was repeated for only those patients who underwent 
a mastectomy (Fig. 1D). This way, we aimed to exclude possible bias arising from the 
fact that all patients undergoing a lumpectomy are irradiated. 
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In this more homogenous group, the association of APOBEC3B expression with disease-
free survival in patients who received radiotherapy was again observed (n = 85, 
P < 0.001), while there was no association between APOBEC3B expression and outcome 
for those patients who did not receive radiotherapy (n = 219, P = 0.447). Therefore, 
APOBEC3B expression is associated with radiosensitivity in this patient cohort. 
Table 1. Clinicopathological characteristics of all patients in the Radboudumc cohort compared 
between groups with APOBEC3B expression levels below and above the median.
APOBEC3B
number (%)  low (<median) high (>median) P
pT 1 168 (56) 134 (44) 0.004
2 112 (43) 149 (57)
3/4 19 (43) 25 (57)
nodal category 0 219 (54) 188 (46) 0.001
1 62 (48) 67 (52)
2 17 (29) 42 (71)
3 2 (22) 7 (78)
Grade 1/2 124 (52) 115 (48) 0.001
3 87 (40) 132 (60)
ER neg 17 (28) 43 (72) 0.001
pos 17 (74) 6 (26)
PgR neg 23 (34) 45 (66) 0.005
pos 11 (73) 4 (27)
ERBB2 neg 29 (48) 32 (52) 0.096
pos 7 (29) 17 (71)
surgery mastectomy 163 (50) 165 (50) 0.501
lumpectomy 152 (50) 152 (50)
adjuvant therapy no 267 (51) 259 (49) 0.456
endocrine 22 (52) 20 (48)
chemo 9 (38) 15 (62)
both 17 (43) 23 (57)
radiotherapy no 118 (49) 122 (51) 0.427
yes 197 (50) 195 (50)
Figure 1. APOBEC3B expression in radioresistant breast cancer cells and association with 
outcome in a breast cancer patient cohort A, Expression of APOBEC family members, measured 
by RNA sequencing in wild-type MCF-7 cells (MCF-7WT) and radioresistant MCF-7 cells (MCF-7RT). 
Depicted are normalized read counts. B, Highly variable expression of APOBEC3B in 632 breast cancer 
patients, measured by qRT-PCR, depicted as expression relative to HPRT. C, Patients in this breast 
cancer cohort were divided into patients treated with (n = 392) or without radiotherapy (n = 240); 
D, or only patients who underwent a mastectomy were divided into groups treated with (n = 85) or 
without radiotherapy (n = 219). For each group, disease-free survival (DFS) was assessed for patients 
with high (above median, black) levels of APOBEC3B, or those with low levels of APOBEC3B (gray). 
Statistical significance was determined with the Breslow method.
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APOBEC3B knock-down increases 53BP1 foci number 
after irradiation, while foci numbers are decreased in cells 
overexpressing APOBEC3B 
Patients with tumors expressing high levels of APOBEC3B appeared to be more 
radioresistant. Therefore, we investigated a potential role for APOBEC3B in 
radiosensitivity in vitro. First, the DNA damage response after irradiation was 
investigated in human breast cancer MCF-7 cell lines in which the levels of APOBEC3B 
were stably modified using shRNA or an overexpression vector (provided by Reuben 
Harris, Minneapolis, USA). MCF-7 cells had been transduced with short hairpin RNAs 
against APOBEC3B [shA3B, (9)] or with a vector expressing APOBEC3B [OE-A3B, (13)]. As 
a control, MCF-7 cells had been transduced with a control short hairpin RNA [shCTRL, 
(9)] or a vector overexpressing a catalytically inactive mutant of APOBEC3B [OE-DCM, 
(13)]. APOBEC3B expression levels were 30.6 times decreased in the shA3B cell line 
compared to the shCTRL cell line, and increased 5.9 and 8.5 times respectively in both 
the OE-DCM and the OE-A3B cell lines compared to the wild-type MCF-7 cells (Fig. 2A). 
The various MCF-7 cells were irradiated with 2 Gy and 53BP1 was visualized after 0, 
1, 6, and 24 hours (Fig. 2B). One hour after irradiation, MCF-7 shA3B cells appear to 
have more pronounced 53BP1 foci than MCF-7 shCTRL cells. There are no obvious 
differences between the cell lines 6 or 24 hours after irradiation, suggesting that DNA 
damage repair is equally efficient in all cell lines. 
APOBEC3B knock-down or overexpression does not influence 
baseline radiosensitivity, and these cells cannot be cultured to 
radioresistance
Next, the effect of APOBEC3B expression levels on radiosensitivity was investigated 
in this MCF-7 model system. Colony forming assays were performed, measuring 
the surviving fraction after 4 Gy in these cells (Fig. 3A). There was no difference in 
surviving fraction between the shA3B cell line and the shCTRL cell line (P = 0.21), nor 
in surviving fraction between the OE-DCM and OE-A3B cell lines (P = 0.90). 
To further investigate a possible role for APOBEC3B in radioresistance in breast cancer 
cells, the five MCF-7 cell lines with varying APOBEC3B expression were cultured to 
radioresistance by irradiating them daily with 1 Gy, 4 fractions a week, up to a total 
dose of 40 Gy. Radiosensitivity after this irradiation schedule was measured by a colony 
forming assay using a single dose of 6 Gy (Fig. 3B). Using this irradiation schedule, 
the wild-type MCF-7 cells became radioresistant, as did the shCTRL and the OE-DCM 
cell lines (P = 0.001, P = 0.003, and P = 0.023, respectively). The shA3B and the OE-
A3B cell line showed no difference in radiosensitivity after 40 times 1 Gy irradiation 
compared to the unirradiated controls (P = 0.123, and P = 0.861, respectively). The 
effect observed in the shA3B cell line after repeated irradiation corresponds to what 
we observed in patients, namely that low APOBEC3B expression is associated with 
radiosensitivity i.e. a better outcome in patients.
Figure 2. APOBEC3B levels affect 53BP1 foci formation 1 hour after irradiation A, APOBEC3B 
levels in wild-type, shCTRL, shA3B, OE-DCM, and OE-A3B MCF-7 cells. qRT-PCR data are depicted 
as relative expression to HPRT and represented as mean + SD (technical replicates, n = 2). B, 53BP1 
expression (green) in MCF-7 cells with different levels of APOBEC3B 0, 1, 6, or 24 hours after irradiation 
with 2 Gy. Nuclei are stained with Hoechst (blue). 
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APOBEC3B expression in breast cancer patients is correlated 
with the expression of genes in DNA damage repair pathways, 
especially with RAD51 expression
We hypothesized that cells with high APOBEC3B levels and associated mutational 
load might require enhanced DNA damage repair activity for accurate replication, 
explaining the association of APOBEC3B with radioresistance as described above. 
Therefore, the correlation of DNA damage repair genes with APOBEC3B expression was 
investigated in a cohort of breast cancer patients. To this end, data generated by the 
TCGA Research Network (https://cancergenome.nih.gov/) were analyzed. We assessed 
various DNA damage repair pathways: base excision repair (BER), mismatch repair 
(MMR), nucleotide excision repair (NER), homologous recombination (HR), and non-
homologous end joining (NHEJ). Expression of genes in these pathways was correlated 
with APOBEC3B expression using the nonparametric Spearman’s Rank-Order correlation 
assay. Spearman’s rank ρ values were plotted (Fig. 4A). Genes involved in HR were more 
often highly correlated with APOBEC3B expression in breast tumors (two-sided t test 
compared to mean = 0; BER: P = 0.051, MMR: P = 0.944, NER: P = 0.476, HR: P = 0.008, 
NHEJ: P = 0.111, Other: P <  0.001).
The genes with a positive Spearman’s correlation coefficient higher than 0.5 were 
plotted in a heat-map, comparing their expression in the TCGA breast cancer cohort 
with that of APOBEC3B. These genes were: NEIL3 (BER), RAD51, RAD51L, EME1, RAD51B 
(all HR), EXO1, FANCA, BLM, POLQ, FEN1, FANCI, PCNA, CHEK1, RECQL4, FANCD2, and 
CHEK2. RAD51 showed the highest correlation with APOBEC3B expression (Fig. 4B). 
Figure 3. MCF-7 shA3B and MCF-7 OE-A3B do not become radioresistant after 40x1 Gy 
irradiation A, Clonogenic survival of MCF-7 wild-type, shCTRL, shA3B, OE-DCM and OE-A3B after 
treatment with irradiation. B, Clonogenic survival of the same parental cell lines, compared to 40x1 
Gy irradiated cell lines after treatment with irradiation. Data are represented as mean + SD (technical 
replicates, n = 3). Statistical significance was determined by Student t tests comparing the parental 
and 40x1 Gy clones of each cell line. * P < 0.05, ** P < 0.01
Figure 4. Correlation of expression 
of DNA damage repair genes with 
APOBEC3B expression in breast 
cancer patients A, Spearman’s rank 
ρ values for DNA damage repair 
genes, measured in the TCGA breast 
cancer cohort. Separate values are 
shown, as well as the mean (line). B, 
Correlation of DNA damage repair 
genes with a Spearman’s rank ρ 
value higher than 0.5 (see line in A) 
with APOBEC3B expression in the 
TCGA breast cancer cohort, depicted 
in a heat-map. At the bottom, 
Spearman rank ρ values are shown.
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Strikingly, when the entire genome is assessed, RAD51 is the third highest correlating 
gene with APOBEC3B expression (data not shown). 
APOBEC3B knock-down prevents RAD51 inhibition-induced 
radiosensitization
Thus, RAD51 expression was highly associated with APOBEC3B expression in breast 
tumors. To assess whether cancer cells indeed rely on RAD51 to compensate for the 
mutational activity of APOBEC3B, its expression and the effect of RAD51 inhibition 
was investigated in the MCF-7 cell line panel with varying APOBEC3B levels. 
RAD51 mRNA expression was not differentially expressed between the wild-type MCF-
7 cell line, shCTRL, shA3B, OE-DCM, and OE-A3B cell lines (Fig. 5A). RAD51 expression 
was also assessed using fluorescent microscopy, and no differences in expression 
were observed between the different cell lines (Fig. 6).
Figuur 5. Association between RAD51 and APOBEC3B in vitro A, RAD51 expression levels in 
wild-type, shCTRL, shA3B, OE-DCM, and OE-A3B MCF-7 cells. qRT-PCR data are depicted as relative 
expression to HPRT and represented as mean + SD (technical replicates, n = 2). B, Cell viability of 
wild-type, shCTRL, shA3B, OE-DCM, and OE-A3B MCF-7 cells after treatment with RAD51 inhibitor B02 
for 24 hours. Data are represented as mean + SD (technical replicates, n = 3). C, Clonogenic survival 
of the same cell lines after treatment with irradiation, pre-treated with B02 or DMSO (control). Data 
are represented as mean + SD (technical replicates, n = 3). Statistical significance was determined 
by Student t tests comparing the control treated and B02-treated results of each cell line. * P < 0.05, 
** P < 0.01
Next, RAD51 was inhibited using the RAD51 inhibitor B02 (21). First, the survival of all five 
MCF-7 cell lines was assessed in a dose-response experiment with B02 concentrations 
ranging from 1 to 100 μmol/L  (Fig. 5B). B02 did not affect the wild-type, shCTRL, shA3B, 
OE-DCM, or OE-A3B cell lines differently, which does not support our hypothesis that 
cells with high APOBEC3B expression levels require RAD51 for survival. 
Finally, we performed a colony forming assay after radiotherapy in combination with 
the RAD51 inhibitor B02 in these cell lines. All five cell lines were treated with B02 
for 2 hours, and then irradiated with 4 Gy (Fig. 5C). The B02-treated wild-type cells 
were more sensitive to irradiation than the control-treated cells, which is in line with 
the role of RAD51 in DNA damage repair. No effect of overexpression of APOBEC3B 
on RAD51 inhibition in combination with radiotherapy was found.  Remarkably, in 
the cell line with an APOBEC3B knock-down, no effect of B02 on radiosensitivity 
Figuur 6. Association between RAD51 and APOBEC3B in vitro RAD51 expression (green) in MCF-7 
cells with different levels of APOBEC3B. Nuclei are stained with Hoechst (blue). 
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was observed. This suggests that in cells with lower APOBEC3B expression the role 
of RAD51 in surviving irradiation-induced DNA damage is less relevant, as per our 
hypothesis.
Discussion
As APOBEC3B-induced mutagenesis is an important player in facilitating clonal 
selection and therefore therapy resistance, we aimed to investigate its role in 
radioresistance. In a breast cancer patient cohort, high levels of APOBEC3B were 
associated with worse disease-free survival when patients received radiotherapy. 
We hypothesized that high levels of APOBEC3B cause a more heterogeneous 
cancer cell population, therefore allowing for clonal selection of resistant cells 
after repeated irradiation. However, while cells carrying an APOBEC3B knock-down 
had more pronounced 53BP1 foci directly after irradiation and less 53BP1 foci were 
observed in cells with overexpressed APOBEC3B, APOBEC3B did not influence 
base-line radiosensitivity in vitro. Contrary, when cells containing a knock-down of 
APOBEC3B or having overexpressed APOBEC3B underwent repeated irradiation, they 
did not become radioresistant, while the control cell lines did. The observations in 
the APOBEC3B knock-down cell line are in line with the patient data described here. 
Next, the association of APOBEC3B expression with the expression of DNA damage 
repair genes was investigated in the TCGA breast cancer cohort. RAD51 expression, 
involved in HR, was highly associated with APOBEC3B expression in this cohort. We 
hypothesized that RAD51 protects cells from DNA damage caused by high APOBEC3B 
levels. Survival assays with a RAD51 inhibitor did not show different effects in cells 
with increased or decreased APOBEC3B levels. However, RAD51 inhibition did not 
sensitize the cells with APOBEC3B knock-down to irradiation, while it did sensitize the 
other cell lines.
RAD51 is involved in HR, one of the repair mechanisms involved in repairing DNA 
double-strand breaks that occur after e.g. irradiation (22). Strikingly, it binds to single-
stranded DNA [together with its binding partner, RPA; (23)], which is APOBEC3B’s 
preferred target (24). Indeed, it has been proposed that repair of deaminase-induced 
lesions depends at least in part on HR (25). When RAD51 is inhibited, it leads to better 
outcomes after irradiation, both in breast cancer and other tumor types (26-28). 
Therefore, the specific contribution of APOBEC3B to radioresistance in breast cancer 
needs to be further investigated, to separate it from the effect RAD51 alone has on 
radioresistance.
One of the factors that needs to be taken into account when further investigating the 
role of APOBEC3B in radioresistance, is TP53. Firstly, active TP53 arrests cells in the G1 
phase to repair any DNA damage done by e.g. APOBEC proteins (29). Therefore, if TP53 
is functional in cancer cells, high APOBEC3B expression is less likely to lead to a very 
heterogeneous tumor, and cells will be more sensitive to treatment. Secondly, TP53 is 
involved in APOBEC3B’s regulation: active TP53 downregulates APOBEC3B expression 
(30). Finally, TP53 also downregulates RAD51 expression, thereby reducing HR activity 
(31). As the MCF-7 cells we used in this study have active TP53, this model may not be 
suitable to determine the role of APOBEC3B alone in breast cancer radioresistance. 
Therefore, cells with inactive TP53 should be used for further research. This can either 
be achieved by knocking out TP53 in MCF-7 cells using CRISPR-Cas9, or another cell 
model should be chosen that has mutated TP53 in which the effects of APOBEC3B 
on radiosensitivity can be investigated without interference of TP53. Moreover, 
APOBEC3B expression is known for a large number of breast cancer cell lines (9). 
Assessing the radiosensitivity of these cell lines could provide more insight in the 
role of APOBEC3B in radioresistance.
In conclusion, we show here that APOBEC3B expression is associated with outcome 
after radiotherapy in breast cancer patients. In vitro, cells carrying an APOBEC3B knock-
down had more DNA damage after irradiation and these cells could not be cultured 
to tamoxifen resistance. APOBEC3B expression correlates with RAD51 expression in 
breast cancer patients, and the contribution of both genes to the observed effect 
ought to be further investigated, preferably in a TP53 free model system. 
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In this thesis, various features involved in both tamoxifen resistance and 
radioresistance in breast cancer are described. Estrogen receptor (ER) positive breast 
cancer cells that were cultured to tamoxifen resistance were found to develop cross-
resistance to irradiation in vitro. If this cross-resistance observed in vitro also occurs 
in breast cancer patients, neoadjuvant tamoxifen treatment – an increasingly applied 
treatment strategy (1) – could decrease the efficacy of subsequent radiotherapy 
applied after surgery. Similarly, breast cancer patients who receive adjuvant tamoxifen 
treatment could be faced with worse outcomes when they are treated with irradiation 
for e.g. bone metastases. Therefore, in this thesis we aimed to identify mechanisms 
involved in both tamoxifen resistance and radioresistance to find possible targets for 
treatment-resistant breast cancer. 
Previously, our group identified the unfolded protein response/LAMP3/autophagy 
pathway as a mechanism involved in both types of resistance (2,3). In this thesis, the 
results of an untargeted approach to find additional mechanisms that may play a 
role in both tamoxifen resistance and radioresistance are described. To this end we 
performed RNA sequencing of ER-positive breast cancer cells that had been cultured 
to tamoxifen resistance or radioresistance. Upregulated and downregulated genes 
were identified in both types of resistant breast cancer cells compared to untreated 
parental cells. Genes that were differentially expressed in both tamoxifen-resistant 
and radioresistant breast cancer cells were further investigated for potential clinical 
relevance in several breast cancer patient cohorts. Next, we specifically analyzed the 
expression of DNA damage repair genes and cell cycle genes in tamoxifen-resistant 
breast cancer cells, mechanisms that were previously implicated in radioresistance. 
In this way we aimed to explain the cross-resistance to irradiation observed in these 
cells. Finally, the role of one IFN-induced antiviral protein that was already shown 
to play a role in tamoxifen-resistant breast cancer, APOBEC3B, was investigated in 
radioresistant breast cancer. In this chapter, these findings are put into a broader 
perspective and suggestions for further research are discussed.
The IFN response: induced by tamoxifen treatment and 
irradiation
Activation of type I and type II IFN signaling was observed in ER-positive breast 
cancer cells that had been cultured to resistance to either tamoxifen treatment or 
irradiation (chapter 2). Although we firmly established the activation of this signaling 
pathway in both types of resistant breast cancer cells, the question remains whether 
IFN-stimulated genes (ISGs) contribute to the development of treatment resistance, 
or whether they are merely part of a treatment-induced stress response. Previous 
research that focused on resistance to aromatase inhibitors showed the induction 
of an IFN response in aromatase inhibitor-resistant breast cancer cells (4). Choi et al. 
assessed several genes that we also found to be upregulated in tamoxifen-resistant 
and radioresistant cells [IFITM1, STAT1, IFI27, IFIT1, OAS1, MX1, and IRF9; Chapter 2; 
(4)]. Interestingly, aromatase inhibitor-resistant breast cancer cells were sensitized 
to aromatase inhibitor treatment by knock-down of one of these genes, i.e. IFITM1, 
suggesting that there is indeed a mechanistic link between ISGs and resistance to 
endocrine treatment (4). In mice, loss of IFITM1 inhibited the growth of aromatase 
inhibitor-resistant breast tumors (5). Another gene that was overexpressed in 
aromatase inhibitor-resistant cells, PLSCR1 (not upregulated in our resistant cells), 
did not sensitize these cells to treatment (4). This suggests a role for specific ISGs 
in the development of resistance to aromatase inhibitors. Tamoxifen resistance 
could therefore likewise be caused by overexpression of specific ISGs. Indeed, 
overexpression of the ISG G1P3 was shown to contribute to tamoxifen resistance 
in breast cancer cells, and knock-down of this gene sensitized cells to tamoxifen 
treatment (6). Moreover, G1P3 was associated with shorter relapse-free survival and 
overall survival in breast cancer patients with an ER-positive tumor (6). Notably, 
LAMP3 is also an ISG and possibly involved in IFN signaling (7). Our group previously 
identified LAMP3 as a protein involved in the development of tamoxifen resistance 
and radioresistance in breast cancer cells in vitro (2,3). 
Concerning radioresistance, our and other data showed a relation between activation 
of IFN signaling and radioresistance in breast cancer cells and in patients with breast 
cancer [Chapter 2, (8)], but a causal relation has not yet been demonstrated. We 
performed several experiments in vitro on radioresistant and tamoxifen-resistant 
breast cancer cells with an IFNα-receptor blocking antibody and STAT1 inhibitors, 
but did not observe increased sensitivity when these cells were irradiated or treated 
with tamoxifen, respectively (data not shown in this thesis). Knock-down assays or 
CRISPR-Cas9 screens could be used to screen tamoxifen-resistant or radioresistant 
cells for ISGs that contribute to the development of resistance. We performed a 
knock-down for one such ISG, APOBEC3B, in breast cancer cells, but did not observe 
differences in sensitivity to irradiation (Chapter 6). Identifying clinically relevant ISGs 
that are instrumental in the development of treatment resistance is of paramount 
importance, as the involved pathways may be considered as targets for treatment. 
We observed a treatment-induced increase of ISG expression in vitro. However, in 
breast cancer patients we have only investigated ISG expression in the primary, 
untreated tumor (Chapter 2). Following our in vitro data, we expect an increase in ISG 
expression after tamoxifen treatment or irradiation in patients as well, but this has 
yet to be determined. To this end ISG expression could be measured in samples of 
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relapsed tumors after tamoxifen treatment or irradiation, or in samples from patients 
that have been treated neoadjuvantly with either of these therapies (1). Ex vivo culture 
of human tumors could also be used to assess the effect of tamoxifen treatment 
or irradiation on ISG expression (9). In this way the increase of ISG expression that 
we observed in vitro could be translated to breast cancer patients. In future, such a 
culture system could also be employed to predict individual responses of the patient 
to tamoxifen treatment and/or irradiation. 
We expect that IFN signaling in tumor cells induced by tamoxifen treatment or 
irradiation induces resistance to either treatment, resulting in a worse outcome for 
patients. However, besides a direct effect on tumor cell sensitivity, the activation of 
IFN signaling in tumor cells could also modulate the immune response in the tumor 
microenvironment, and contribute to the development of treatment resistance in 
an indirect way. The effects IFNs have in the tumor microenvironment can be either 
immunostimulatory or immune suppressive. Immunostimulatory effects of type I 
IFNs are the induction of dendritic cell maturation and cross-presentation, which is 
essential for the activation of cytotoxic T-cells and subsequent antitumor immune 
effects (10). Moreover, deficient IFNα production by dendritic cells is associated with 
poor outcome for breast cancer patients (11). Therefore, modulation of the immune 
response by treatment with IFNs therefore seems suitable. Indeed, type I IFNs inhibit 
the accumulation and activity of a subset of T-cells that has immune suppressive 
effects (12). Also, when specifically targeting protein-engineered IFN to dendritic 
cells, growth of breast tumors in a 4T1 mouse model was inhibited (13). 
However, both type I and type II IFN signaling also have immunosuppressive effects, 
mostly as a result of persistent IFN signaling, via STAT3 (14, 15). For example, IFNγ 
can upregulate the inhibitory molecule PD-L1 on lung cancer cells (16). Although 
the immunosuppressive effects of IFNs are not as well described as its immune 
enhancing effects, the association of high ISG expression in tumors with a worse 
outcome after tamoxifen treatment or radiotherapy [Chapter 2; (8)], implies that 
tumor-promoting immune effects are taking place, either in tumor cells or in the 
tumor microenvironment.
Not only irradiation-induced IFN signaling could have an effect on immune cells, 
radiotherapy also directly affects immune cells. The composition of immune cells in 
the tumor microenvironment is likely dependent on the radiation dose that is applied 
(17). In a melanoma mouse model, radioresistant tumors had decreased numbers 
of cytotoxic T-cells after irradiation, which was attributed to altered chemokine 
production by the resistant tumor cells (18). An example of radiation causing immune-
modulated radioresistance was found in a mouse model of colon cancer, where 
irradiation with a single dose of 20 Gy resulted in the influx of monocytic myeloid 
cells that mediated radioresistance (19). These cells also suppressed cytotoxic T-cell 
activity (19). Moreover, radiotherapy induces PD-L1 on murine colon and lung tumors 
(20), a further example of immune suppression in the tumor microenvironment.
The presence of various immune cell subsets in the tumor microenvironment after 
tamoxifen treatment should likewise be determined. Therefore, mouse models of 
tamoxifen-resistant breast cancer, or samples of relapsed or neoadjuvantly treated 
tumors should be further assessed. So far, we have only shown that ISG expression 
in the primary tumor of breast cancer patients before treatment is associated with 
a tumor-infiltrating lymphocytes expression profile (chapter 2). We did not identify 
the cell types involved. Doing so could reveal whether there is an active antitumor 
immune response, or whether a suppressive microenvironment is induced after 
treatment with tamoxifen or radiotherapy and subsequent IFN signaling.
 
The link between cytoplasmic DNA and IFN signaling
Erdal et al. observed cytoplasmic ssDNA in irradiated cells (21). We showed here that 
tamoxifen treatment also results in the occurrence of cytoplasmic ssDNA (chapter 2). 
Given the strong induction of ISGs after both tamoxifen treatment and irradiation, we 
hypothesized that this ssDNA induces an IFN response via a specific DNA sensor. After 
investigating several candidate DNA sensors and signaling molecules, we propose 
that the cGAS-STING DNA sensing pathway is a possible link between cytoplasmic 
ssDNA and the activation of an IFN response in breast cancer cells after tamoxifen 
treatment or irradiation (chapter 3).
Cytoplasmic DNA is a trigger for DNA sensors as it signifies the presence of viruses or 
bacteria. The IFN signaling pathway is subsequently activated to induce an immune 
response. Cytoplasmic ssDNA in tumor cells, triggered by tamoxifen treatment 
(chapter 2) or irradiation (21), also appears to activate an IFN response via STING 
signaling. A role for the STING-related DNA sensor cGAS in the recognition of 
cytoplasmic DNA was proposed earlier (21, 22). However, most studies find that only 
dsDNA is capable of activating an IFN response after irradiation. Erdal et al. propose 
an additional role for cGAS in recognizing ssDNA (21), even though cGAS is primarily 
activated by dsDNA (23). 
It remains unknown how ssDNA appears in the cytoplasm. For dsDNA, micronuclei 
were implicated in this process (24). These small nuclei are considered a marker of 
radiation damage (24), and the cytosolic DNA it contains can activate the cGAS-STING 
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pathway and subsequent IFN signaling (25). Although micronuclei in ovarian cancer 
were found to contain ssDNA, that was only the case 36 hours after the appearance of 
micronuclei (26). Tang et al. suggest this is due to the processing of broken DNA ends 
of the dsDNA by nucleases, thereby producing ssDNA (26). However, the occurrence 
of ssDNA after tamoxifen treatment cannot be explained in the same manner, as 
we observed the presence of cytosolic ssDNA within hours after treatment, without 
any dsDNA present. Instead of micronuclei, cytoplasmic ssDNA could be clustered 
into “speckles” [reviewed in: (27)]. These “speckles” of ssDNA, observed after DNA 
damaging agents, may form double-stranded secondary structures that are able to 
potently induce cGAS signaling [reviewed in: (27)], as cGAS does not bind ssDNA (23).
STING signaling by tumor cells was recently found to not only activate ISGs in tumor 
cells, but also in dendritic cells, via exosome-transfer of dsDNA from irradiated cancer 
cells to the immune cells (28). Likewise, radiotherapy activates STING in immune 
cells as well as in tumor cells. This leads to increased IFN production by dendritic 
cells, which promotes tumor rejection (29). However, STING also promotes immune 
suppression by recruiting myeloid cells that contribute to radioresistance (19). So 
while STING signaling usually leads to immune activation (30), in some situations 
STING signaling may promote immune suppression. Like with IFN signaling, a chronic 
activation of this pathway might lead to regulatory feedback that leads to immune 
suppressive effects.
Matrix Gla protein
With our untargeted RNA sequencing approach, we also discovered genes that 
were commonly downregulated in tamoxifen-resistant and radioresistant breast 
cancer cells. Of these 20 genes, only Matrix Gla Protein (MGP) was associated with 
clinical outcome after tamoxifen treatment or radiotherapy in breast cancer patients 
(chapter 4). Interestingly, one of the regulators of MGP is microRNA miR-155 (31), 
which is overexpressed in breast cancer (32), and downregulates MGP expression 
(31). Earlier, it was found to be upregulated in tamoxifen-resistant breast cancer 
cells, and its suppression sensitized resistant cells to treatment (33), suggesting a 
mechanistic role for this microRNA in tamoxifen resistance, and therefore maybe also 
for MGP. Moreover, high miR-155 expression was correlated with lower disease-free 
survival rates and overall survival rates in breast cancer patients (34). However, in 
triple negative breast cancer patients the opposite was found: decreased miR-155 
expression was correlated with reduced overall survival (35, 36). This might suggest 
that increased miR-155 expression, and therefore decreased MGP expression, is only 
associated with a worse outcome in hormone receptor-positive tumors. 
Knock-down of miR-155 sensitizes MCF-7 and MDA-MB-231 breast cancer cells to 
irradiation (34), suggesting that this microRNA confers radioresistance to breast 
cancer cells. However, a later study found that miR-155 downregulates RAD51 
expression in MCF-7 cells, thereby inhibiting homologous recombination and 
enhancing radiosensitivity (35). Moreover, BRCA1 and TP53 were found to drive miR-
155 overexpression in breast cancer (37, 38). 
Interestingly, miR-155 was found to be induced by IFN-α as well. Not only in 
immune cells (39, 40), but also in human retinal pigment epithelial cells and 
human dermal lymphatic endothelial cells (41, 42). This induction of miR-155 is 
mediated by downstream signaling pathways of the IFN receptor (41). MiR-155 in 
turn downregulates IFN expression in human plasmacytoid dendritic cells (40). In 
breast cancer cells, miR-155 was found to induce IFN signaling, but Goldgraben et 
al. attributed that to the response of DNA sensors to the microRNA mimic as a target 
(43). However, in hepatoma cells miR-155 also induced IFN signaling via the JAK/
STAT pathway (44). These studies emphasize the importance of proper controls when 
working with miRNAs and other nucleic acid mimetics, in order to separate cellular 
responses to the specific miRNA as opposed to effects induced by any nucleic acid 
mimetic.
As miR-155 is induced by type I IFN (39-42) and in turn downregulates MGP (31), 
the downregulation of MGP in resistant breast cancer cells could be an effect of IFN 
signaling, instead of a direct effect of tamoxifen treatment or irradiation. As such, 
our data suggest that MGP downregulation is a biomarker for resistance to these two 
types of treatment, rather than being mechanistically involved in the development of 
resistance. Even though the effects of miR-155 on radiosensitivity and IFN signaling 
are not clearly defined, its role as a central player in both IFN signaling and MGP 
induction makes it an interesting subject of research as a new therapy target for 
tamoxifen-resistant and radioresistant breast cancer.
DNA damage repair and cell cycle genes
After investigating common mechanisms for tamoxifen resistance and radioresistance 
using an untargeted approach, we attempted to explain the observed cross-resistance 
for irradiation in tamoxifen-resistant breast cancer cells by assessing the expression 
of DNA damage repair genes and cell cycle genes in tamoxifen-resistant breast cancer 
cells (chapter 5). The observed radioresistance could be caused by altered expression 
of these genes, as downregulation of DNA damage repair genes and cell cycle arrest 
in G1 or S phase are correlated with radioresistance (45, 46). 
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Luzhna et al. previously also observed cross-resistance to irradiation in tamoxifen-
resistant cells (47), but they did not compare baseline levels of DNA damage repair 
genes in the tamoxifen-resistant cells with levels in parental cells. They did find 
altered expression of DNA damage repair genes in tamoxifen-resistant breast cancer 
cells in response to irradiation (47). However, they did not draw conclusions about the 
mechanism behind the observed cross-resistance. Others observed that tamoxifen-
resistant MCF-7 cells had increased levels of DNA damage repair enzymes PARP1 and 
LIG3 (48), or BRCA1 and BARD1 (49). However, both studies did not analyze sensitivity 
for irradiation in these cells.
Regarding cell cycle genes, it was shown previously that tamoxifen-resistant cells 
had increased levels of genes regulating the G1/S transition [CCNE1, CDK2, and E2F1; 
(50)]. Also CCND1 and MYC were reportedly upregulated in tamoxifen-resistant breast 
cancer cells, which could lead to G1/S phase blockade (51). Cell cycle arrest in G1 or S 
phase is correlated with radioresistance (45, 46). However, Louie et al. and Butt et al. 
did not assess radiosensitivity in their tamoxifen-resistant cells (50, 51).
We did not find differentially expressed DNA damage repair genes or cell cycle genes 
that could explain the cross-resistance to irradiation in tamoxifen-resistant breast 
cancer cells. Therefore, other pathways that could induce radioresistance should be 
investigated in tamoxifen-resistant cells. Next to proliferation and DNA damage repair, 
hypoxia is the third crucial feature causing radioresistance (52). Hypoxia leads to 
radioresistance, because the lack of oxygen prevents DNA damage to occur. However, 
hypoxia-induced proteins such as HIF-1α can also have an hypoxia-independent 
effect on radioresistance. HIF-1α is activated by reactive oxygen species (53), which 
in turn is thought to be affected by tamoxifen (54). Therefore, HIF-1α signaling could 
be an important pathway that might induce radioresistance in tamoxifen-resistant 
breast cancer cells. 
APOBECs: fuel for cancer evolution 
To assess the role of ISGs in tamoxifen resistance and radioresistance in breast cancer, 
their effect on the development of resistance ought to be investigated. For one ISG, 
namely  APOBEC3B, an IFN-induced antiviral protein that was already shown to play 
a role in tamoxifen resistance (55), we analyzed its role in radioresistance. Originally, 
a role in the innate immune defense was described for the APOBEC family of cytosine 
deaminases. APOBECs mutate viral DNA in order to restrict their replication (56). 
Multiple family members - APOBEC3A, -B, -C, -D/E, and -G - were found to be induced 
by IFNα (57-59). 
APOBEC3B is a relevant candidate to further investigate in the cross-resistance to 
radiotherapy observed in tamoxifen-resistant breast cancer cells, as it plays a role in 
tamoxifen resistance (55), and promotes clonal evolution by inducing mutations (60). 
We found that it is associated to clinical responses after radiotherapy in breast cancer 
patients. Its expression in tumor tissues of these patients was correlated to the expression 
of DNA damage repair gene RAD51 (chapter 6). We hypothesized that cells can only 
survive the mutations caused by APOBEC3B by having sufficient levels of intact RAD51. 
This hypothesis  could not yet be confirmed, as we found that MCF-7 cells with a stable 
knock-down of APOBEC3B or overexpressed APOBEC3B did not show different responses 
to a RAD51 inhibitor, compared to wild-type cells. 
As APOBEC3B is induced by IFNα (57-59), IFN signaling could be the cause for high 
APOBEC3B levels in tamoxifen-resistant and radioresistant breast cancer cells. This remains 
to be validated. Likewise RAD51, which is highly correlated to APOBEC3B in breast cancer 
patients, plays a role in the processing of ssDNA (61), linking it to IFN signaling as well. 
However, its role as a protector of ssDNA from recognition by DNA sensors in the cytosol 
(61), contradicts the increase of IFN signaling that is observed in radioresistant breast 
cancer cells. The role of APOBEC3B and RAD51 with respect to radioresistance, as well as 
their relation with STING and IFN signaling, should be further investigated.
Conclusion and future directions
We have identified various IFN signaling-related features that are associated with 
tamoxifen resistance and radioresistance in ER-positive breast cancer cells. First, the 
induction of ISGs after tamoxifen treatment and irradiation was described, as well 
as the role of DNA sensors in this process (Chapter 2 and 3). Second, we discovered 
that the IFN-induced gene MGP was downregulated in both types of resistance 
(chapter 4), and third, we found a role for APOBEC3B, also an IFN-induced gene, in 
radioresistance in breast cancer (chapter 6). 
We propose that prolonged treatment with tamoxifen or repeated fractions of 
irradiation induces IFN signaling that ultimately results in a chronic activation of 
this signaling pathway, thereby causing resistance to tamoxifen treatment and 
irradiation in breast cancer cells. The main challenge that remains to be investigated 
is the translation of our in vitro studies to breast cancer patients. Optimally, we would 
like to investigate ISG expression in patients with relapsed disease after tamoxifen 
treatment or radiotherapy, or in patients that have been treated neoadjuvantly with 
either of these treatment modalities. However, as limited material is available from 
such patients, ex vivo models could be used as the closest equivalent. Moreover, 
it has yet to be determined whether ISGs, MGP and APOBEC3B contribute to the 
development of treatment resistance or are merely a result of this phenomenon.
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Next to tumor-autonomous signaling that could cause resistance to tamoxifen 
treatment and irradiation, the role of the tumor microenvironment should be 
investigated in further studies. The effects of IFN signaling on treatment resistance 
should be further assessed in breast cancer patients, as IFN signaling by the tumor 
will have great implications on tumor-infiltrating immune cells. A closer investigation 
of immune cell populations after tamoxifen treatment or irradiation in breast cancer 
patients could reveal whether the induced IFN signaling has an immune enhancing 
or immune suppressing effect. Immune suppression could contribute to resistance to 
both tamoxifen treatment and irradiation.
We suggest caution in targeting IFN signaling for cancer therapies with the aim of 
stimulating that pathway. Inhibition of the IFN response was shown to sensitize 
breast cancer cells resistant to aromatase inhibitors (4), and this might also be the 
case for tamoxifen-resistant cells. However, these results do not take into account 
the complex tumor microenvironment and immune modulatory effects of tamoxifen 
treatment, irradiation and the subsequent IFN signaling. To properly assess whether 
inhibition of IFN signaling is a possible treatment option, more research in mouse 
models is required. One of the aspects of research that requires further study is the 
radiation dose and fractionation schedule that needs to be applied to evoke optimal 
immunostimulatory signals, both for tumor cells regarding IFN signaling, as well as 
for direct and indirect effects on immune cells. 
The other area of interest in this thesis is the cross-resistance to radiotherapy observed 
in tamoxifen-resistant breast cancer cells. Here, we propose further research into this 
phenomenon, as it may have great implications for the progression of neoadjuvant 
administration of tamoxifen (1).
In conclusion, we have shown that many IFN-induced mechanisms are involved 
in tamoxifen resistance and radioresistance in breast cancer. Moreover, we have 
identified a clear link between both types of resistance, as many mechanisms 
are commonly activated or downregulated in both tamoxifen resistance and 
radioresistance. Understanding the interplay between these tumor-autonomous 
signaling pathways, immune cells, and the tumor microenvironment can provide 
new treatment targets for the treatment of resistant breast cancer.
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Summary
Treatment resistance is an important cause of adverse disease outcome in cancer 
patients. In this thesis, features of resistance to two major treatment options for 
breast cancer patients were investigated, namely endocrine treatment (tamoxifen) 
and radiotherapy. Estrogen receptor-positive breast cancer cells that were cultured to 
tamoxifen resistance in vitro were found to be cross-resistant for irradiation. Therefore, 
we hypothesized that common mechanisms were involved in both types of treatment 
resistance. RNA sequencing of tamoxifen-resistant and radioresistant breast cancer 
cells was performed to identify genes that were differentially regulated in both types 
of resistant cells. Subsequently, the relation between the expression of these genes in 
tumor tissue from breast cancer patients and outcome was investigated. 
First, genes with increased expression levels in tamoxifen-resistant and radioresistant 
breast cancer cells were assessed (Chapter 2). In both resistant cell types, genes 
involved in type I IFN signaling were upregulated compared with nonresistant cells. 
Further experiments showed that IFN-stimulated genes (ISG) were induced in a dose-
dependent and time-dependent manner after tamoxifen treatment and irradiation 
of breast cancer cells. Moreover, cytoplasmic ssDNA occurred in the cytoplasm of 
these cells after tamoxifen treatment. Cytoplasmic ssDNA is known to induce the 
expression of ISGs, a phenomenon that has already been described for irradiation. 
Moreover, in a breast cancer patient cohort high expression levels of ISGs were 
found in the primary tumor before treatment in approximately half of the patients. 
Expression of these genes was associated with a tumor-infiltrating lymphocyte (TIL) 
expression signature, although ISGs were also expressed by tumor cells. Importantly, 
the expression of ISGs correlated with relapse-free survival in breast cancer patients 
treated with adjuvant tamoxifen. There was no correlation in patients who did not 
receive systemic treatment or patients that were treated with chemotherapy only. In 
a different cohort, expression of ISGs correlated with disease-free survival in breast 
cancer patients who were not systemically treated and received radiotherapy. We 
concluded that expression of ISGs by tumor cells is involved in acquired, treatment-
induced resistance to tamoxifen treatment and irradiation in breast cancer cells 
in vitro. Moreover, clinical data suggest that ISGs play a role in intrinsic treatment 
resistance in breast cancer patients via interaction with TILs. 
Subsequently, the role of DNA sensors and related signaling proteins in recognizing 
cytoplasmic ssDNA and inducing an IFN response after tamoxifen treatment or 
irradiation was investigated in breast cancer cells (Chapter 3). We assessed the 
possible role of the DNA sensors DNA-PK (PRKDC) and DDX60, and the signaling 
molecule STING (TMEM173). Knock-down or inhibition of DNA-PK or DDX60 in 
tamoxifen-treated or irradiated breast cancer cells did not affect the ISG induction 
after these treatments. However, when STING was inhibited, treatment-enhanced 
expression of ISGs seemed decreased, compared to control-treated cells. We therefore 
propose that STING, and not DNA-PK or DDX60, is involved in the induction of an 
IFN response after tamoxifen treatment or irradiation in breast cancer cells. The DNA 
sensor activating STING in these conditions was not identified in this study. In future 
studies, the colocalization with cytoplasmic ssDNA should be investigated for several 
DNA sensors that are known to activate STING, among which cGAS is the primary 
candidate.
Next, the genes that were commonly downregulated in tamoxifen-resistant and 
radioresistant breast cancer cells were assessed (Chapter 4). Twenty genes showed 
decreased expression in both types of resistant cells in vitro. Of these, only the 
expression of matrix Gla protein (MGP) in the primary tumor was associated 
with relapse-free survival in breast cancer patients after tamoxifen treatment 
or radiotherapy. Both in patients treated with tamoxifen or radiotherapy, lower 
expression levels of MGP were associated with a worse outcome. This corresponds 
to our in vitro data, where low MGP levels were associated with treatment resistance. 
Together, these data suggest a role for MGP in resistance to tamoxifen treatment 
and radiotherapy in breast cancer. MGP plays a role in various pathways involved in 
tumor biology, such as vitamin D and vitamin K signaling, as well as VEGF-induced 
angiogenesis. However, it is currently unknown through which of these pathways 
MGP exerts its effects on outcome in breast cancer patients.
After investigating common mechanisms for tamoxifen resistance and radioresistance, 
we aimed to specifically assess the expression of genes that could be responsible 
for the observed cross-resistance for irradiation in tamoxifen-resistant breast cancer 
cells (Chapter 5). Previous studies suggested that DNA damage repair or cell cycle 
genes could be involved, and targeting these could preclude the occurrence of 
cross-resistance. None of the DNA damage repair pathways we investigated showed 
differential gene expression in tamoxifen-resistant breast cancer cells compared to 
wild-type cells. Two DNA damage repair genes were more than 2 times upregulated 
(NEIL1, and EME2), and three DNA damage repair genes were more than 2 times 
downregulated (PCNA, BRIP1, and BARD1). However, the expression of these 5 genes 
was not associated with outcome after radiotherapy in a breast cancer patient 
cohort. Genes involved in G1, G1/S, G2, and G2/M phase were lower expressed in 
tamoxifen-resistant breast cancer cells compared to wild-type cells. However, 
expression of individual genes that were more than 2 times upregulated (MAPK13) 
146
8 
Su
m
m
ar
y
147
or downregulated (E2F2, CKS2, GINS2, PCNA, MCM5, and EIF5A2) was not associated 
with the response to radiotherapy in the breast cancer patient cohort investigated. 
Therefore, differences in expression of DNA damage repair genes or cell cycle genes 
could not explain the cross-resistance for irradiation in the tamoxifen-resistant breast 
cancer cells. 
Finally, we assessed the role of APOBEC3B, an IFN-induced DNA cytosine deaminase, 
in radioresistant breast cancer (Chapter 6). APOBEC3B promotes genetic instability, 
thereby facilitating clonal selection and subsequent treatment resistance. A previous 
study described that APOBEC3B is involved in tamoxifen resistance in breast cancer. 
In this thesis, we found that high levels of APOBEC3B were also associated with 
worse disease-free survival in breast cancer patients who received radiotherapy. 
In vitro, breast cancer cells carrying an APOBEC3B knock-down showed increased 
53BP1 foci directly after irradiation. This indicates an increase in the number of 
DNA double-strand breaks. Moreover, breast cancer cells containing either a stable 
APOBEC3B knockdown or a vector overexpressing APOBEC3B could not be cultured 
to radioresistance, suggesting that there is an optimal APOBEC3B level that favors 
radioresistance in these cells. In a breast cancer patient cohort, expression of genes 
involved in homologous recombination, in particular RAD51, was highly correlated 
with APOBEC3B expression. However, breast cancer cells with stable APOBEC3B knock-
down or overexpressed APOBEC3B were not differentially sensitive to the RAD51 
inhibitor B02. On the other hand, APOBEC3B knock-down prevented B02-induced 
sensitization of breast cancer cells to irradiation. We conclude that APOBEC3B 
is involved in radioresistance in breast cancer patients. Its possible interaction 
with RAD51 suggests that APOBEC3B influences DNA damage repair. The precise 
mechanism by which APOBEC3B mediates radioresistance is however yet to be 
elucidated. 
To conclude, in this thesis several features were identified that are related to 
tamoxifen resistance and radioresistance in breast cancer. We showed that IFN 
signaling is strongly associated with both types of resistance. Moreover, we suggest a 
role for MGP-downregulation in sensitivity to tamoxifen treatment and radiotherapy. 
Although the cross-resistance for irradiation in tamoxifen-resistant breast cancer cells 
could not be explained by the expression of DNA damage repair genes and cell cycle 
genes, we did find a role for the DNA damage repair protein RAD51 together with 
the IFN-induced protein APOBEC3B. Identification of tumor-autonomous signaling 
pathways that cause therapy resistance, as investigated in this thesis, may lead to 
new treatment targets for resistant breast cancer. 
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bij intrinsieke therapieresistentie bij borstkankerpatiënten, mogelijk via interactie 
met TILs.
Vervolgens werd nagegaan hoe cytoplasmatisch ssDNA herkend werd, en een 
daaropvolgende IFN-respons geïnduceerd werd na tamoxifenbehandeling of 
bestraling van borstkankercellen in vitro (hoofdstuk 3). We hebben de mogelijke 
rol van de DNA-sensoren DNA-PK (PRKDC), DDX60 en het signaalmolecuul STING 
(TMEM173) onderzocht. Inhibitie of knock-down van DNA-PK of DDX60 in met 
tamoxifen behandelde of bestraalde borstkankercellen had geen invloed op de ISG-
inductie na deze behandelingen. Echter, na inhibitie van STING leek de expressie van 
ISGs, die verhoogd is na tamoxifenbehandeling of bestraling, af te nemen wanneer 
dit vergeleken werd met controlecellen. Wij achten het daarom waarschijnlijk dat 
STING, en niet DNA-PK of DDX60, betrokken is bij de inductie van een IFN-respons 
in borstkankercellen na tamoxifenbehandeling of bestraling. Hoe STING geactiveerd 
wordt in deze omstandigheden is niet onderzocht in deze studie. Toekomstige 
studies moeten uitwijzen welke DNA-sensor STING activeert, onder andere door 
de co-lokalisatie van verschillende sensoren met het cytoplasmatische ssDNA in 
borstkankercellen te onderzoeken. 
Aansluitend werden de genen onderzocht die in zowel tamoxifen- als radioresistente 
borstkankercellen verlaagd tot expressie kwamen (Hoofdstuk 4). Twintig genen 
vertoonden een verminderde expressie in beide soorten resistente cellen in 
vitro. Van deze genen was alleen de expressie van matrix Gla protein (MGP) in de 
primaire tumor geassocieerd met ziektevrije overleving na tamoxifenbehandeling 
of radiotherapie bij borstkankerpatiënten. Bij deze patiënten, die met tamoxifen 
of radiotherapie werden behandeld, waren lagere expressieniveaus van MGP 
geassocieerd met een slechtere uitkomst na de behandeling. Onze in vitro gegevens, 
waar lage MGP-niveaus voorkwamen bij therapieresistentie, komen hiermee 
overeen. Samen suggereren deze data dat MGP een rol speelt in de resistentie 
tegen tamoxifenbehandeling en radiotherapie bij borstkanker. MGP speelt een rol 
bij verschillende signaleringsroutes van tumoren, zoals vitamine D- en vitamine 
K-signalering, en VEGF-geïnduceerde angiogenese. Het is momenteel echter niet 
bekend via welke van deze signaleringsroutes MGP zijn effecten op de uitkomst bij 
borstkankerpatiënten uitoefent.
Na gemeenschappelijke mechanismen voor tamoxifen- en radioresistentie te 
hebben onderzocht, hebben we specifiek de expressie van genen geanalyseerd 
die verantwoordelijk zouden kunnen zijn voor de waargenomen kruisresistentie 
tegen bestraling in tamoxifen-resistente borstkankercellen (hoofdstuk 5). Eerdere 
Samenvatting
De ziekte-uitkomst van patiënten met kanker wordt sterk negatief beïnvloed door 
het hebben of ontwikkelen van therapieresistentie. In dit proefschrift zijn mogelijke 
oorzaken van resistentie tegen twee belangrijke behandelingsmodaliteiten voor 
borstkankerpatiënten onderzocht: endocriene therapie (tamoxifen) en radiotherapie. 
Oestrogeen receptor-positieve borstkankercellen die in vitro tamoxifen-resistent 
werden gemaakt, bleken onverwacht kruisresistent te zijn tegen bestraling. Daarom 
onderzochten we gemeenschappelijke mechanismen die betrokken zouden kunnen 
zijn bij beide vormen van therapieresistentie. RNA sequencing van tamoxifen- 
en radioresistente borstkankercellen werd uitgevoerd om genen te identificeren 
die verschillend tot expressie kwamen in beide soorten resistente cellen. 
Vervolgens werd de relatie tussen de expressie van deze genen in tumorweefsel 
van borstkankerpatiënten en de ziekte-uitkomst na tamoxifenbehandeling en 
radiotherapie onderzocht.
Eerst werden genen met verhoogde expressieniveaus in tamoxifen- en radioresistente 
borstkankercellen geanalyseerd (hoofdstuk 2). In beide soorten resistente cellen 
kwamen genen die betrokken zijn bij type I IFN signalering verhoogd tot expressie, in 
vergelijking met niet-resistente cellen. Verdere experimenten toonden aan dat IFN-
gestimuleerde genen (“IFN-stimulated genes”, ISGs) in parentale borstkankercellen 
werden geïnduceerd na tamoxifenbehandeling en bestraling, op een dosis-
afhankelijke en tijdsafhankelijke manier. Bovendien werd enkelstrengs DNA (ssDNA) 
aangetroffen in het cytoplasma van borstkankercellen na behandeling met tamoxifen. 
Van cytoplasmatisch ssDNA is bekend dat het de expressie van ISGs induceert, een 
fenomeen dat door anderen reeds eerder beschreven was na bestraling. Bovendien 
werden in een cohort van borstkankerpatiënten hoge expressieniveaus van ISGs 
gevonden in de primaire tumor al vóór de behandeling. Dit was het geval bij ongeveer 
de helft van de patiënten. De expressie van deze genen was geassocieerd met een 
tumor-infiltrerend lymfocyt (TIL) expressie patroon. De ISGs werden ook door de 
tumorcellen zelf tot expressie gebracht. De expressie van ISGs was gecorreleerd met 
ziektevrije overleving bij borstkankerpatiënten die adjuvant behandeld werden met 
tamoxifen. Er was geen correlatie met ziektevrije overleving bij patiënten die geen 
systemische behandeling ontvingen of patiënten die alleen met chemotherapie 
werden behandeld. In een ander cohort was de expressie van ISGs gecorreleerd 
met ziektevrije overleving bij niet-systemisch behandelde borstkankerpatiënten die 
bestraald werden. Concluderend, de expressie van ISGs door tumorcellen is betrokken 
bij verworven, door behandeling veroorzaakte resistentie tegen tamoxifen en 
bestraling in vitro. Bovendien suggereren klinische gegevens dat ISGs een rol spelen 
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Samenvattend, in dit proefschrift zijn een aantal kenmerken geïdentificeerd die 
betrokken zijn bij tamoxifen- en radioresistentie bij (patiënten met) borstkanker. We 
hebben laten zien dat IFN-signalering een belangrijke rol speelt bij beide vormen 
van resistentie. Verder suggereren we een rol voor MGP in de gevoeligheid voor 
tamoxifenbehandeling en radiotherapie bij borstkanker. Hoewel de kruisresistentie 
voor bestraling in tamoxifen-resistente borstkankercellen niet verklaard kon 
worden door de expressie van DNA-reparatiegenen en celcyclusgenen, vonden we 
wel een rol voor het DNA-reparatie eiwit RAD51 samen met het IFN-geïnduceerde 
eiwit APOBEC3B. Identificatie van tumor-autonome signaleringsroutes die 
therapieresistentie veroorzaken, zoals onderzocht in dit proefschrift, kan leiden tot 
nieuwe aangrijpingspunten voor de behandeling van therapieresistente borstkanker.
studies suggereren dat DNA-reparatiegenen of celcyclusgenen hierbij betrokken 
zijn. Deze zouden nieuwe aangrijpingspunten kunnen vormen voor interventies om 
de waargenomen kruisresistentie te voorkomen. Echter, geen van de onderzochte 
DNA-reparatieprocessen kwam verschillend tot expressie in tamoxifen-resistente 
cellen vergeleken met de parentale borstkankercellen. Twee DNA-reparatiegenen 
kwamen meer dan twee keer verhoogd tot expressie (NEIL1 en EME2) en drie DNA-
reparatiegenen waren meer dan twee keer verlaagd (PCNA, BRIP1 en BARD1). Geen 
van deze vijf genen was geassocieerd met de ziekte-uitkomst na radiotherapie 
van borstkankerpatiënten. Genen betrokken bij de G1, G1/S, G2 en G2/M fase van de 
celcyclus kwamen lager tot expressie in tamoxifen-resistente cellen in vergelijking 
met parentale borstkankercellen. Echter, de genen die meer dan twee keer 
verhoogd (MAPK13) of verlaagd (E2F2, CKS2, GINS2, PCNA, MCM5 en EIF5A2) tot 
expressie kwamen, waren niet geassocieerd met de uitkomst na radiotherapie in het 
onderzochte borstkankercohort. Concluderend, de verschillen in expressie van DNA-
reparatiegenen of celcyclusgenen konden de kruisresistentie voor bestraling in de 
tamoxifen-resistente cellen niet verklaren.
Tot slot hebben we de rol van APOBEC3B, een IFN-geïnduceerd DNA-cytosine-
deaminase, onderzocht in radioresistente borstkanker (hoofdstuk 5). APOBEC3B 
leidt tot genetische instabiliteit en bevordert zo mogelijk klonale selectie en 
therapieresistentie. Een eerdere studie beschreef dat APOBEC3B betrokken is bij 
de ontwikkeling van tamoxifenresistentie in borstkanker. In dit proefschrift stelden 
we vast dat hoge APOBEC3B-niveaus ook geassocieerd waren met een slechtere 
ziektevrije overleving bij borstkankerpatiënten, maar alleen wanneer de patiënten 
bestraald werden. In vitro werden in borstkankercellen met verlaagde APOBEC3B-
niveaus direct na bestraling verhoogde 53BP1 foci waargenomen. Dit wijst op een 
toename van DNA dubbelstrengsbreuken. Bovendien konden borstkankercellen 
met een stabiele APOBEC3B knock-down of een vector die APOBEC3B verhoogd tot 
expressie brengt, niet tot radioresistentie gekweekt worden. In een borstkankercohort 
was de expressie van genen die betrokken zijn bij homologe recombinatie, in het 
bijzonder RAD51, sterk gecorreleerd met APOBEC3B expressie. Borstkankercellen met 
stabiele APOBEC3B knock-down of hoge APOBEC3B expressie waren niet verschillend 
gevoelig voor RAD51-inhibitie door B02. Echter, APOBEC3B knock-down voorkwam 
de verhoogde radiogevoeligheid van borstkankercellen geïnduceerd door B02. 
APOBEC3B lijkt dus betrokken te zijn bij radioresistente borstkanker. De mogelijke 
interactie met RAD51 suggereert dat APOBEC3B invloed heeft op het herstel van DNA-
schade. Het exacte mechanisme waardoor APOBEC3B betrokken is bij radioresistentie 
in borstkanker moet echter nog worden opgehelderd. Sa
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techniek die al het boodschapper-RNA in een cel scant en weergeeft hoe actief 
elk gen is. Ik heb onderzocht welke genen meer en welke minder actief zijn in de 
resistente borstkankercellen ten opzichte van gevoelige cellen. Zo kon ik uitzoeken 
welke processen ‘aan’ of ‘uit’ stonden, en het geheime wapen van de resistente 
kankercellen identificeren.
Behandeling van borstkanker
Borstkanker is nog steeds de meest voorkomende kanker bij vrouwen. Hoewel 
de overlevingskansen toenemen, sterven er jaarlijks in Nederland nog ongeveer 
3000 vrouwen aan borstkanker. Eén van de belangrijkste oorzaken hiervoor 
is terugkeer van de ziekte. Dit wordt vaak veroorzaakt door kankercellen die 
ongevoelig zijn voor de eerste behandeling, ze zijn resistent geworden. 
 Eén van de gangbare behandelingen voor borstkanker is hormoon-
behandeling. Een bekend voorbeeld hiervan is tamoxifen. Bij behandeling 
met tamoxifen wordt de overleving van borstkankercellen geremd door de 
oestrogeen-receptor te blokkeren. Deze receptor geeft overlevingssignalen 
door aan de cel in reactie op hormonen. Bij borstkanker is deze receptor 
vaak continue actief, waardoor het de overleving en vermenigvuldiging 
van borstkankercellen stimuleert. Een andere veelgebruikte behandeling is 
bestraling. Hierbij wordt schade in het DNA aangericht, om de cel onherstelbaar 
te beschadigen. 
 Een kankercel kan van zichzelf al aanpassingen hebben die deze 
behandelingen minder effectief maken, dit wordt intrinsieke resistentie 
genoemd. Daarnaast kunnen ze, juist doordat deze behandelingen worden 
toegepast, processen activeren die hen helpen te overleven. Dit laatste heet 
verkregen resistentie, en hier gaat mijn proefschrift vooral over.
‘Aan’
Eerst heb ik in het laboratorium gekeken welke processen meer actief zijn in de 
resistente borstkankercellen (de processen die ‘aan’ staan). Deze processen zouden 
resistentie tegen tamoxifen of bestraling kunnen veroorzaken. Daarna heb ik 
onderzocht of de genen die meer actief zijn in de resistente cellen invloed hadden 
op het behandelsucces van tamoxifen of bestraling bij borstkankerpatiënten.
Ik ontdekte dat genen die betrokken zijn bij Interferon signalering meer actief zijn 
in borstkankercellen die een behandeling met tamoxifen of bestraling overleven 
(hoofdstuk 2).  Interferon signalering is normaal gesproken belangrijk voor afweer 
Kenmerken van een slimme kankercel
Hoe kan het dat de behandeling van kanker bij de ene patiënt wel aanslaat en bij 
de andere niet? Om daar achter te komen, is het belangrijk om te weten wat zich 
bij deze patiënten in de kankercellen afspeelt. In mijn promotieonderzoek heb 
ik gekeken naar processen in kankercellen die betrokken zijn bij ongevoeligheid 
voor hormoonbehandeling of bestraling bij borstkanker. Een beter begrip 
hiervan kan op termijn helpen om deze behandelingen beter op patiënten af 
te stemmen.
Een gewone lichaamscel die zich ontwikkelt tot kankercel heeft maar één doel: zo 
veel mogelijk vermenigvuldigen. Zolang het klompje kankercellen klein is, blijft het 
onopgemerkt, maar na een tijdje kan het zich niet langer verbergen. En dan begint de 
ellende: alle mogelijke middelen worden ingezet om de kankercellen te vernietigen. 
Een hoge dosis straling wordt op ze afgevuurd, hand in hand met giftige stoffen, die 
er samen voor moeten zorgen dat de kankercellen onherstelbaar beschadigd worden.
Maar soms gaan niet alle kankercellen ten onder aan deze behandeling (zie kader 
‘Behandeling borstkanker’, pagina 155). Als ook maar één cel de behandeling 
overleeft, kan het verhaal weer van voor af aan beginnen, met een nieuwe groep 
kankercellen tot gevolg. Deze groep kankercellen is nog gevaarlijker dan de eerste. 
Ze hebben namelijk een geheim wapen dat ertoe heeft geleid dat ze de eerste 
behandeling overleefden. Daardoor zijn ze nu nóg moeilijker te behandelen. 
Om deze slimme kankercellen wél te kunnen aanpakken, moet hun geheime wapen 
ontmanteld worden. Stap één: het geheime wapen ontdekken. Daar gaat mijn 
proefschrift over.
Behandelingsresistentie
In mijn promotie-onderzoek heb ik borstkankercellen onderzocht die een langdurige 
hormoonbehandeling met tamoxifen of meerdere doses bestraling overleven, 
zogenaamde resistente cellen. In het laboratorium groeide ik kankercellen in een 
schaaltje en die behandelde ik elke week (zie kader ‘Celkweek’, pagina 157). Na een 
aantal weken zijn de overlevende cellen ongevoelig geworden voor de behandeling 
die ze ondergingen. 
In deze resistente kankercellen zijn bepaalde veranderingen opgetreden die 
hen helpen te overleven. Om erachter te komen welke veranderingen dit zijn, 
heb ik gekeken naar verschillen in genexpressie tussen resistente en gevoelige 
borstkankercellen (zie kader ‘Genexpressie’, pagina 158). Hiervoor gebruikte ik een 
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Na deze experimenten in het laboratorium heb ik gekeken of de activiteit van 
Interferon signalering bij een groep reeds behandelde borstkankerpatiënten 
mogelijk effect heeft gehad op het succes van een behandeling met tamoxifen of 
bestraling (hoofdstuk 2). Hiervoor heb ik het boodschapper-RNA van een aantal 
genen die betrokken zijn bij Interferon signalering in een stukje kankerweefsel van 
deze patiënten onderzocht. Dit kan in het materiaal van een biopsie, die bij patiënten 
wordt gedaan om de diagnose te stellen. De patiënten werden in twee groepen 
verdeeld, één groep bij wie Interferon signalering een hoge activiteit had en één 
bij wie dit proces een lage activiteit had. Vervolgens wilde ik weten of de ene groep 
beter had gereageerd op de behandeling met tamoxifen of bestraling dan de andere. 
Het bleek dat patiënten met een hoge activiteit van Interferon signalering slechter 
reageerden op deze behandelingen. Dit komt overeen met wat ik in het laboratorium 
had ontdekt. Daar hadden resistente cellen een actievere Interferon signalering. 
Ongevoeligheid voor tamoxifen of bestraling  kan verklaren waarom deze patiënten 
slechter reageerden op deze behandelingen.
tegen ziekteverwekkers. Dat dit proces meer actief is in resistente borstkankercellen 
lijkt vreemd, maar het zou kunnen dat borstkankercellen Interferon signalering 
activeren in reactie op stress, in dit geval tamoxifen of bestraling. Deze aanname 
onderzocht ik door borstkankercellen in het laboratorium met een enkele dosis 
tamoxifen te behandelen of ze te bestralen. Ik zag dat deze cellen na één behandeling al 
een hogere expressie hadden van genen die betrokken zijn bij Interferon signalering. 
Welke gebeurtenissen zorgen er in deze kankercellen voor dat ze Interferon signalering 
activeren in reactie op tamoxifen of bestraling? Een andere wetenschapper had ontdekt 
dat bestraling ervoor zorgt dat er kleine stukjes DNA buiten de kern van de cel terecht 
komen. Ik kwam erachter dat tamoxifen hetzelfde effect heeft. Dit DNA hoort daar 
niet thuis, het hoort in de kern van de cel te zitten. Als DNA buiten de celkern terecht 
komt, lijkt het voor de cel alsof er een ziekteverwekker is binnengedrongen, omdat 
een ziekteverwekker ook kleine stukjes DNA met zich meeneemt. Dit is voor de cel een 
teken om Interferon signalering te activeren en de ziekteverwekker op te ruimen. Als 
tamoxifen en bestraling voor de aanwezigheid van deze kleine stukjes DNA zorgen, is 
het logisch dat de cel als reactie hierop ook Interferon signalering activeert. 
Maar voordat een cel Interferon signalering kan activeren, moet een specifiek eiwit de 
stukjes DNA herkennen. Dit eiwit geeft vervolgens een signaal voor de activatie van 
genen die betrokken zijn bij Interferon signalering. Ik heb drie eiwitten onderzocht die 
deze link zouden kunnen vormen. Van deze drie had alleen het eiwit STING te maken 
met de activatie van Interferon signalering na tamoxifenbehandeling of bestraling in 
borstkankercellen (hoofdstuk 3). Maar STING kan zelf geen DNA herkennen, er moet 
dus nog een ander eiwit zijn dat met STING samenwerkt. Welk eiwit dit is moet nog 
verder onderzocht worden. 
Behandeling met tamoxifen of bestraling (A) leidt ertoe dat kleine stukjes DNA buiten de kern van de cel 
terechtkomen (B). Dit DNA wordt herkend door een specifiek eiwit (C), dat vervolgens STING activeert 
(D). STING zorgt voor de activatie van genen die te maken hebben met Interferon signalering (E).
Celkweek
In mijn onderzoek heb ik voornamelijk gebruik gemaakt van ‘in vitro’ 
experimenten. Met deze benaming worden experimenten aangeduid die ‘in 
glas’, oftewel in een reageerbuisje of andere laboratoriummaterialen worden 
uitgevoerd. Hiervoor gebruikte ik kankercellen die in een ver verleden uit 
tumoren van patiënten gehaald zijn, en in het laboratorium onsterfelijk zijn 
gemaakt. Deze cellen kunnen zich oneindig vermenigvuldigen en verouderen 
niet zoals de cellen in ons lichaam. In het laboratorium kunnen de effecten van 
verschillende behandelingen op deze cellen  geanalyseerd worden. Hiervoor 
keek ik bijvoorbeeld naar de aanwezigheid en hoeveelheid van boodschapper-
RNA en eiwitten.
Celkweek in het laboratorium
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Interferon signalering is (en hoe groot de kans op resistentie), zou dit een rol kunnen 
spelen bij de keuze voor de behandeling. Verder zou het remmen van dit proces 
mogelijk een aanvullende behandelmethode kunnen zijn voor borstkankerpatiënten 
die resistent zijn geworden tegen behandeling met tamoxifen of bestraling. Hierbij 
moet echter nog veel meer informatie worden verkregen, onder andere over de rol 
van de afweercellen, die zo’n behandeling kunnen maken of breken. 
‘Uit’
Naast processen die meer actief zijn, kunnen processen die minder actief zijn (‘uit’ 
staan) in resistente cellen ook bijdragen aan deze behandelongevoeligheid. Denk 
hierbij bijvoorbeeld aan processen die normaal gesproken de vermenigvuldiging van 
cellen remmen. Negatief keer negatief maakt positief, dus als deze processen minder 
actief zijn, gaat de cel juist meer vermenigvuldigen. 
Ik vond twintig genen die minder actief waren in zowel tamoxifen-resistente cellen 
als bestralingsresistente cellen, vergeleken met gevoelige cellen (hoofdstuk 4). Dit 
deed ik door in de cellen die ik lange tijd had behandeld met tamoxifen of regelmatig 
had bestraald, naar al het boodschapper-RNA te kijken. Om er vervolgens achter te 
komen welke van deze genen mogelijk interessant zijn voor verder onderzoek, keek 
ik of deze twintig genen ook effect hadden op het succes van een behandeling met 
tamoxifen of bestraling bij borstkankerpatiënten. 
Alleen de activiteit van het gen ‘Matrix Gla Protein’ (MGP) had mogelijk invloed op de 
reactie op behandeling in reeds behandelde borstkankerpatiënten. Patiënten met 
een lage MGP-activiteit reageerden slechter op tamoxifenbehandeling of bestraling 
dan patiënten met veel MGP boodschapper-RNA. MGP zou dus een rol kunnen spelen 
bij ongevoeligheid voor deze twee behandelingen.
Er moet nog verder onderzocht worden of MGP inderdaad verantwoordelijk is voor 
resistentie of alleen een effect hiervan, en hóe MGP precies een rol speelt. Eén van 
de processen waarbij MGP betrokken is, is de vorming van nieuwe bloedvaten. Dit is 
belangrijk voor tumoren omdat ze het best kunnen groeien als ze beschikken over 
zuurstof, wat via bloedvaten aangevoerd wordt. Door het aanleggen van nieuwe 
vaten in en om de tumor, komt er meer zuurstof beschikbaar voor de kankercellen. Er 
is echter nog veel onduidelijkheid over de rol van MGP, en er is veel meer onderzoek 
nodig naar de rol die het speelt in resistentie voordat deze ontdekking kan leiden tot 
een verbeterde behandeling van borstkankerpatiënten.
Mijn onderzoek roept nog veel vragen op. Ik heb laten zien dat Interferon signalering 
een rol speelt in resistentie tegen behandeling met tamoxifen en bestraling. Maar ik 
heb niet onderzocht of dit veróórzaakt wordt door Interferon signalering of dat dit 
proces alleen een gevolg van de resistentie is. Hiervoor zijn verdere experimenten 
nodig. Ook moet er nog meer onderzoek gedaan worden bij borstkankerpatiënten. In 
het laboratorium kan ik namelijk maar een gedeelte van de werkelijkheid nabootsen: 
de kankercellen zelf. Er zijn naast kankercellen echter nog veel meer soorten cellen 
die onderdeel uitmaken van een tumor. Cellen die in de context van Interferon 
signalering heel belangrijk zijn, zijn de afweercellen. Deze zijn verantwoordelijk 
voor het vernietigen van ziekteverwekkers doordat ze reageren op (onder andere) 
Interferon signalering. Afweercellen kunnen ook helpen om kankercellen te 
vernietigen. Daarom is het belangrijk om te weten wat het effect van behandeling 
met tamoxifen of bestraling op afweercellen in een tumor is: worden ze meer actief 
(= goed), of minder actief (= slecht)? 
Genexpressie
De belangrijkste analyse van het gedrag van een cel heb ik gedaan door te 
kijken naar genexpressie. Om dit goed uit te leggen, moeten we terug naar de 
kern van ons bestaan: DNA. Elke cel van ons lichaam bevat DNA, die de cellen 
aanstuurt en bepaalt wat er mee gaat gebeuren. Het DNA bestaat uit een groot 
aantal genen, stukjes genetische informatie die elk kunnen leiden tot een eiwit. 
Eiwitten zijn de werkpaarden van de cel, die ervoor zorgen dat alle processen 
plaatsvinden, bijvoorbeeld het transport van bepaalde stoffen in en uit de cel, 
het omzetten van suiker naar energie, en zelfs het omzetten van de genetische 
informatie in DNA naar eiwitten. Deze omzetting van DNA naar eiwit heeft een 
belangrijke tussenstap: boodschapper-RNA. De hoeveelheid hiervan bepaalt 
hoeveel van een bepaald eiwit er gevormd wordt en daardoor ook hoe actief 
een bepaald proces is. Door de hoeveelheid boodschapper-RNA te meten 
probeerde ik er achter te komen welke processen meer of juist minder actief 
zijn in een cel. 
Op termijn kan dit onderzoek bijdragen aan een effectievere behandeling van 
borstkanker. Ik ontdekte dat patiënten met actieve Interferon signalering slechter 
reageerden op behandeling met tamoxifen en bestraling. Dit betekent niet gelijk 
dat dit veroorzaakt wordt door de actieve Interferon signalering. Maar als duidelijk 
wordt dat dit wel zo is, zou de activiteit van dit proces onderzocht kunnen worden 
in de biopsie van borstkankerpatiënten. Als voor een patiënt bekend is hoe actief 
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reden kunnen zijn waarom tamoxifen-resistente cellen minder gevoelig zijn voor 
bestraling. In borstkankerpatiënten had verhoogde of verlaagde activiteit van deze 
genen echter geen effect op het succes van bestraling. 
Ik heb niet kunnen vaststellen welke genen of signaleringsroutes verantwoordelijk 
zijn voor de bestralingsresistentie in tamoxifen-resistente borstkankercellen. 
Om dit verder te onderzoeken, kunnen genen die mogelijk een rol spelen in het 
laboratorium worden ‘weggeknipt’ uit de resistente cellen. Als deze cellen dan nog 
steeds bestralingsresistent zijn, zijn deze genen waarschijnlijk niet betrokken bij 
de resistentie tegen bestraling. Als ze door het wegknippen van deze genen juist 
gevoelig worden voor bestraling, is dit gen essentieel voor de bestralingsresistentie. 
APOBEC3B en bestralingsresistentie
Het laatste hoofdstuk van mijn proefschrift gaat over de rol die het APOBEC3B eiwit 
speelt in de gevoeligheid van borstkankercellen tegen bestraling. Net als Interferon 
signalering is APOBEC3B normaal gesproken betrokken bij de afweer tegen virussen. 
Maar ook hier is er een link met borstkanker en behandelingsresistentie. Collega-
wetenschappers hebben laten zien dat de aanwezigheid van veel APOBEC3B 
boodschapper-RNA leidt tot resistentie tegen tamoxifen. Omdat tamoxifen-resistentie 
en bestralingsresistentie veel overeenkomsten hebben, wilde ik onderzoeken of 
APOBEC3B ook een rol speelt bij bestralingsresistentie.
In een groep reeds behandelde borstkankerpatiënten bleek dat patiënten met veel 
APOBEC3B boodschapper-RNA slechter reageerden op bestraling dan patiënten 
met weinig APOBEC3B. Daarnaast ontdekte ik dat de hoeveelheid APOBEC3B 
boodschapper-RNA in patiënten overeen kwam met de hoeveelheid boodschapper-
RNA van een bepaald DNA-reparerend gen, RAD51. Dit zou kunnen verklaren waarom 
patiënten met veel APOBEC3B slechter reageren op bestraling, namelijk omdat er 
veel reparatie van de DNA-fouten kan plaatsvinden door de aanwezigheid van veel 
RAD51.
In celkweekmodellen zag ik vervolgens dat borstkankercellen met verlaagde niveaus 
van APOBEC3B meer DNA-fouten hadden na bestraling, terwijl cellen met meer 
APOBEC3B juist minder DNA-fouten hadden. Dit zou kunnen verklaren waarom 
patiënten met veel APOBEC3B slechter reageren op bestraling, de cellen kunnen dan 
namelijk beter de schade die gemaakt is door de bestraling herstellen. 
Dubbel resistent 
Tot mijn verbazing waren borstkankercellen die ik wekenlang had behandeld met 
tamoxifen, de tamoxifen-resistente cellen, ook resistent tegen bestraling. Om dit te 
verklaren, heb ik in deze cellen gekeken naar specifieke genen die betrokken zijn 
bij de processen van DNA reparatie en het verloop van de celcyclus (hoofdstuk 5). 
Als deze meer of minder actief zijn in de tamoxifen-resistente cellen, zou dat de 
resistentie tegen bestraling kunnen verklaren.
Waarom DNA-reparerende genen? Bestraling maakt het DNA van kankercellen stuk. 
In reactie hierop activeert de cel genen die het DNA kunnen repareren. Stel, er zit 
een breuk in een streng DNA. Die breuk wordt herkend door een eiwit dat daaraan 
blijft kleven. Andere eiwitten blijven hier weer aan kleven, zoals een eiwit dat de 
twee uiteinden DNA aan elkaar vast kan plakken. Zo repareert de cel een DNA-breuk. 
Als tamoxifen-resistente cellen een verhoogde activiteit van DNA-reparerende genen 
zouden hebben, kunnen ze schade van bestraling beter repareren en zijn ze ook 
minder gevoelig, resistent, tegen bestraling.
Van de 152 DNA-reparerende genen die ik onderzocht in de tamoxifen-resistente 
cellen waren er maar 5 meer of minder actief in deze cellen vergeleken met 
onbehandelde kankercellen. Om te onderzoeken of deze genen belangrijk zijn voor 
de gevoeligheid voor bestraling, keek ik of er een verschil was in het succes van 
radiotherapie in patiënten met veel of weinig boodschapper-RNA van deze genen. 
Dat bleek niet het geval. Het blijft daardoor onduidelijk of deze 5 DNA-reparerende 
genen zorgen voor de resistentie tegen bestraling in de tamoxifen-resistente cellen. 
Naast DNA-reparerende genen kunnen ook celcyclus genen invloed hebben op het 
succes van bestraling. Cellen gaan bij hun vermenigvuldiging door een vaste cyclus 
heen. Deze bestaat uit 4 stappen: 1. Rust, 2. Verdubbeling van DNA, 3. Pauze, 4. 
Celdeling. In stap 2 van deze cyclus vindt veel foutencontrole plaats om te zorgen 
dat de verdubbeling van het DNA foutloos gebeurt. Daardoor zijn cellen in deze stap 
minder gevoelig voor bestraling. Als de tamoxifen-resistente cellen zich voornamelijk 
in deze stap van de cyclus zouden bevinden, zou dit hun bestralingsresistentie 
kunnen verklaren. 
Ik onderzocht per stap van de celcyclus de activiteit van twintig genen om te kijken in 
welke stap de tamoxifen-resistente cellen zich bevinden. Tamoxifen-resistente cellen 
hadden een hoge activiteit van genen die bij stap 1 horen, en een lagere activiteit 
van de genen van stap 3, de overgang tussen stap 1 en 2, of de overgang tussen 
stap 3 en 4. In stap 3 en 4 zijn cellen meer gevoelig voor bestraling, dus dit zou een 
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Dankwoord
“Yes, I began my journey alone, and I ended it alone. 
But that does not mean that I walked alone.”
(Brandon Sanderson – Oathbringer)
Het is ondertussen al meer dan vijf jaar geleden dat ik de afdeling Radiotherapie 
binnenstapte voor mijn eerste werkdag. Sinds die dag heb ik het geluk gehad 
om met ontzettend leuke mensen samen te werken. Ik wil mijn (co-)promotoren, 
collega’s binnen en buiten Nijmegen, vrienden en familie ontzettend bedanken voor 
alle gezelligheid, hulp en steun tijdens mijn promotietraject. Zonder jullie was dit 
niet gelukt!
Waarom veel APOBEC3B leidt tot meer DNA schade en een slechtere respons op 
bestraling is nog niet bekend. Het DNA-reparerende eiwit RAD51 zou hierbij een 
rol kunnen spelen. De interactie tussen APOBEC3B en RAD51 moet beter worden 
onderzocht, net als hun gezamenlijke effect op bestralingsgevoeligheid.
En nu?
Wat is de volgende stap, nu ik in mijn promotie-onderzoek een aantal processen 
heb geïdentificeerd die te maken hebben met resistentie tegen behandeling met 
tamoxifen en bestraling? Eerst moet onderzocht worden hoe deze processen hierbij 
betrokken zijn: zijn ze de oorzaak of het gevolg van behandelingsresistentie? Door 
processen te identificeren die voorspellen of patiënten resistent worden tegen een 
bepaalde behandeling, kunnen behandelingen per patiënt afgestemd worden.  En als 
de processen die ervoor zorgen dat een kankercel de behandeling overleeft bekend 
zijn, kunnen nieuwe therapieën worden ontwikkeld die deze processen remmen. 
Hopelijk kan dan op termijn ook de slimme borstkankercel, die de behandeling 
overleeft, vernietigd worden.
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begeleiding van prof. Kamil Kranc en dr. Milica Vukovic. In 2014 studeerde ze cum 
laude af.
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Span, PhD. During her PhD, she followed several courses at the Radboud University, 
amongst others the courses ‘the art of presenting science’ and ‘science journalism’. In 
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published in various scientific journals.
After finishing her PhD, Annemarie performed an internship in science communication 
with the research press officers at the Communication department of the Radboud 
university medical center. Moreover, she completed a course in science journalism at 
the Foundation for Courses in Science Correspondence (SCW).
At present, Annemarie is employed as project manager at the Eberhard Karls 
University of Tübingen, Germany.
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PHD PORTFOLIO
Name PhD student: Annemarie Post
Department: Laboratory Medicine; Radiation 
Oncology
Graduate School: Radboud Institute for Health 
Sciences
PhD period: 01-09-2014 – 31-08-
2018
Promotor(s): Prof. C.G.J. Sweep
                               Prof. J. Bussink
Co-promotor(s): P.N. Span, PhD 
Year(s) ECTS
TRAINING ACTIVITIES
A) Courses & Workshops
Radiation Safety (level 5A)
RIHS PhD introduction course
The Art of Presenting Science 
Science Journalism
Scientific Integrity
Pre-meeting course ESTRO36: Biomarkers
Education in a Nutshell
Career development
2014
2015
2015
2015 – 2016
2015
2017
2017
2017
1.5
1.5
1.5
3
1
0.5
1
1
B) Seminars & lectures
Lecture of the RIMLS graduate course
Workshop on statistics in small patient groups
Radboud Research Rounds
RIMLS seminars
RIMLS Technical Forums/Meet the Expert
Taskforce Genetic Therapy meeting
Spinoza lecture Mihai Netea
Cancer Immunotherapy Meeting
Workshop infographics
2014
2014
2014 – 2017
2014 – 2017
2015 – 2018
2015
2016
2017
2018
0.1
0.1
1.5
0.9
0.4
0.1
0.1
0.1
0.1
C) Symposia & congresses^
Radboudumc Oncology Science Day++
RIHS PhD retreats#+
Scientific meeting of the Dutch Society for Radiobiology**
Wolfsberg meeting on Molecular Radiation Biology/Oncology##
ESTRO meeting#*
European Radiation Research meeting*
EORTC PathoBiology Group meeting**
Radboud Frontiers in Cancer Research#
Opening symposium Radiotherapy and OncoImmunology Laboratory
Scientific meeting of the Dutch Society for Radiation Oncology and 
Radiobiology*
EORTC Gyneacological Cancer Group meeting*
2014/2016
2014 – 2017
2015 – 2017
2015/2017
2016/2017
2016
2016/2017
2016
2017
2018
2018
1
2.75
1.25
2.5
3
1.5
2
1
0.25
0.75
0.5
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Research data management
The data obtained between 2014 and 2016 at the Radboud university medical center 
have been recorded in a digital lab book, which is backed-up on a hard disk drive 
at the department of Radiation Oncology of the Radboud university medical center. 
Data from 2017 and 2018 are captured and stored on Labguru, a digital lab book 
client which is centrally stored and daily backed-up on the local Radboudumc server. 
All data archives (view only) are stored on Labguru and accessible by the associated 
senior staff members. The published data in chapter II, IV and V in this thesis are part 
of published articles and its supplementary files are available from the associated 
corresponding authors on request. All raw and processed RNA-seq data described in 
Chapter II is available at request from Paul Span, PhD, at the department of Radiation 
Oncology of the Radboud university medical center. 
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Secretary of the RIHS PhD council
Journal clubs Radiotherapy and OncoImmunology Laboratory*
Organizing Radboud Research Round Women’s Cancer
Pitch competition Radboud Talks
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2016 – 2018
2017 
2018
2017 - 2018
2017
2018
0.5
0.3
1
0.5
0.5
1
0.5
1
TEACHING ACTIVITIES
E) Lecturing
Teaching practical course
Workshop BMW bachelor congress
RIHS Introdution course: Peer2Peer
RIHS Introduction course: Managing your PhD
2017
2017
2018
2018
0.5
0.2
0.1
0.2
F) Supervision of internships / other
Honours Programme: preparation internship abroad – Victoria Lasscher
Honours Programme: introduction theme Women’s Cancer
Bachelor student: 1-week mini-internship – Tirza Wubs
Bachelor student: internship – Bas Adriaansen
Honours Programme: preparation internship abroad – Sterre Leenen
Master student: literature thesis – Sylvia van der Weegen
Master student: internship – Sylvia van der Weegen
Master student: internship – Mirte Meijerink
2015 – 2016
2016/2017/2018
2016
2016
2016 – 2017
2016
2017
2018
1
0.5
0.5
1
1
0.5
2
2
TOTAL
^Presentations are indicated: * oral presentation, # poster presentation, + laptop 
presentation
 
